Ventura County Medi-Cal Managed Care Commission (VCMMCC) dba Gold Coast Health Plan Commission Meeting

DATE: Monday, April 23, 2012

TIME: 3:00-5:00 pm

PLACE: 2240 E. Gonzales Road, Suite 200, Oxnard CA 93036

AGENDA

Call to Order and Welcome

Pledge of Allegiance

Roll Call

Public Comment / Correspondence

1. Approve Minutes - None available at this time.

2. Election of Chair and Vice-Chair Action Required

3. CEO Management Update For Information

4. Accept and File Financial Report

a. March Financials Action Required

5. Review and Approve CEO Priorities Action Required

6. Ratification of Legal Services Contract with Nordman
Cormany Hair & Compton LLP

Action Required

Meeting Agenda available at http://www.goldcoasthealthplan.org

ADMINISTRATIVE REPORTS RELATING TO THIS AGENDA AND MATERIALS RELATED TO AN AGENDA ITEM SUBMITTED TO THE COMMISSION AFTER DISTRIBUTION OF THE AGENDA PACKET ARE AVAILABLE FOR PUBLIC REVIEW DURING NORMAL BUSINESS HOURS AT THE OFFICE OF THE CLERK OF THE BOARD, 2220 E. GONZALES ROAD, SUITE 200, OXNARD, CA.

IN COMPLIANCE WITH THE AMERICANS WITH DISABILITIES ACT, IF YOU NEED SPECIAL ASSISTANCE TO PARTICIPATE IN THIS MEETING, PLEASE CONTACT TRACI AT 805/981-5320. REASONABLE ADVANCE NOTIFICATION OF THE NEED FOR ACCOMMODATION PRIOR TO THE MEETING (48 HOURS ADVANCE NOTICE IS PREFERABLE) WILL ENABLE US TO MAKE REASONABLE ARRANGEMENTS TO ENSURE ACCESSIBILITY TO THIS MEETING

Ventura County Medi-Cal Managed Care Commission (VCMMCC) dba Gold Coast Health Plan April 23, 2012 Commission Meeting Agenda (continued)

TIME: 3:00-5:00 pm

7. <u>Management Recommendations & Reports</u>

a. ScriptCare Presentation For Information

b. Approve Contract with Healthcare Effectiveness Data and Information Set (HEDIS) Vendor to collect and Provide Statistical Data

Action Required

c. Changes to Provider Advisory Committee

Action Required

8. Special Committee Report

- a. Possible Solutions
 - 1. CEO
 - 2. CFO
 - 3. Claims Director
 - 4. Recruiting Firm
 - 5. Legal Counsel
 - 6. Human Resources Director
 - 7. Consultants contract for services not to exceed \$150,000

Comments from Commissioners

Adjourn to Closed Session

- a. Conference with legal counsel-anticipated litigation GC § 54956.9(b) -1 case
- b. Public Employment GC § 54957 Title: Permanent Chief Executive Officer

Return to Open Meeting

Announcements from Closed Session, if any.

Adjournment

Unless otherwise determined by the Commission, the next regular meeting of the Commission will be held on May 21, 2012 at 3:00 p.m. at 2240 E. Gonzales Road, Suite 200, Oxnard CA 93036

Meeting Agenda available at http://www.goldcoasthealthplan.org

ADMINISTRATIVE REPORTS RELATING TO THIS AGENDA AND MATERIALS RELATED TO AN AGENDA ITEM SUBMITTED TO THE COMMISSION AFTER DISTRIBUTION OF THE AGENDA PACKET ARE AVAILABLE FOR PUBLIC REVIEW DURING NORMAL BUSINESS HOURS AT THE OFFICE OF THE CLERK OF THE BOARD, 2220 E. GONZALES ROAD, SUITE 200, OXNARD, CA.

IN COMPLIANCE WITH THE AMERICANS WITH DISABILITIES ACT, IF YOU NEED SPECIAL ASSISTANCE TO PARTICIPATE IN THIS MEETING, PLEASE CONTACT TRACI AT 805/981-5320. REASONABLE ADVANCE NOTIFICATION OF THE NEED FOR ACCOMMODATION PRIOR TO THE MEETING (48 HOURS ADVANCE NOTICE IS PREFERABLE) WILL ENABLE US TO MAKE REASONABLE ARRANGEMENTS TO ENSURE ACCESSIBILITY TO THIS MEETING

Chief Executive's Monthly Report to Commission

April 23, 2012

I would like to open with a thank you to all of the staff at Gold Coast Health Plan for their commitment to our members and providers. Many dedicated a lot of their personal time to resolve issues to help the members and providers under our responsibility. Listed below are some examples of accomplishments since Go-Live:

- #1 Accomplishment every day is our commitments to our members to provide the best customer service. We are also committed to obtaining quality healthcare services for our members.
- Two day training session with ACS to develop both additional training materials and processes for the customer service unit
- Implemented a program with our sister health plan in Northern California to provide healthcare services for our members when they seek seasonal work in other counties
- Outreach to the Mixteco community
- Over 25 provider training sessions
- Significant reduction in claims backlog
- Cash advances to providers to continue the cash flow during the backlog of claims
- Claims turnaround time within State guidelines
- Implemented Compliance 360 software to manage the State Contract
- California Children's Services (CCS) and Gold Coast Health Plan have implemented a coordination process for the custodial care of mutual clients
- Signed contracts for Cultural and Linguistic services and ASL Interpreter services
- Health Education staff developed a group needs assessment survey of 10,000 members to assess cultural and language barriers to service
- Cultural and linguistic training of 50% of staff with the remainder of the training to be completed by the end of May
- Participation in the Statewide Tobacco Prevention Advisory Committee (DHCS).
- Transition of the Adult Day Health Care program to Community-Based Adult Services (CBAS) has been completed
- First meeting of the Medical Advisory Committee on 3/22/2012
- Monthly outreach calendar to members to provide plan information

California Department of Health Care Services (DHCS)

 GCHP staff from Claims, Provider Relations, Compliance, Government Affairs, and Finance Departments continue to have regular scheduled weekly calls with DHCS. The purpose of these calls is to respond to inquiries concerning policies, procedures, and other deliverables. We currently are not auto assigning based on the filed auto assignment policy (system will not handle) and have 30 days to comply. A proposed (revised) policy is being presented today. We are under a corrective action plan monitored by the State through their contract with Berkely Research Group. I met (via telephone) with Joan Ogle, Deputy Director-Health Care Delivery Systems; Margaret Tartar, Chief- Medi-Cal Managed Care; Stuart Busby, Chief-Capitated Rates Development Division; to discuss our responses to the monitoring report. We have received additional issues that will be included in future reports.

Personnel

Additions:

- Nancy, Sellers, RN Grievance & Appeals and NICU Nurse
- Colette Torres Clinical Operations Assistant
- Julie Booth MS Public Health Director of Quality Improvement

Transitions:

 Nurses that have been under the direction of our Vendor, ACS are being transitioned to Gold Coast Health Plan

Resignations:

Paul Roberts, Director of Provider Contracting and Provider services

Under the requirements of California Law AB 1825, we have conducted Preventing Harassment, Discrimination & Retaliation Training

Current office space is very limited in the ability to meet staffing requirements. In the short term, we are relocating several staff presently in single person offices so that 2 to 4 staff can be relocated to those offices. We are also using part of the lunch room for space, to mention a few examples. We have posted an RFQ for broker services to assist us in finding the appropriate needed space.

Community Outreach& Education

- March 31, outreach in support of the Mixteco/Indigena Community Organizing Project (MICOP)
- April 3, Presentation to healthcare professionals at the Community Networking Meeting hosted by St. John's Regional Medical Center
- April 21, Channel Island Health Fair
- April 19, Ventura County Human Service Agency IHSS Meeting. To discuss a "Wrap Around" system for care coordination for mutual members

Claims

Average claim receipts	23,343
Average weekly production	19,393
Inventory as of April 23 (includes 14,480 processed claims that will be "paid" tomorrow)	50,604
Days inventory on hand	17
Auto adjudication rate	31%

Government Affairs

- Healthy Families Program Transition to Medi-Cal Managed Care: The Assembly Budget Subcommittee on Health approved a partial transition of the Healthy Families Program to Medi-Cal managed care. The transition is limited to the so-called "brightline" children, or those families at 133 percent below the federal poverty level (approximately \$30,000 for a family of four). If the Senate does not take an action similar to the Assembly the item will go to conference committee. Currently there are approximately 20,000 children enrolled in the Healthy Families Program in Ventura County.
- Community Based Adult Services; As part of the state budget cuts the state DHCS proposed the elimination of Adult Day Health Care Program (ADHC) under Medi-Cal. Senior advocates filed suit and argued that the elimination of the ADHC Program without adequate replacement services placed disabled seniors and others at risk of unnecessary institutionalization and violated the Americans with Disabilities Act. The court agreed and ordered the state to implement a replacement program- Community Based Adult Services (CBAS). DHCS expects the CBAS Program to go into operation on July 1, 2012. There are approximately 976 CBAS eligible beneficiaries in Ventura County that will receive ADHC-like services at five CBAS centers in Ventura County. The CBAS Centers are expected to contract with GCHP. On April 2, 2012 the state sent the first of three notices to beneficiaries informing them of the elimination of the ADHC and implementation of CBAS Programs respectively. For those beneficiaries deemed ineligible for the CBAS Program, GCHP is required to provide enhanced case management (ECM). GCHP is in the process of developing ECM plans for those ineligible for CBAS services.

Health Education, Cultural & Linguistic Services

Lupe Gonzalez, Health Education Manager at Gold Coast Health Plan, was selected to serve on the California Medicaid Incentives for the Prevention of Chronic Disease Advisory Committee: Quitting among Medi-Cal Smokers.

Health Services

- Gold Coast Health Plan continues to collaborate with the State and participate in weekly consultation sessions to discuss the transition of members from licensed/certified care to deliver custodial care. Health Services and Member Services continue to work closely on a case by case basis, educating families with alternate non-clinical services that is available to the member. We have identified 14 members whose services are covered by Title II. A total of six cases approved by CCS for shift care nursing, five under review, and three denied but transition back to GCHP for re-evaluation.
- Community Based Adult Services (CBAS) conversion 48 of the 53
 assessments for non-eligible CBAS members for Enhanced Case Management
 (ECM) have been conducted by an outside Vendor. On-going meetings with the
 administrators of the ADHC/CBAS facilities and the Director of the VC Area

Agency on Aging to discuss coordination of care. ECM care plans completed to meet the 4/1/12 deadline.

Member Services

State Fair Hearing preparation continues with members requesting continued custodial care services. We have had two that have gone as far as this process. Currently 1 is still being reviewed and 1 was upheld.

The following Call Center Statistics appear reasonable:

	12-Mar	Calls Offered	Calls Handled	Calls Abandoned	Abandoned Percent	Avg Speed Answer (in min)	Average Talk Time (in min)	Average Hold Time (in min)
Member Calls	Month Totals	2653	2637	15	0.57%	0.1	4.75	0.45
Provider Calls	Month Totals	3840	3808	28	0.73%	0.15	4.48	0.69
Combined Calls	Month Totals	7730	7665	59	0.76%	0.13	4.75	0.57
Spanish member Calls	Month Totals	1237	1220	16	1.29%	0.11	5.63	0.48

Provider Contracting

All our provider contracts need to be renewed for an effective date July 1. We will begin this process next week.

Information Technology

I have reviewed our current situation with the website. At this point, I have significant concerns that this format will ever meet our needs. We investigated alternatives and are taking a different approach.

Consumer Advisory Group

April's Consumer Advisory Committee meeting has been rescheduled for May 16th 2012.

Tentative agenda for next Consumer Advisory Committee items are; Group Needs Assessment, Fraud and Abuse Hotline, Interpretation Services, Goal and Objectives, Plan update by Cassie Undlin - CEO.

Provider Advisory Group

A member of the Provider Advisory Committee has resigned effective March 31, 2012. Suggestions for a replacement would be appreciated.

Auto Assignment Committee

The Commission delegated the responsibility of the determining the Auto Assignment policy to the CEO in the November 28, 2011 meeting. The CEO met with the committee to listen to the comments and concerns from the committee members. With this input

and input from State Agency, a policy has been developed for submission to the Commission today.

Tatum Team Assessment

I have been here for almost three weeks. During that time and with the additional information provided from the assessment, I believe we may need to commit additional resources in the form of contractors or employees.

Respectfully submitted,

Cassie Undlin Interim Chief Executive Officer

Gold Coast Health Plan	Policies and Procedures	 (Comment [CU1]:
Title: Member Assignment to a Primary Care Physician	Policy Number: 13.G / 16.A Revised XXXX		Formatted: Indent: Left: 0"

Purpose:

To describe the process by which new members who do not select a Primary Care Provider (PCP) on their own are assigned to one.

Policy:

GCHP will ensure that new members who do not select a PCP on their own are assigned to one in accordance with all applicable statutory, regulatory and contractual requirements. A Member may select a different PCP by contacting GCHP Member Services. Administrative Members are not required to select a PCP.

Definitions:

Administrative Members: The following are considered Administrative Members:

- Share of Cost: A Member who has Medi-Cal with share of cost requirement.
 - Long-Term Care: A Member who is residing in a skilled or intermediatecare nursing facility for more than 30 days after the month of admission.
 - Out of Area: A Member who resides out of the Plan's Ventura County service area but whose Medi-Cal case remains in Ventura County. This may include out- of-area foster-care or adoption-assistance placements and long-term care placements.
 - Other Health Coverage: A Member who has other health insurance that is primary to their Medi-Cal; this includes Members with both Medi-Cal and Medicare Part B, as well as Members with both Medi-Cal and commercial insurance. Gold Coast Health Plan Members with other health coverage must access care through their primary insurance.
- Members who are enrolled under special aid categories such as Breast and Cervical Cancer Treatment Program.

The term, "Administrative Member" will be printed on the Health Plan ID cards in the PCP section, rather than the name of a doctor or clinic. The change of a Member's status from enrolled to administrative is not automatic — the Plan must be informed of the Member's circumstances by the Participating Provider or the Member him/herself in order to make the change in status effective.

Enrolled Member: An individual who has selected or been assigned to a PCP and will have the name of the PCP Physician or Clinic Provider on the Member's ID card. These individuals are sometimes referred to as "Linked Members."

Newly Eligible Member: An individual who is not yet assigned to a specific Participating Primary Care Physician or Clinic and, therefore, may see any willing Medi-Cal provider within the Plan's service area. Newly eligible GCHP Members will have "Newly Eligible" on their ID cards in the PCP section.

Page 1 of 3

	Policies and Procedures
Title: Member Assignment to a Primary	Policy Number: 13.G / 16.A
Care Physician	

Safety Net Provider: Recognized disproportionate share hospitals, federally qualified health centers, and rural health centers.

Traditional Provider: Providers that have served Ventura County Medi-Cal beneficiaries for at least three years, and with a patient population / payor mix of at least 30% Medi-Cal and/or uninsured/charity care.

Procedure:

1. At the end of each month, after the monthly eligibility file is downloaded and processed, all newly eligible members who have not selected a PCP, within the last 30 days will be assigned to a PCP. The assignment will be done through the GCHP System PCP auto-assignment program.

The auto-assignment program logic considers the following factors:

- · Zip code of Member's residence and location of PCP facility
- Age of Member
- · Gender of Member
- Member's preferred language
 - Provider status in terms of safety-net versus traditional Medi-Cal versus non safety-net or traditional, capacity, practice type and any historical ties to the Member (such as previous patient of specific Participating Providers, etc.)
- <u>Mid-level Providers.(Nurse Practioners and Physicians Assistants) will be included in the calculation</u>
- 2. The auto-assignment program reads the member data set and checks and checks each record to see if the provider number is blank. If the provider number is blank, it finds every member with that particular family number who is not already linked to a PCP. The program will assign all members with the same family number to the same PCP, taking into consideration age, gender and provider capacity restrictions.
- 3. The provider data set for this program contains only those PCPs contracted with GCHP and allowed to participate in the auto-assignment program. The provider data set contains any age, gender and capacity restrictions.
- 4. For each zip code in the GCHP service area, there is a corresponding list of PCPs accepting auto-assignment. This enables each member requiring auto-assignment to be linked to a PCP located near the member's residence.
- 5. The Plan will assign returning Member to the last known PCP.
- 6. If there is are no open PCP's in a member's area, the member will be left unassigned and a detailed report will be generated for staff to review.

Page 2 of 3

Formatted: List Paragraph, Bulleted + Level: 1 + Aligned at: 0.58" + Indent at: 0.83"

Formatted: Font: (Default) Arial, 12 pt Formatted: Font: (Default) Arial, 12 pt

Formatted: Indent: Left: 0.5"

Gold Coast Health Plan	Policies and Procedures
Title: Member Assignment to a Primary	Policy Number: 13.G / 16.A
Care Physician	Revised

7. The PCP auto-assignment program logic is weighted to give preference to traditional and safety-net providers. Safety-Net Providers will be assigned three members for every one member assigned to a Traditional Provider.

<u>87.</u> If a member is dissatisfied with the provider he/she has been assigned to, he/she can select a different PCP by contacting Member Services Department.

Revision History:

Formatted: Font: (Default) Times New Roman, 10 pt

Formatted: Font: (Default) Times New Roman, 10 pt

Gold Coast Health Plan	Policies and Procedures
Title: Member Assignment to a Primary	Policy Number: 13.G / 16.A
Care Physician	Revised XXXX

Purpose:

To describe the process by which new members who do not select a Primary Care Provider (PCP) on their own are assigned to one.

Policy:

GCHP will ensure that new members who do not select a PCP on their own are assigned to one in accordance with all applicable statutory, regulatory and contractual requirements. A Member may select a different PCP by contacting GCHP Member Services. Administrative Members are not required to select a PCP.

Definitions:

Administrative Members: The following are considered Administrative Members:

- Share of Cost: A Member who has Medi-Cal with share of cost requirement.
 - Long-Term Care: A Member who is residing in a skilled or intermediate-care nursing facility for more than 30 days after the month of admission.
 - Out of Area: A Member who resides out of the Plan's Ventura County service area but whose Medi-Cal case remains in Ventura County. This may include outof-area foster-care or adoption-assistance placements and long-term care placements.
 - Other Health Coverage: A Member who has other health insurance that is primary to their Medi-Cal; this includes Members with both Medi-Cal and Medicare Part B, as well as Members with both Medi-Cal and commercial insurance. Gold Coast Health Plan Members with other health coverage must access care through their primary insurance.
- Members who are enrolled under special aid categories such as Breast and Cervical Cancer Treatment Program.

The term, "Administrative Member" will be printed on the Health Plan ID cards in the PCP section, rather than the name of a doctor or clinic. The change of a Member's status from enrolled to administrative is not automatic — the Plan must be informed of the Member's circumstances by the Participating Provider or the Member him/herself in order to make the change in status effective.

Enrolled Member: An individual who has selected or been assigned to a PCP and will have the name of the PCP Physician or Clinic Provider on the Member's ID card. These individuals are sometimes referred to as "Linked Members."

Newly Eligible Member: An individual who is not yet assigned to a specific Participating Primary Care Physician or Clinic and, therefore, may see any willing Medi-Cal provider within the Plan's service area. Newly eligible GCHP Members will have "Newly Eligible" on their ID cards in the PCP section.

Page 1 of 3

Gold Coast Health Plan	Policies and Procedures
Title: Member Assignment to a Primary	Policy Number: 13.G / 16.A
Care Physician	

Safety Net Provider: Recognized disproportionate share hospitals, federally qualified health centers, and rural health centers.

Procedure:

1. At the end of each month, after the monthly eligibility file is downloaded and processed, all newly eligible members who have not selected a PCP, within the last 30 days will be assigned to a PCP. The assignment will be done through the GCHP System PCP auto-assignment program.

The auto-assignment program logic considers the following factors:

- Zip code of Member's residence and location of PCP facility
- · Age of Member
- Gender of Member
- Member's preferred language
 - Provider status in terms of safety-net versus traditional Medi-Cal versus non safety-net or traditional, capacity, practice type and any historical ties to the Member (such as previous patient of specific Participating Providers, etc.)
- Mid-level Providers, (Nurse Practioners and Physicians Assistants) will be included in the calculation
- 2. The auto-assignment program reads the member data set and checks each record to see if the provider number is blank. If the provider number is blank, it finds every member with that particular family number who is not already linked to a PCP. The program will assign all members with the same family number to the same PCP, taking into consideration age, gender and provider capacity restrictions.
- 3. The provider data set for this program contains only those PCPs contracted with GCHP and allowed to participate in the auto-assignment program. The provider data set contains any age, gender and capacity restrictions.
- 4. For each zip code in the GCHP service area, there is a corresponding list of PCPs accepting auto-assignment. This enables each member requiring auto-assignment to be linked to a PCP located near the member's residence.
- 5. The Plan will assign returning Member to the last known PCP.
 - 6. If there is are no open PCP's in a member's area, the member will be left unassigned and a detailed report will be generated for staff to review.

Page 2 of 3

Gold Coast Health Plan	Policies and Procedures
Title: Member Assignment to a Primary Care Physician	Policy Number: 13.G / 16.A Revised

7. If a member is dissatisfied with the provider he/she has been assigned to, he/she can select a different PCP by contacting Member Services Department.


Revision History:

Review Date	Revised Date	Approved By
	5/31/2011	Earl of Brunz
	4/23/2012	

GOLD COAST HEALTH PLAN SUMMARY FINANCIAL RESULTS Nine Months & Year-to-Date

				Ventura	Ventura County Medi-Cal	i-Cal				
	JUL 11	AUG 11	SEP 11	OCT 11	NOV 11	DEC 11	JAN 12	FEB 12	MAR 12	YTD
Member Months	102,033	103,689	104,821	105,245	104,979	105,079	104,418	104,839	106,503	941,606
Revenue pmpm	24,678,298 241.87	25,035,423 241.45	23,740,361 226.48	25,199,998 239.44	24,946,694 237.64	25,440,875 242.11	24,990,447 239.33	24,231,927 231.13	25,411,162 238.60	223,675,185 237.55
Health Care Costs pmpm % of Revenue	20,722,297 203.09 84.0%	21,245,838 204.90 84.9%	21,839,899 208.35 92.0%	22,065,987 209.66 87.6%	22,003,480 209.60 88.2%	22,415,249 213.32 88.1%	22,121,202 211.85 88.5%	26,111,143 249.06 107.8%	23,045,202 216.38 90.7%	201,570,297 214.07 90.1%
Admin Exp pmpm % of Revenue	1,341,729 13.15 5.4%	1,354,008 <i>13.06</i> 5.4%	1,413,721 13.49 6.0%	1,672,837 15.89 6.6%	1,084,862 10.33 4.3%	1,440,127 13.71 5.7%	1,529,225 <i>14.</i> 65 6.1%	1,516,129 14.46 6.3%	1,615,365 15.17 6.4%	12,968,004 13.77 5.8%
Net Income pmpm % of Revenue	2,614,273 25.62 10.6%	2,435,577 23.49 9.7%	486,741 4.64 2.1%	1,461,174 13.88 5.8%	1,858,351 17.70 7.4%	1,585,499 15.09 6.2%	1,340,019 <i>1</i> 2.83 5.4%	(3,395,346) (32.39) -14.0%	750,595 7.05 3.0%	9,136,884 9.70 4.1%
100% TNE Required TNE GCHP TNE	14,242,618 - (1,808,546)	14,455,522 - 627,031	14,671,236 - 1,113,773	14,837,677 - 2,574,946	14,925,890 - 4,433,298	15,048,230 - 6,018,797	15,101,073 3,020,215 7,358,815	15,615,661 3,123,132 3,963,469	15,685,187 3,137,037 4,714,064	

GOLD COAST HEALTH PLAN Financial Scorecard - March 2012



Gold Coast Health Plan Balance Sheet March 31, 2012

ASSETS

Current Assets	
Total Cash and Cash Equivalents	53,074,719
Medi-Cal Receivable	2,011,361
Provider Receivable	784,704
Other Receivables	30,231
Total Accounts Receivable	2,826,295
Total Prepaid Accounts	214,604
Total Other Current Assets	750,000
Total Current Assets	56,865,619
Total Fixed Assets	94,878
Total Assets	56,960,496
LIABILITIES & FUND BALANCE	
Current Liabilities	
Incurred But Not Reported	23,748,422
Claims Payable	17,189,037
Capitation Payable	631,179
Accrued Premium Reduction	5,005,645
Accounts Payable	60,636
Accrued ACS	664,165
Accrued RGS	474,030
Accrued Premium Tax	1,851,653
Current Portion of Deferred Revenue	460,000
Current Portion Of Long Term Debt	500,000
Total Current Liabilities	50,584,765
Long-Term Liabilities	
Other Long-term Liability	166,667
Deferred Revenue - Long Term Portion	1,495,000
Notes Payable	- 4 004 007
Total Long-Term Liabilities	1,661,667
Total Liabilities	52,246,432
Beginning Fund Balance	(4,422,819)
Net Income Current Year	9,136,884
Total Fund Balance	4,714,064
Total Liabilities & Fund Balance	56,960,496

Gold Coast Health Plan Income Statement Period Ended March 31, 2012

	JAN 2012	FEB 2012	MAR 2012	<u>Budget</u>	Variance Fav/(Unfav)	<u>YTD</u>	% of Rev	Budget	Variance Fav/(Unfav)
Members (Member/Months)	100,636	100,768	101,439	101,746	(307)	911,869		915,085	(3,216)
Revenues									
Premium	26,093,935	25,423,527	26,551,649	24,750,119	1,801,530	233,709,596	101 98%	223,358,783	10,350,813
Reserve for Retro-Active Rate Reduction	(556,929)	(553,821)	(561,704)	-	(561,704)	(5,005,645)	-2.18%	(1,658,225)	(3,347,420)
Interest Income	18,094	21,284	13,833	14,850	(1,017)	118,408	0.05%	106,112	12,296
Miscellaneous Income	38,333	38,333	38,333	38,333	0	345,000	0.15%	344,997	3
Total Revenues	25,593,434	24,929,324	26,042,112	24,803,302	1,238,810	229,167,360	100.00%	222,151,667	7,015,693
MCO Tax	602,987	697,397	630,949	569,253	(61,696)	5,492,176	2.40%	5,136,285	355,891
Net Revenue	24,990,447	24,231,927	25,411,162	24,234,049	1,177,113	223,675,185	97.60%	217,015,382	6,659,803
Cost of Health Care									
<u>Capitation</u>	638,740	620,892	631,179	735,781	104,602	5,635,072	2.46%	6,247,608	612,536
Claims									
Inpatient FFS Expense	3,814,390	8,633,321	4,461,281	3,716,785	(744,496)	39,771,146	17.35%	33,592,860	(6,178,286)
LTC/SNF Expense	7,029,419	2,310,147	6,530,526	6,849,547	319,021	58,002,045	25.31%	61,915,551	3,913,506
Outpatient FFS Expense	2,178,213	5,665,031	2,687,937	2,180,419	(507,518)	24,002,525	10.47%	20,365,694	(3,636,831)
Laboratory and Radiology Expense	232,763	126,753	227,068	232,999	5,931	2,026,126	0.88%	2,010,225	(15,901)
Emergency Room Facility Services FFS	405,556	1,234,941	522,102	405,967	(116,135)	4,670,796	2.04%	4,451,926	(218,870)
Physician Specialty Services FFS Professional FFS Expense	2,039,790	2,108,578	2,038,710	1,950,472	(88,238)	18,184,546 121	7.94% 0.00%	17,657,650	(526,896)
Other Medical Professional	212,811	260,562	285,034	203,492	(91 542)	2,010,099	0.88%	1,832,261	(121)
		*			(81,542)	26,154,797		29,078,635	(177,838)
Pharmacy Reinsurance	3,102,270	3,053,291	3,257,618	3,561,113	303,495		11.41%		2,923,838
	92,131	91,579	91,244	92,589	1,345	832,170	0.36%	832,728	558
Other Redical Care Expenses		4 000 000	916	4 405 400	(916)	916	0.00%	-	(916)
Other Fee For Service Expense	1,558,468	1,328,009	1,510,761	1,485,493	(25,268)	13,472,370	5.88%	12,352,818	(1,119,552)
Transportation FFS	310,704	190,317	293,805	297,099	3,294	2,630,399	1.15%	2,543,383	(87,016)
Medical & Care Management	505,948	487,722	507,022	558,862	51,840	4,177,170	1.82%	2,195,071	(1,982,099)
Total Claims	21,482,462	25,490,251	22,414,023	21,534,837	(879,186)	195,935,226	85.50%	188,828,802	(7,106,424)
Total Cost of Health Care	22,121,202	26,111,143	23,045,202	22,270,618	(774,584)	201,570,298	87.96%	195,076,410	(6,493,888)
Administrative Expenses									
Salaries and Wages	250,054	240,262	207,163	332,873	125,710	2,132,235	0.93%	2,425,620	293,385
Payroll Taxes and Benefits	75,300	102,090	110,151	114,925	4,774	782,527	0.34%	837,970	55,443
Total Travel and Training	1,155	6,710	4,932	10,390	5,458	37,399	0.02%	78,809	41,410
Outside Service - ACS Outside Service - CQS	948,983	951,390	1,084,489	940,676	(143,813)	8,665,113	3.78%	8,432,827	(232,286)
Outside Service - CQS Outside Service - RGS	9,763	9,628	9,314	- 12,446	3,132	84,108	0.00% 0.04%	50,956 94,604	50,956 10,496
Outside Service - Script Care	9,709	9,020	3,314	0	5,132	-	0.04%	34,004	-
Outside Services - Other	16,198	56,099	73,973	29,887	(44,086)	168,296	0.07%	131,542	(36,754)
Accounting & Actuarial Services	-	7,127	-	5,000	5,000	29,253	0.01%	123,445	94,192
Legal Expense	-	11,172	418	3,000	2,582	32,759	0.01%	35,667	2,908
Insurance	2,959	2,959	2,959	2,959	0	29,090	0.01%	29,093	3
Lease Expense -Office	13,089	11,869	13,469	26,080	12,611	116,667	0.05%	156,480	39,813
Consulting Services Expense	-	9,460	56,675	8,100	(48,575)	70,864	0.03%	42,630	(28,234)
Translation Services	483	12	1,106	1,397	291	6,184	0.00%	9,857	3,673
Advertising and Promotion Expense	-	15,793	1,484	996	(488)	170,879	0.07%	232,236	61,357
General Office Expenses	49,125	40,867	28,463	77,599	49,136	301,665	0.13%	361,251	59,586
Depreciation & Amortization Expense	1,806	1,461	1,461	1,461	0	13,491	0.01%	13,149	(342)
Printing Expense	5,370	2,344	1,353	24,250	22,897	20,072	0.01%	165,214	145,142 45,155
Shipping & Postage Expense Interest Exp	- 154,942	13,034 33,852	412 17,543	8,575	8,163 (17,543)	14,894 292,507	0.01%	60,049 5 175	45,155 (287,332)
Total Administrative Expenses	1,529,225	1,516,129	1,615,365	1,600,614	(17,543) (14,751)	12,968,004	0.13% 5.66%	5,175 13,286,574	318,570
Net Income / (Loss)	1,340,019	(3,395,346)	750,595	362,817	387,778	9,136,884	3.99%	8,652,398	484,486
=	.,0 10,010	(0,000,040)	. 50,000	32,017	331,110	5,100,004	2.50 /0	3,332,000	.0 1,100

Gold Coast Health Plan Income Statement PMPM Period Ended March 31, 2012

	JAN 2012	FEB 2012	MAR 2012	<u>Budget</u>	<u>Variance</u> Fav/(Unfav)	YTD	<u>Budget</u>	Variance Fav/(Unfav)
Members (Member/Months)	100,636	100,768	101,439	101,746	(307)	911,869	915,085	(3,216)
Revenues								
Premium	259.29	252.30	261.75	243.25	18.50	256.30	244.09	12.21
Reserve for Retro-Active Rate Reduction	(5.53)	(5.50)	(5.54)	-	(5.54)	(5.49)	(1.81)	(3.68)
Interest Income	0.18	0.21	0.14	0.15	(0.01)	0.13	0.12	0.01
Miscellaneous Income	0.38	0.38	0.38	0.38	0.00	0.38	0.38	0.00
Total Revenues	254.32	247.39	256.73	243.78	12.95	251.32	242.77	8.55
MCO Tax	5.99	6.92	6.22	5.59	(0.63)	6.02	5.61	0.41
Net Revenue	248.33	240.47	250.51	238.18	12.32	245.29	237.15	8.14
Cost of Health Care								
Capitation	6.35	6.16	6.22	7.23	1.01	6.18	6.83	0.65
<u>Claims</u>								
Inpatient FFS Expense	37.90	85.68	43.98	36.53	(7.45)	43.61	36.71	(6.90)
LTC/SNF Expense	69.85	22.93	64.38	67.32	2.94	63.61	67.66	4.05
Outpatient FFS Expense	21.64	56.22	26.50	21.43	(5.07)	26.32	22.26	(4.07)
Laboratory and Radiology Expense	2.31	1.26	2.24	2.29	0.05	2.22	2.20	(0.03)
Emergency Room Facility Services FFS	4.03	12.26	5.15	3.99	(1.16)	5.12	4.87	(0.26)
Physician Specialty Services FFS	20.27	20.93	20.10	19.17	(0.93)	19.94	19.30	(0.65)
Professional FFS Expense	-	-	-	-	-	0.00	-	(0.00)
Other Medical Professional	2.11	2.59	2.81	2.00	(0.81)	2.20	2.00	(0.20)
Pharmacy	30.83	30.30	32.11	35.00	2.89	28.68	31.78	3.09
Reinsurance	0.92	0.91	0.90	0.91	0.01	0.91	0.91	(0.00)
Other Medical Care Expenses	-	-	0.01	-	(0.01)	0.00	-	(0.00)
Other Fee For Service Expense	15.49	13.18	14.89	14.60	(0.29)	14.77	13.50	(1.28)
Transportation FFS	3.09	1.89	2.90	2.92	0.02	2.88	2.78	(0.11)
Medical & Care Management	5.03	4.84	5.00	5.49	0.49	4.58	2.40	(2.18)
Total Claims	213.47	252.96	220.96	211.65	(9.31)	214.87	206.35	(8.52)
Total Cost of Health Care	219.81	259.12	227.18	218.88	(8.30)	221.05	213.18	(7.87)
Administrative Expenses								
Salaries and Wages	2.48	2.38	2.04	3.27	1.23	2.34	2.65	0.31
Payroll Taxes and Benefits	0.75	1.01	1.09	1.13	0.04	0.86	0.92	0.06
Total Travel and Training	0.01	0.07	0.05	0.10	0.05	0.04	0.09	0.05
Outside Service - ACS	9.43	9.44	10.69	9.25	(1.45)	9.50	9.22	(0.29)
Outside Service - CQS	- 0.10	- 0.10	0.09	0.12	- 0.03	-	0.06 0.10	0.06
Outside Service - RGS Outside Service - Script Care	0.10	0.10	0.09	0.12	0.03	0.09	0.10	0.01
Outside Services - Other	0.16	0.56	0.73	0.29	(0.44)	0.18	0.14	(0.04)
Accounting & Actuarial Services	0.10	0.07	-	0.25	0.05	0.03	0.13	0.10
Legal Expense	-	0.07	0.00	0.03	0.03	0.04	0.13	0.10
Insurance	0.03	0.03	0.03	0.03	(0.00)	0.03	0.03	(0.00)
Lease Expense -Office	0.03	0.03	0.03	0.03	0.12	0.03	0.03	0.04
Consulting Services Expense	-	0.09	0.56	0.08	(0.48)	0.08	0.05	(0.03)
Translation Services	0.00	0.00	0.01	0.01	0.00	0.01	0.01	0.00
Advertising and Promotion Expense	-	0.16	0.01	0.01	(0.00)	0.19	0.25	0.07
General Office Expenses	0.49	0.41	0.28	0.76	0.48	0.33	0.39	0.06
Depreciation Expense	0.02	0.01	0.01	0.01	(0.00)	0.01	0.01	(0.00)
Depreciation & Amortization Expense	0.02	0.01	0.01	0.01	(0.00)	0.01	0.01	(0.00)
Printing Expense	0.05	0.02	0.01	0.24	0.22	0.02	0.18	0.16
Shipping & Postage Expense	-	0.13	0.00	0.08	0.08	0.02	0.07	0.05
Interest Exp	1.54	0.34	0.17	-	(0.17)	0.32	0.01	(0.32)
Total Administrative Expenses	15.20	15.05	15.92	15.73	(0.19)	14.22	14.52	0.30
Net Income / (Loss)	13.32	(33.69)	7.40	3.57	3.83	10.02	9.46	0.56

Gold Coast Health Plan Income Statement Current Month vs. Prior Month

Variance Explanation	Gains mainly in Adult/Famility Category	Includes quarterly HYDE Payment Health Services + Scriptcare management	Prior month included addition to reserves
% Variance Fav/(Unfav)		4.44% -1.42% -35.01% 4.46% 9.53% 4.87% -1.66% 52.55% -79.14% 57.72% 3.31% -9.39% -0.37% -100.00% -13.76% -54.38%	12.07%
Variance Fav/(Unfav)	671	1,128,123 (7,884) (7,481) 	3,076,228 3,065,941
MAR 2012	101,439	26,551,649 (561,704) 13,833 38,333 26,042,112 630,949 25,411,162 25,411,162 25,411,162 25,411,162 25,411,162 25,411,162 25,411,162 25,411,162 25,411,162 25,411,162 25,411,162 25,411,162 25,1102 22,038,710 285,034 3,257,618 91,244 3,257,618 916 1,510,761 293,805	22,414,023 23,045,202
FEB 201 <u>2</u>	100,768	25,423,527 (553,821) 21,284 38,333 24,929,324 697,397 24,231,927 2,310,147 5,665,031 1,234,941 2,108,578 260,562 3,053,291 91,579 190,317 487,722	25,490,251
	Members (Member/Months)	Premium Reserve for Retro-Active Rate Reduction Interest Income Miscellaneous Income Total Revenues MCO Tax MCO Tax Net Revenue Capitation Claims Inpatient FFS Expense LTC/SNF Expense Laboratory and Radiology Expense Emergency Room Facility Services FFS Physician Specialty Services FFS Other Medical Professional Pharmacy Reinsurance Other Medical Care Expenses Other Medical Care Expenses Other Medical Care Expenses Transportation FFS Medical & Care Management	Total Claims Total Cost of Health Care

Gold Coast Health Plan Income Statement Current Month vs. Prior Month

	FEB 2012	MAR 2012	Variance Fav/(Unfav)	% Variance Fav/(Unfav)	Variance Explanation
Administrative Expenses Salaries and Wages	240.262	207.163	33.099	13.78%	
Payroll Taxes and Benefits	102,090	110,151	(8,061)	-7.90%	
Total Travel and Training	6,710	4,932	1,778	26.50%	
Outside Service - ACS	951,390	1,084,489	(133,099)	-13.99%	Rec'd invoice for 3 mos retroactivity \$163K
Outside Service - CQS			•	0.00%	
Outside Service - RGS	9,628	9,314	314	3.26%	
Outside Service - Script Care		•	•	0.00%	
Outside Services - Other	26,099	73,973	(17,874)	-31.86%	\$54K BRG
Accounting & Actuarial Services	7,127	•	7,127	100.00%	
Legal Expense	11,172	418	10,754	96.26%	
Insurance	2,959	2,959		0.00%	
Lease Expense -Office	11,869	13,469	(1,600)	-13.48%	
Consulting Services Expense	9,460	56,675	(47,215)	-499.11%	H/R consulting by RGS \$47,489
Translation Services	12	1,106	(1,094)	-9326.43%	
Advertising and Promotion Expense	15,793	1,484	14,309	%09.06	
General Office Expenses	40,867	28,463	12,404	30.35%	
Depreciation & Amortization Expense	1,461	1,461		%00.0	
Printing Expense	2,344	1,353	991	42.27%	
Shipping & Postage Expense	13,034	412	12,622	96.84%	
Interest Exp	33,852	17,543	16,310	48.18%	
Total Administrative Expenses	1,516,129	1,615,365	(99,236)	-6.55%	
Net Income / (Loss)	(3,395,346)	750,595	4,145,941	122.11%	

Gold Coast Health Plan General Office Expense Period Ended March 31, 2012

	FEB 2012	MAR 2012
Committee/Advisory	1,100	-
Non-Capital - Furniture & Equip.	537	3,040
Non-Capital Equipment - Computer	1,399	895
Software Licenses	9,618	4,887
Repairs & Maintenance	485	236
Telephone Services/ Internet Charges	1,121	4,724
Office & Operating Supplies	3,562	3,216
Bank Service Fees Expense	796	30
EE Recruitment	15,850	4,784
Prof Dues, Fees and Licenses	6,399	6,651
General Office Expenses	40,867	28,463

Gold Coast Health Plan

Fiscal Year July 1, 2011 - June 30, 2012 *Reforecasted P & L - 04.17.12*

					Actual											
·	<u>Jul-11</u>	<u>Aug-11</u>	<u>Sep-11</u>	Oct-11	<u>Nov-11</u>	<u>Dec-11</u>	<u>Jan-12</u>	<u>Feb-12</u>	<u>Mar-12</u>	<u>Apr-12</u>	May-12	<u>Jun-12</u>	<u>8+4 Total</u>	Approved 3+9	Var Fav/(Unfav)	% Change
Enrollment-Members	102,033	101,487	101,470	101,619	101,174	101,243	100,636	100,768	101,439	101,464	101,490	101,515	1,216,338			
Retroactivity	-	2,202	3,351	3,626	3,805	3,836	3,782	4,071	5,064	4,120	4,128	4,131	42,116			
Member Months	102,033	103,689	104,821	105,245	104,979	105,079	104,418	104,839	106,503	105,584	105,618	105,646	1,258,455	1,220,476	37,979	3.1%
Average Membership													104,871	101,706	3,165	3.1%
<u>Revenue</u>																
Premium	25,231,919	25,578,699	25,934,155	26,300,397	26,051,388	26,543,927	26,093,935	25,423,527	26,551,649	25,720,798	25,743,874	25,751,360	310,925,629	297,646,272	13,279,356	4.5%
Reserve for Retro Rate Decrease	-	-	(1,658,225)	(556,951)	(557,959)	(560,056)	(556,929)	(553,821)	(561,704)				(5,005,645)	(1,658,225)	(3,347,420)	201.9%
Adjusted Revenue	25,231,919	25,578,699	24,275,931	25,743,446	25,493,429	25,983,871	25,537,006	24,869,706	25,989,945	25,720,798	25,743,874	25,751,360	305,919,984	295,988,047	9,931,936	3.4%
Interest Income	-	5,816	11,251	15,348	15,968	16,814	18,094	21,284	13,833	15,432	15,446	15,451	164,738	150,684	14,054	9.3%
Other Income	38,333	38,333	38,333	38,333	38,333	38,333	38,333	38,333	38,333	38,333	38,333	38,333	459,999	459,996	3	0.0%
Total Gross Revenue	25,270,252	25,622,849	24,325,515	25,797,127	25,547,730	26,039,018	25,593,434	24,929,324	26,042,112	25,774,564	25,797,654	25,805,143	306,544,721	296,598,728	9,945,993	3.4%
MCO Tax	591,954	587,426	585,154	597,129	601,035	598,144	602,987	697,397	630,949	591,578	592,109	592,281	7,268,144	6,844,898	423,246	6.2%
Net Revenue	24,678,298	25,035,423	23,740,361	25,199,998	24,946,694	25,440,875	24,990,447	24,231,927	25,411,162	25,182,985	25,205,545	25,212,862	299,276,577	289,753,830	9,522,747	3.3%
Health Care Costs																
Capitation	588,173	582,177	665,127	625,098	637,089	646,596	638,740	620,892	631,179	765,940	764,890	765,093	7,930,994	8,456,054	525,060	6.2%
Claims																
Inpatient	10,596,127	10,768,103	10,885,661	10,929,693	10,902,069	10,912,454	10,843,809	10,943,468	10,991,807	10,971,273	10,974,779	10,977,679	130,696,921	127,223,256	(3,473,664)	-2.7%
Outpatient	2,827,335	2,873,222	2,920,801	2,939,463	2,921,288	2,936,974	2,816,532	7,026,725	3,437,107	3,446,274	3,447,375	3,448,286	41,041,383	34,824,166	(6,217,217)	-17.9%
Professional	2,160,039	2,195,217	2,219,060	2,228,037	2,222,405	2,224,523	2,252,601	2,369,140	2,323,744	2,259,506	2,260,228	2,260,825	26,975,324	25,955,036	(1,020,288)	-3.9%
Pharmacy	2,276,259	2,701,995	2,747,049	2,884,784	2,913,958	3,217,573	3,102,270	3,053,291	3,257,618	3,167,531	3,168,544	3,169,381	35,660,253	39,767,317	4,107,064	10.3%
Other	1,760,535	1,790,171	1,803,967	1,843,404	1,851,697	1,860,930	1,869,172	1,518,326	1,805,482	1,804,437	1,805,014	1,805,491	21,518,626	20,712,711	(805,915)	-3.9%
Reinsurance	92,850	92,353	92,338	94,616	92,928	92,131	92,131	91,579	91,244	96,082	96,112	96,138	1,120,503	1,110,633	(9,869)	-0.9%
Care Management	420,979	242,600	505,896	520,891	462,046	524,067	505,948	487,722	507,022	528,738	530,808	529,988	5,766,703	6,104,562	337,859	5.5%
Total Claims	20,134,124	20,663,661	21,174,772	21,440,889	21,366,391	21,768,653	21,482,462	25,490,251	22,414,023	22,273,840	22,282,860	22,287,787	262,779,712	255,697,681	(7,082,031)	-2.8%
Total Health Care Costs	20,722,297	21,245,838	21,839,899	22,065,987	22,003,480	22,415,249	22,121,202	26,111,143	23,045,202	23,039,780	23,047,749	23,052,879	270,710,706	264,153,735	(6,556,971)	-2.5%
Administrative Expenses	1,341,729	1,354,008	1,413,721	1,672,837	1,084,862	1,440,127	1,529,225	1,516,129	1,615,365	1,559,589	1,631,469	1,563,474	17,722,536	18,120,558	398,021	2.2%
Net Income	2,614,273	2,435,577	486,741	1,461,174	1,858,351	1,585,499	1,340,019	(3,395,346)	750,595	583,616	526,326	596,509	10,843,334	7,479,537	3,363,797	45.0%

Gold Coast Health Plan Fiscal Year July 1, 2011 - June 30, 2012 Reforecasted P & L - 04.17.12

				Actual											
<u>Jul-11</u>	<u>Aug-11</u>	<u>Sep-11</u>	Oct-11	Nov-11	<u>Dec-11</u>	<u>Jan-12</u>	<u>Feb-12</u>	Mar-12	<u>Apr-12</u>	May-12	<u>Jun-12</u>	8+4 Total	Approved 3+9	Var Fav/(Unfav)	% Change
247.29														0.57	0.2%
-															
0.38	0.37														-1.9%
247.67	247.11														0.2%
															3.0%
241.87	241.45	226.48	239.44	237.64	242.11	239.33	231.13	238.60	238.51	238.65	238.65	237.81	237.41	0.40	0.2%
5.76	5.61	6.35	5.94	6.07	6.15	6.12	5.92	5.93	7.25	7.24	7.24	6.30	6.93	0.63	9.0%
103.85	103.85	-	-	-	-	-	-	-	-	-	-	103.86	104.24	0.39	0.4%
27.71	27.71	-	-	-	-	-	-	-	-	-	-	32.61	28.53	(4.08)	-14.3%
21.17	21.17	-	-	-	-	-	-	-	-	-	-	21.44	21.27	(0.17)	-0.8%
22.31	26.06	26.49	-	-	-	-	-	-	-	-	-	28.34	32.58	4.25	13.0%
17.25	17.26	-	-	-	-	-	-	-	-	-	-	17.10	16.97	(0.13)	-0.8%
0.91	0.89	0.91	0.91	-	-	-	-	-	-	-	-	0.89	0.91	0.02	2.2%
4.13	2.34														
197.33	199.28	202.01	203.72	203.53	207.16	205.74	243.14	210.45	210.96	210.98	210.97	208.81	209.51	0.70	0.3%
203.09	204.90	208.35	209.66	209.60	213.32	211.85	249.06	216.38	218.21	218.22	218.21	215.11	216.44	1.32	0.6%
13.15	13.06	13.49	15.89	10.33	13.71	14.65	14.46	15.17	14.77	15.45	14.80	14.08	14.85	0.76	5.1%
25.62	23.49	4.64	13.88	17.70	15.09	12.83	(32.39)	7.05	5.53	4.98	5.65	8.62	6.13	2.49	40.6%
	247.29 - 0.38 247.67 5.80 241.87 5.76 103.85 27.71 21.17 22.31 17.25 0.91 4.13 197.33 203.09 13.15	247.29 246.69 - 0.06 0.38 0.37 247.67 247.11 5.80 5.67 241.87 241.45 5.76 5.61 103.85 103.85 27.71 27.71 21.17 21.17 22.31 26.06 17.25 17.26 0.91 0.89 4.13 2.34 197.33 199.28 203.09 204.90 13.15 13.06	247.29 246.69 231.59 - 0.06 0.11 0.38 0.37 0.37 247.67 247.11 232.07 5.80 5.67 5.58 241.87 241.45 226.48 5.76 5.61 6.35 103.85 103.85 - 27.71 27.71 - 22.31 26.06 26.49 17.25 17.26 - 0.91 0.89 0.91 4.13 2.34 197.33 199.28 202.01 203.09 204.90 208.35 13.15 13.06 13.49	247.29 246.69 231.59 244.60 - 0.06 0.11 0.15 0.38 0.37 0.37 0.37 247.67 247.11 232.07 245.11 5.80 5.67 5.58 5.67 241.87 241.45 226.48 239.44 5.76 5.61 6.35 5.94 103.85 - - - 27.71 27.71 - - 21.17 21.17 - - 22.31 26.06 26.49 - 17.25 17.26 - - 0.91 0.89 0.91 0.91 4.13 2.34 2.34 202.01 203.72 203.09 204.90 208.35 209.66 13.15 13.06 13.49 15.89	247.29 246.69 231.59 244.60 242.84 - 0.06 0.11 0.15 0.15 0.38 0.37 0.37 0.37 0.37 247.67 247.11 232.07 245.11 243.36 5.80 5.67 5.58 5.67 5.73 241.87 241.45 226.48 239.44 237.64 5.76 5.61 6.35 5.94 6.07 103.85 103.85 - - - 27.71 27.71 - - - 21.17 21.17 - - - 22.31 26.06 26.49 - - - 17.25 17.26 - - - - 0.91 0.89 0.91 0.91 - - 4.13 2.34 202.01 203.72 203.53 203.09 204.90 208.35 209.66 209.60 13.15 13.06 13.49 15.89 10.33	247.29 246.69 231.59 244.60 242.84 247.28 - 0.06 0.11 0.15 0.15 0.16 0.38 0.37 0.37 0.37 0.37 0.37 247.67 247.11 232.07 245.11 243.36 247.80 5.80 5.67 5.58 5.67 5.73 5.69 241.87 241.45 226.48 239.44 237.64 242.11 5.76 5.61 6.35 5.94 6.07 6.15 103.85 103.85 - - - - 27.71 27.71 - - - - 21.17 21.17 - - - - 22.31 26.06 26.49 - - - - 17.25 17.26 - - - - - 0.91 0.89 0.91 0.91 - - - 4.13 <t< td=""><td>247.29 246.69 231.59 244.60 242.84 247.28 244.57 - 0.06 0.11 0.15 0.15 0.16 0.17 0.38 0.37 0.37 0.37 0.37 0.37 0.37 247.67 247.11 232.07 245.11 243.36 247.80 245.11 5.80 5.67 5.58 5.67 5.73 5.69 5.77 241.87 241.45 226.48 239.44 237.64 242.11 239.33 5.76 5.61 6.35 5.94 6.07 6.15 6.12 103.85 - - - - - - 27.71 27.71 - - - - - 21.17 21.17 - - - - - - 22.31 26.06 26.49 - - - - - - - - - - - <td< td=""><td>247.29 246.69 231.59 244.60 242.84 247.28 244.57 237.22 - 0.06 0.11 0.15 0.15 0.16 0.17 0.20 0.38 0.37 0.37 0.37 0.37 0.37 0.37 0.37 247.67 247.11 232.07 245.11 243.36 247.80 245.11 237.79 5.80 5.67 5.58 5.67 5.73 5.69 5.77 6.65 241.87 241.45 226.48 239.44 237.64 242.11 239.33 231.13 5.76 5.61 6.35 5.94 6.07 6.15 6.12 5.92 103.85 103.85 - - - - - - - 27.71 27.71 - - - - - - - 22.31 26.06 26.49 - - - - - - - -</td><td>247.29 246.69 231.59 244.60 242.84 247.28 244.57 237.22 244.03 - 0.06 0.11 0.15 0.15 0.16 0.17 0.20 0.13 0.38 0.37</td><td>247.29 246.69 231.59 244.60 242.84 247.28 244.57 237.22 244.03 243.60 - 0.06 0.11 0.15 0.15 0.16 0.17 0.20 0.13 0.15 0.38 0.37</td><td>247.29 246.69 231.59 244.60 242.84 247.28 244.57 237.22 244.03 243.60 243.74 - 0.06 0.11 0.15 0.15 0.16 0.17 0.20 0.13 0.15 0.15 0.38 0.37</td></td<><td>247.29 246.69 231.59 244.60 242.84 247.28 244.57 237.22 244.03 243.60 243.74 243.75 - 0.06 0.11 0.15 0.15 0.16 0.17 0.20 0.13 0.15 0.15 0.15 0.38 0.37<!--</td--><td>247.29 246.69 231.59 244.60 242.84 247.28 244.57 237.22 244.03 243.60 243.74 243.75 243.09 - 0.06 0.11 0.15 0.15 0.15 0.15 0.13 0.37 0</td><td>247.29 246.69 231.59 244.60 242.84 247.28 244.57 237.22 244.03 243.60 243.74 243.75 243.09 242.52 - 0.06 0.11 0.15 0.15 0.15 0.15 0.15 0.15 0.13 0.12 0.38 0.37 0.38 0.36 0.35 0.36 243.60 247.80 2425.11 225.11 225.11 225.11 227.11 227.11 227.11 23.61 285.31 238.65</td><td>247.29 246.69 231.59 244.60 242.84 247.28 244.57 237.22 244.03 243.60 243.74 243.75 243.09 242.52 0.57 0.06 0.11 0.15 0.15 0.16 0.17 0.20 0.13 0.15 0.15 0.15 0.13 0.12 247.67 247.11 232.07 245.11 243.60 247.80 245.11 237.79 244.52 244.11 244.25 244.66 243.59 243.09 0.57 5.80 5.67 5.58 5.67 5.73 5.69 5.77 6.65 5.92 5.60 5.61 5.78 5.61 0.17 241.87 241.45 226.48 239.44 237.64 242.11 239.33 231.13 238.60 238.51 238.65 238.65 237.81 237.41 0.40 103.85 103.85 </td></td></td></t<>	247.29 246.69 231.59 244.60 242.84 247.28 244.57 - 0.06 0.11 0.15 0.15 0.16 0.17 0.38 0.37 0.37 0.37 0.37 0.37 0.37 247.67 247.11 232.07 245.11 243.36 247.80 245.11 5.80 5.67 5.58 5.67 5.73 5.69 5.77 241.87 241.45 226.48 239.44 237.64 242.11 239.33 5.76 5.61 6.35 5.94 6.07 6.15 6.12 103.85 - - - - - - 27.71 27.71 - - - - - 21.17 21.17 - - - - - - 22.31 26.06 26.49 - - - - - - - - - - - <td< td=""><td>247.29 246.69 231.59 244.60 242.84 247.28 244.57 237.22 - 0.06 0.11 0.15 0.15 0.16 0.17 0.20 0.38 0.37 0.37 0.37 0.37 0.37 0.37 0.37 247.67 247.11 232.07 245.11 243.36 247.80 245.11 237.79 5.80 5.67 5.58 5.67 5.73 5.69 5.77 6.65 241.87 241.45 226.48 239.44 237.64 242.11 239.33 231.13 5.76 5.61 6.35 5.94 6.07 6.15 6.12 5.92 103.85 103.85 - - - - - - - 27.71 27.71 - - - - - - - 22.31 26.06 26.49 - - - - - - - -</td><td>247.29 246.69 231.59 244.60 242.84 247.28 244.57 237.22 244.03 - 0.06 0.11 0.15 0.15 0.16 0.17 0.20 0.13 0.38 0.37</td><td>247.29 246.69 231.59 244.60 242.84 247.28 244.57 237.22 244.03 243.60 - 0.06 0.11 0.15 0.15 0.16 0.17 0.20 0.13 0.15 0.38 0.37</td><td>247.29 246.69 231.59 244.60 242.84 247.28 244.57 237.22 244.03 243.60 243.74 - 0.06 0.11 0.15 0.15 0.16 0.17 0.20 0.13 0.15 0.15 0.38 0.37</td></td<> <td>247.29 246.69 231.59 244.60 242.84 247.28 244.57 237.22 244.03 243.60 243.74 243.75 - 0.06 0.11 0.15 0.15 0.16 0.17 0.20 0.13 0.15 0.15 0.15 0.38 0.37<!--</td--><td>247.29 246.69 231.59 244.60 242.84 247.28 244.57 237.22 244.03 243.60 243.74 243.75 243.09 - 0.06 0.11 0.15 0.15 0.15 0.15 0.13 0.37 0</td><td>247.29 246.69 231.59 244.60 242.84 247.28 244.57 237.22 244.03 243.60 243.74 243.75 243.09 242.52 - 0.06 0.11 0.15 0.15 0.15 0.15 0.15 0.15 0.13 0.12 0.38 0.37 0.38 0.36 0.35 0.36 243.60 247.80 2425.11 225.11 225.11 225.11 227.11 227.11 227.11 23.61 285.31 238.65</td><td>247.29 246.69 231.59 244.60 242.84 247.28 244.57 237.22 244.03 243.60 243.74 243.75 243.09 242.52 0.57 0.06 0.11 0.15 0.15 0.16 0.17 0.20 0.13 0.15 0.15 0.15 0.13 0.12 247.67 247.11 232.07 245.11 243.60 247.80 245.11 237.79 244.52 244.11 244.25 244.66 243.59 243.09 0.57 5.80 5.67 5.58 5.67 5.73 5.69 5.77 6.65 5.92 5.60 5.61 5.78 5.61 0.17 241.87 241.45 226.48 239.44 237.64 242.11 239.33 231.13 238.60 238.51 238.65 238.65 237.81 237.41 0.40 103.85 103.85 </td></td>	247.29 246.69 231.59 244.60 242.84 247.28 244.57 237.22 - 0.06 0.11 0.15 0.15 0.16 0.17 0.20 0.38 0.37 0.37 0.37 0.37 0.37 0.37 0.37 247.67 247.11 232.07 245.11 243.36 247.80 245.11 237.79 5.80 5.67 5.58 5.67 5.73 5.69 5.77 6.65 241.87 241.45 226.48 239.44 237.64 242.11 239.33 231.13 5.76 5.61 6.35 5.94 6.07 6.15 6.12 5.92 103.85 103.85 - - - - - - - 27.71 27.71 - - - - - - - 22.31 26.06 26.49 - - - - - - - -	247.29 246.69 231.59 244.60 242.84 247.28 244.57 237.22 244.03 - 0.06 0.11 0.15 0.15 0.16 0.17 0.20 0.13 0.38 0.37	247.29 246.69 231.59 244.60 242.84 247.28 244.57 237.22 244.03 243.60 - 0.06 0.11 0.15 0.15 0.16 0.17 0.20 0.13 0.15 0.38 0.37	247.29 246.69 231.59 244.60 242.84 247.28 244.57 237.22 244.03 243.60 243.74 - 0.06 0.11 0.15 0.15 0.16 0.17 0.20 0.13 0.15 0.15 0.38 0.37	247.29 246.69 231.59 244.60 242.84 247.28 244.57 237.22 244.03 243.60 243.74 243.75 - 0.06 0.11 0.15 0.15 0.16 0.17 0.20 0.13 0.15 0.15 0.15 0.38 0.37 </td <td>247.29 246.69 231.59 244.60 242.84 247.28 244.57 237.22 244.03 243.60 243.74 243.75 243.09 - 0.06 0.11 0.15 0.15 0.15 0.15 0.13 0.37 0</td> <td>247.29 246.69 231.59 244.60 242.84 247.28 244.57 237.22 244.03 243.60 243.74 243.75 243.09 242.52 - 0.06 0.11 0.15 0.15 0.15 0.15 0.15 0.15 0.13 0.12 0.38 0.37 0.38 0.36 0.35 0.36 243.60 247.80 2425.11 225.11 225.11 225.11 227.11 227.11 227.11 23.61 285.31 238.65</td> <td>247.29 246.69 231.59 244.60 242.84 247.28 244.57 237.22 244.03 243.60 243.74 243.75 243.09 242.52 0.57 0.06 0.11 0.15 0.15 0.16 0.17 0.20 0.13 0.15 0.15 0.15 0.13 0.12 247.67 247.11 232.07 245.11 243.60 247.80 245.11 237.79 244.52 244.11 244.25 244.66 243.59 243.09 0.57 5.80 5.67 5.58 5.67 5.73 5.69 5.77 6.65 5.92 5.60 5.61 5.78 5.61 0.17 241.87 241.45 226.48 239.44 237.64 242.11 239.33 231.13 238.60 238.51 238.65 238.65 237.81 237.41 0.40 103.85 103.85 </td>	247.29 246.69 231.59 244.60 242.84 247.28 244.57 237.22 244.03 243.60 243.74 243.75 243.09 - 0.06 0.11 0.15 0.15 0.15 0.15 0.13 0.37 0	247.29 246.69 231.59 244.60 242.84 247.28 244.57 237.22 244.03 243.60 243.74 243.75 243.09 242.52 - 0.06 0.11 0.15 0.15 0.15 0.15 0.15 0.15 0.13 0.12 0.38 0.37 0.38 0.36 0.35 0.36 243.60 247.80 2425.11 225.11 225.11 225.11 227.11 227.11 227.11 23.61 285.31 238.65	247.29 246.69 231.59 244.60 242.84 247.28 244.57 237.22 244.03 243.60 243.74 243.75 243.09 242.52 0.57 0.06 0.11 0.15 0.15 0.16 0.17 0.20 0.13 0.15 0.15 0.15 0.13 0.12 247.67 247.11 232.07 245.11 243.60 247.80 245.11 237.79 244.52 244.11 244.25 244.66 243.59 243.09 0.57 5.80 5.67 5.58 5.67 5.73 5.69 5.77 6.65 5.92 5.60 5.61 5.78 5.61 0.17 241.87 241.45 226.48 239.44 237.64 242.11 239.33 231.13 238.60 238.51 238.65 238.65 237.81 237.41 0.40 103.85 103.85

Gold Coast Health Plan Statement of Cash Flows Month Ended March 31, 2012

Cash Flow From Operating Activities	
Collected Premium	51,942,498
Miscellaneous Income	13,833
Paid Claims	
Medical & Hospital Expenses	(13,054,973)
Pharmacy	(3,356,649)
Capitation	(620,892)
Reinsurance of Claims	(91,244)
Reinsurance Recoveries	-
Payment of Withhold / Risk Sharing Incentive	-
Paid Administration	(3,208,751)
Repay Initial Net Liabilities	-
MCO Taxes Expense	-
Net Cash Provided by Operating Activities	31,623,822
Cash Flow From Investing/Financing Activities	
Proceeds from Paid in Surplus/Issuance of Stock	-
Costs of Capitalization	-
Net Acquisition of Property/Equipment	-
Net Cash Provided by Investing/Financing	-
Net Cash Flow	31,623,822
Cash and Cash Equivalents (Beg. of Period)	21,450,897
	21,450,897 53,074,719
Cash and Cash Equivalents (Beg. of Period)	21,450,897
Cash and Cash Equivalents (Beg. of Period)	21,450,897 53,074,719
Cash and Cash Equivalents (Beg. of Period) Cash and Cash Equivalents (End of Period)	21,450,897 53,074,719
Cash and Cash Equivalents (Beg. of Period) Cash and Cash Equivalents (End of Period) Adjustment to Reconcile Net Income to Net	21,450,897 53,074,719
Cash and Cash Equivalents (Beg. of Period) Cash and Cash Equivalents (End of Period) Adjustment to Reconcile Net Income to Net Cash Flow	21,450,897 53,074,719 31,623,822
Cash and Cash Equivalents (Beg. of Period) Cash and Cash Equivalents (End of Period) Adjustment to Reconcile Net Income to Net Cash Flow Net Income/(Loss)	21,450,897 53,074,719 31,623,822 750,595
Cash and Cash Equivalents (Beg. of Period) Cash and Cash Equivalents (End of Period) Adjustment to Reconcile Net Income to Net Cash Flow Net Income/(Loss) Depreciation & Amortization	21,450,897 53,074,719 31,623,822 750,595 1,461
Cash and Cash Equivalents (Beg. of Period) Cash and Cash Equivalents (End of Period) Adjustment to Reconcile Net Income to Net Cash Flow Net Income/(Loss) Depreciation & Amortization Decrease/(Increase) in Receivables	21,450,897 53,074,719 31,623,822 750,595 1,461 25,691,640
Cash and Cash Equivalents (Beg. of Period) Cash and Cash Equivalents (End of Period) Adjustment to Reconcile Net Income to Net Cash Flow Net Income/(Loss) Depreciation & Amortization Decrease/(Increase) in Receivables Decrease/(Increase) in Prepaids & Other Current Assets	21,450,897 53,074,719 31,623,822 750,595 1,461 25,691,640 (46,374)
Cash and Cash Equivalents (Beg. of Period) Cash and Cash Equivalents (End of Period) Adjustment to Reconcile Net Income to Net Cash Flow Net Income/(Loss) Depreciation & Amortization Decrease/(Increase) in Receivables Decrease/(Increase) in Prepaids & Other Current Assets (Decrease)/Increase in Payables	21,450,897 53,074,719 31,623,822 750,595 1,461 25,691,640 (46,374) (1,259,263)
Cash and Cash Equivalents (Beg. of Period) Cash and Cash Equivalents (End of Period) Adjustment to Reconcile Net Income to Net Cash Flow Net Income/(Loss) Depreciation & Amortization Decrease/(Increase) in Receivables Decrease/(Increase) in Prepaids & Other Current Assets (Decrease)/Increase in Payables (Decrease)/Increase in LT Liabilities	21,450,897 53,074,719 31,623,822 750,595 1,461 25,691,640 (46,374) (1,259,263)
Cash and Cash Equivalents (Beg. of Period) Cash and Cash Equivalents (End of Period) Adjustment to Reconcile Net Income to Net Cash Flow Net Income/(Loss) Depreciation & Amortization Decrease/(Increase) in Receivables Decrease/(Increase) in Prepaids & Other Current Assets (Decrease)/Increase in Payables (Decrease)/Increase in LT Liabilities Purchase of fixed Assets	21,450,897 53,074,719 31,623,822 750,595 1,461 25,691,640 (46,374) (1,259,263)
Cash and Cash Equivalents (Beg. of Period) Cash and Cash Equivalents (End of Period) Adjustment to Reconcile Net Income to Net Cash Flow Net Income/(Loss) Depreciation & Amortization Decrease/(Increase) in Receivables Decrease/(Increase) in Prepaids & Other Current Assets (Decrease)/Increase in Payables (Decrease)/Increase in LT Liabilities Purchase of fixed Assets Changes in Withhold / Risk Incentive Pool	21,450,897 53,074,719 31,623,822 750,595 1,461 25,691,640 (46,374) (1,259,263) (80,000)
Cash and Cash Equivalents (Beg. of Period) Cash and Cash Equivalents (End of Period) Adjustment to Reconcile Net Income to Net Cash Flow Net Income/(Loss) Depreciation & Amortization Decrease/(Increase) in Receivables Decrease/(Increase) in Prepaids & Other Current Assets (Decrease)/Increase in Payables (Decrease)/Increase in LT Liabilities Purchase of fixed Assets Changes in Withhold / Risk Incentive Pool Change in MCO Tax Liability	21,450,897 53,074,719 31,623,822 750,595 1,461 25,691,640 (46,374) (1,259,263) (80,000)
Cash and Cash Equivalents (Beg. of Period) Cash and Cash Equivalents (End of Period) Adjustment to Reconcile Net Income to Net Cash Flow Net Income/(Loss) Depreciation & Amortization Decrease/(Increase) in Receivables Decrease/(Increase) in Prepaids & Other Current Assets (Decrease)/Increase in Payables (Decrease)/Increase in LT Liabilities Purchase of fixed Assets Changes in Withhold / Risk Incentive Pool Change in MCO Tax Liability Changes in Claims and Capitation Payable	21,450,897 53,074,719 31,623,822 750,595 1,461 25,691,640 (46,374) (1,259,263) (80,000)

Gold Coast Health Plan Statement of Cash Flows Nine Months Ended March 31, 2012

Collected Premium 139,648 Paid Claims Medical & Hospital Expenses (128,581,931) Pharmacy (23,837,946) Capitation (5,633,525) Reinsurance of Claims (740,039) Reinsurance Recoveries Payment of Withhold / Risk Sharing Incentive Paid Administration (16,969,910) Repay Initial Net Liabilities MCO Taxes Expense (3,640,523) Net Cash Provided by Operating Activities Proceeds from Paid in Surplus/Issuance of Stock Costs of Capitalization 5 Net Acquisition of Property/Equipment (20,731) Net Cash Provided/(Used) by Investing/Financing (20,731) Net Cash Flow Cash and Cash Equivalents (Beg. of Period) 660,697 Cash and Cash Equivalents (End of Period) 53,074,719 Each and Cash Equivalents (End of Period) 53,074,719 Adjustment to Reconcile Net Income to Net Cash Flow Net (Loss) Income 9,136,884 Depreciation & Amortization 13,491 Decrease/(Increase) in Receivables (28,17,141) Decrease/(Increase) in Receivables (28,17,141) Decrease/(Increase in ET Liabilities (678,333) Purchase of fixed Assets (20,731) Changes in Withhold / Risk Incentive Pool Change in MCO Tax Liability 1,851,653 Changes in Claims and Capitation Payable (22,825,861) Changes in IBNR 52,414,022 Net Cash Flow from Operating Activities 52,414,022	Cash Flow From Operating Activities	
Miscellaneous Income Paid Claims Medical & Hospital Expenses Medical & Hospital Expenses Medical & Hospital Expenses Pharmacy Capitation Capitation Reinsurance of Claims Reinsurance Recoveries Payment of Withhold / Risk Sharing Incentive Paid Administration Repay Initial Net Liabilities MCO Taxes Expense Net Cash Provided by Operating Activities Proceeds from Paid in Surplus/Issuance of Stock Costs of Capitalization Net Acquisition of Property/Equipment Net Cash Provided/(Used) by Investing/Financing Net Cash Provided/(Used) by Investing/Financing Cash and Cash Equivalents (Beg. of Period) Cash and Cash Equivalents (End of Period) Adjustment to Reconcile Net Income to Net Cash Flow Net (Loss) Income Depreciation & Amortization Net Cash Provided/(Used) by Investing/Financing Adjustment to Reconcile Net Income to Net Cash Flow Net (Loss) Income Depreciation & Amortization 13,491 Decrease/(Increase) in Receivables (2,817,141) Decrease/(Increase) in Prepaids & Other Current Assets (924,477) (Decrease)/Increase in LT Liabilities (Adjustment of Receivables (Decrease)/Increase in LT Liabilities (Adjustment of Receivables (Decrease)/Increase in LT Liabilities (Adjustment of Receivables (Decrease)/Increase in LT Liabilities (Adjustment of Receivables (Decrease)/Increase in LT Liabilities (Adjustment of Receivables (Decrease)/Increase in LT Liabilities (Adjustment of Receivables (Decrease)/Increase in LT Liabilities (Adjustment of Receivables (Decrease)/Increase in LT Liabilities (Adjustment of Receivables (Adjustme	-	231,698,980
Medical & Hospital Expenses (128,581,931) Pharmacy (23,837,946) Capitation (5,633,525) Reinsurance of Claims (740,039) Reinsurance Recoveries Payment of Withhold / Risk Sharing Incentive Paid Administration (16,969,910) Repay Initial Net Liabilities MCO Taxes Expense (3,640,523) Net Cash Provided by Operating Activities Proceeds from Paid in Surplus/Issuance of Stock Costs of Capitalization (20,731) Net Acquisition of Property/Equipment (20,731) Net Cash Provided/(Used) by Investing/Financing (20,731) Net Cash Equivalents (Beg. of Period) (53,074,719) S2,414,022 Adjustment to Reconcile Net Income to Net Cash Flow Net (Loss) Income (9,136,884) Depreciation & Amortization (13,491) Decrease/(Increase) in Receivables (22,817,141) Decrease/(Increase) in Prepaids & Other Current Assets (924,477) (Decrease)/Increase in Payables (721,606) (Decrease)/Increase in Payables (721,606) (Decrease)/Increase in Payables (721,606) (Decrease)/Increase in LT Liabilities (678,333) Purchase of fixed Assets (20,731) Changes in Withhold / Risk Incentive Pool Change in MCO Tax Liability (1,851,653) Changes in IBNR (23,748,422) S2,414,022	Miscellaneous Income	
Pharmacy (23,837,946) Capitation (5,633,525) Reinsurance of Claims (740,039) Reinsurance Recoveries Payment of Withhold / Risk Sharing Incentive Paid Administration (16,969,910) Repay Initial Net Liabilities MCO Taxes Expense (3,640,523) Net Cash Provided by Operating Activities Proceeds from Paid in Surplus/Issuance of Stock Costs of Capitalization (20,731) Net Cash Provided/(Used) by Investing/Financing (20,731) Net Cash Provided/(Used) by Investing/Financing (20,731) Net Cash Flow 52,414,022 Cash and Cash Equivalents (Beg. of Period) 660,697 Cash and Cash Equivalents (End of Period) 53,074,719 52,414,022 Adjustment to Reconcile Net Income to Net Cash Flow Net (Loss) Income 9,136,884 Depreciation & Amortization 13,491 Decrease/(Increase) in Receivables (2,817,141) Decrease/(Increase) in Receivables (2,817,141) Decrease/(Increase in Payables (721,606) (Decrease)/Increase in Payables (721,606) (Decrease)/Increase in LT Liabilities (678,333) Purchase of fixed Assets (20,731) Changes in Withhold / Risk Incentive Pool Change in MCO Tax Liability 1,851,653 Changes in Claims and Capitation Payable 22,825,861 Changes in IBNR 23,748,422 52,414,022	Paid Claims	
Capitation (5,633,525) Reinsurance of Claims (740,039) Reinsurance Recoveries Payment of Withhold / Risk Sharing Incentive Paid Administration (16,969,910) Repay Initial Net Liabilities MCO Taxes Expense (3,640,523) Net Cash Provided by Operating Activities Proceeds from Paid in Surplus/Issuance of Stock Costs of Capitalization - Net Acquisition of Property/Equipment (20,731) Net Cash Provided/(Used) by Investing/Financing (20,731) Net Cash Flow 52,414,022 Cash and Cash Equivalents (Beg. of Period) 660,697 Cash and Cash Equivalents (End of Period) 53,074,719 52,414,022 Adjustment to Reconcile Net Income to Net Cash Flow 9,136,884 Depreciation & Amortization 13,491 Decrease/(Increase) in Receivables (2,817,141) Decrease/(Increase) in Receivables (2,817,141) Decrease/(Increase) in Prepaids & Other Current Assets (924,477) (Decrease)/Increase in Payables (721,606) (Decrease)/Increase in Payables (678,333) Purchase of fixed Assets (20,731) Changes in Withhold / Risk Incentive Pool - Change in MCO Tax Liability 1,851,653 Changes in Claims and Capitation Payable 22,825,861 Changes in IBNR 23,748,422	Medical & Hospital Expenses	(128,581,931)
Reinsurance of Claims Reinsurance Recoveries Payment of Withhold / Risk Sharing Incentive Paid Administration Repay Initial Net Liabilities MCO Taxes Expense Net Cash Provided by Operating Activities Cash Flow From Investing/Financing Activities Proceeds from Paid in Surplus/Issuance of Stock Costs of Capitalization Net Acquisition of Property/Equipment Net Cash Provided/(Used) by Investing/Financing Net Cash Provided/(Used) by Investing/Financing Cash and Cash Equivalents (Beg. of Period) Cash and Cash Equivalents (End of Period) Adjustment to Reconcile Net Income to Net Cash Flow Net (Loss) Income Depreciation & Amortization Decrease/(Increase) in Receivables Depreciation & Amortization Decrease/(Increase) in Prepaids & Other Current Assets (Decrease)/Increase in Payables (Decrease)/Increase in LT Liabilities (Decrease)/Increase in LT Liabilities (Decrease)/Increase in LT Liabilities (Canges in Withhold / Risk Incentive Pool Changes in Withhold / Risk Incentive Pool Changes in Claims and Capitation Payable Changes in IBNR 22,825,861 Changes in IBNR 23,748,422 52,414,022	Pharmacy	(23,837,946)
Reinsurance Recoveries Payment of Withhold / Risk Sharing Incentive Paid Administration Repay Initial Net Liabilities MCO Taxes Expense (3,640,523) Net Cash Provided by Operating Activities Proceeds from Paid in Surplus/Issuance of Stock Costs of Capitalization Net Acquisition of Property/Equipment Net Cash Provided/(Used) by Investing/Financing Ret Cash and Cash Equivalents (Beg. of Period) Cash and Cash Equivalents (End of Period) Cash and Cash Equivalents (End of Period) Adjustment to Reconcile Net Income to Net Cash Flow Net (Loss) Income Net	Capitation	(5,633,525)
Payment of Withhold / Risk Sharing Incentive Paid Administration Repay Initial Net Liabilities MCO Taxes Expense (3,640,523) Net Cash Provided by Operating Activities Cash Flow From Investing/Financing Activities Proceeds from Paid in Surplus/Issuance of Stock Costs of Capitalization Net Acquisition of Property/Equipment Net Cash Provided/(Used) by Investing/Financing Cash and Cash Equivalents (Beg. of Period) Cash and Cash Equivalents (End of Period) Cash and Cash Equivalents (End of Period) Adjustment to Reconcile Net Income to Net Cash Flow Net (Loss) Income Depreciation & Amortization Decrease/(Increase) in Receivables Depreciation & Amortization Decrease/(Increase) in Prepaids & Other Current Assets (924,477) (Decrease)/Increase in LT Liabilities (678,333) Purchase of fixed Assets Changes in Withhold / Risk Incentive Pool Change in MCO Tax Liability Changes in Claims and Capitation Payable Cash Plan (16,969,910) 23,644,022 Cash Flow Cash Flow Net (Loss) Income 9,136,884 9,1	Reinsurance of Claims	(740,039)
Paid Administration Repay Initial Net Liabilities MCO Taxes Expense MCO Taxes Expense MCO Taxes Expense Net Cash Provided by Operating Activities Cash Flow From Investing/Financing Activities Proceeds from Paid in Surplus/Issuance of Stock Costs of Capitalization Net Acquisition of Property/Equipment Net Cash Provided/(Used) by Investing/Financing Cash and Cash Provided/(Used) by Investing/Financing Cash and Cash Equivalents (Beg. of Period) Cash and Cash Equivalents (End of Period) Adjustment to Reconcile Net Income to Net Cash Flow Net (Loss) Income Depreciation & Amortization Decrease/(Increase) in Receivables Depreciation & Amortization Decrease/(Increase) in Prepaids & Other Current Assets (Decrease)/Increase in Payables (Decrease)/Increase in Li Liabilities (Decrease)/Increase in Li Liabilities (Decrease)/Increase in Liabilities Changes in Withhold / Risk Incentive Pool Change in MCO Tax Liability Changes in Claims and Capitation Payable Changes in IBNR 23,748,422 52,414,022	Reinsurance Recoveries	
Repay Initial Net Liabilities MCO Taxes Expense (3,640,523) Net Cash Provided by Operating Activities Cash Flow From Investing/Financing Activities Proceeds from Paid in Surplus/Issuance of Stock Costs of Capitalization Net Acquisition of Property/Equipment Net Cash Provided/(Used) by Investing/Financing Cash and Cash Equivalents (Beg. of Period) Cash and Cash Equivalents (End of Period) Cash and Cash Equivalents (End of Period) Adjustment to Reconcile Net Income to Net Cash Flow Net (Loss) Income Depreciation & Amortization Decrease/(Increase) in Receivables Decrease/(Increase) in Prepaids & Other Current Assets (Decrease)/Increase in Payables (Decrease)/Increase in Li Liabilities (Decrease)/Increase in LT Liabilities (Decrease)/Increase in Withhold / Risk Incentive Pool Changes in Withhold / Risk Incentive Pool Changes in IBNR Cash Flow 1,640,523 2,6414,022 2,825,861 2,7414,022	Payment of Withhold / Risk Sharing Incentive	
MCO Taxes Expense Net Cash Provided by Operating Activities Cash Flow From Investing/Financing Activities Proceeds from Paid in Surplus/Issuance of Stock Costs of Capitalization Net Acquisition of Property/Equipment Net Cash Provided/(Used) by Investing/Financing Cash and Cash Equivalents (Beg. of Period) Cash and Cash Equivalents (End of Period) Cash and Cash Equivalents (End of Period) Adjustment to Reconcile Net Income to Net Cash Flow Net (Loss) Income Net (Loss) Income Depreciation & Amortization Decrease/(Increase) in Receivables Decrease/(Increase) in Prepaids & Other Current Assets (Decrease)/Increase in Labilities (Decrease)/Increase in Labilities (Decrease)/Increase in Labilities (Decrease)/Increase in Claims and Capitation Payable Changes in IBNR 23,748,422 52,414,022	Paid Administration	(16,969,910)
Cash Flow From Investing/Financing Activities Proceeds from Paid in Surplus/Issuance of Stock Costs of Capitalization Net Acquisition of Property/Equipment Net Cash Provided/(Used) by Investing/Financing Net Cash Provided/(Used) by Investing/Financing Net Cash Flow 52,414,022 Cash and Cash Equivalents (Beg. of Period) Cash and Cash Equivalents (End of Period) 53,074,719 52,414,022 Adjustment to Reconcile Net Income to Net Cash Flow Net (Loss) Income Net (Loss) Income Depreciation & Amortization Decrease/(Increase) in Receivables (Decrease)/Increase in Payables (Decrease)/Increase in Payables (Decrease)/Increase in LT Liabilities (Decrease)/Increase in LT Liabilities (Decrease)/Increase in LT Liabilities (Decrease)/Increase in Mithhold / Risk Incentive Pool Changes in Withhold / Risk Incentive Pool Changes in Claims and Capitation Payable Changes in IBNR 23,748,422 52,414,022	Repay Initial Net Liabilities	
Cash Flow From Investing/Financing Activities Proceeds from Paid in Surplus/Issuance of Stock Costs of Capitalization Net Acquisition of Property/Equipment (20,731) Net Cash Provided/(Used) by Investing/Financing (20,731) Net Cash Flow 52,414,022 Cash and Cash Equivalents (Beg. of Period) 660,697 Cash and Cash Equivalents (End of Period) 53,074,719 52,414,022 Adjustment to Reconcile Net Income to Net Cash Flow Net (Loss) Income 9,136,884 Depreciation & Amortization 13,491 Decrease/(Increase) in Receivables (2,817,141) Decrease/(Increase) in Prepaids & Other Current Assets (924,477) (Decrease)/Increase in Payables (721,606) (Decrease)/Increase in Lt Liabilities (678,333) Purchase of fixed Assets (20,731) Changes in Withhold / Risk Incentive Pool Change in MCO Tax Liability 1,851,653 Changes in Claims and Capitation Payable 22,825,861 Changes in IBNR 23,748,422	MCO Taxes Expense	(3,640,523)
Proceeds from Paid in Surplus/Issuance of Stock Costs of Capitalization Net Acquisition of Property/Equipment (20,731) Net Cash Provided/(Used) by Investing/Financing (20,731) Net Cash Flow 52,414,022 Cash and Cash Equivalents (Beg. of Period) Cash and Cash Equivalents (End of Period) 53,074,719 52,414,022 Adjustment to Reconcile Net Income to Net Cash Flow Net (Loss) Income Pepreciation & Amortization Decrease/(Increase) in Receivables Decrease/(Increase) in Prepaids & Other Current Assets (Decrease)/Increase in Payables (Decrease)/Increase in LT Liabilities (Decrease)/Increase in LT Liabili	Net Cash Provided by Operating Activities	52,434,753
Proceeds from Paid in Surplus/Issuance of Stock Costs of Capitalization Net Acquisition of Property/Equipment (20,731) Net Cash Provided/(Used) by Investing/Financing (20,731) Net Cash Flow 52,414,022 Cash and Cash Equivalents (Beg. of Period) Cash and Cash Equivalents (End of Period) 53,074,719 52,414,022 Adjustment to Reconcile Net Income to Net Cash Flow Net (Loss) Income Pepreciation & Amortization Decrease/(Increase) in Receivables Decrease/(Increase) in Prepaids & Other Current Assets (Decrease)/Increase in Payables (Decrease)/Increase in LT Liabilities (Decrease)/Increase in LT Liabili		
Costs of Capitalization Net Acquisition of Property/Equipment (20,731) Net Cash Provided/(Used) by Investing/Financing (20,731) Net Cash Provided/(Used) by Investing/Financing (20,731) Net Cash Flow 52,414,022 Cash and Cash Equivalents (Beg. of Period) Cash and Cash Equivalents (End of Period) 53,074,719 52,414,022 Adjustment to Reconcile Net Income to Net Cash Flow Net (Loss) Income Net (Loss) Income Perciation & Amortization Decrease/(Increase) in Receivables Decrease/(Increase) in Prepaids & Other Current Assets (924,477) (Decrease)/Increase in Payables (Decrease)/Increase in LT Liabilities (678,333) Purchase of fixed Assets (20,731) Changes in Withhold / Risk Incentive Pool Change in MCO Tax Liability 1,851,653 Changes in Claims and Capitation Payable Changes in IBNR 23,748,422 52,414,022		
Net Cash Provided/(Used) by Investing/Financing (20,731) Net Cash Provided/(Used) by Investing/Financing (20,731) Net Cash Flow 52,414,022 Cash and Cash Equivalents (Beg. of Period) Cash and Cash Equivalents (End of Period) 53,074,719 52,414,022 Adjustment to Reconcile Net Income to Net Cash Flow Net (Loss) Income Net (Loss) Income Depreciation & Amortization Decrease/(Increase) in Receivables Decrease/(Increase) in Prepaids & Other Current Assets (Decrease)/Increase in Payables (Decrease)/Increase in LT Liabilities (Decrease)/Increase in LT	·	-
Net Cash Provided/(Used) by Investing/Financing (20,731) Net Cash Flow Cash and Cash Equivalents (Beg. of Period) Cash and Cash Equivalents (End of Period) Adjustment to Reconcile Net Income to Net Cash Flow Net (Loss) Income Net (Loss) Income Period) Decrease/(Increase) in Receivables (Decrease)/Increase in Prepaids & Other Current Assets (Decrease)/Increase in Payables (Decrease)/Increase in LT Liabilities (Decrease)/Increase in LT L	•	-
Net Cash Flow Cash and Cash Equivalents (Beg. of Period) Cash and Cash Equivalents (End of Period) Adjustment to Reconcile Net Income to Net Cash Flow Net (Loss) Income Net (Loss) Income Period) Decrease/(Increase) in Receivables (2,817,141) Decrease/(Increase) in Prepaids & Other Current Assets (Decrease)/Increase in Payables (Decrease)/Increase in LT Liabilities (Decrease)/Increase in LT Liabilities (C721,606) (Decrease)/Increase in Withhold / Risk Incentive Pool Changes in Withhold / Risk Incentive Pool Changes in Claims and Capitation Payable Changes in IBNR 23,748,422 52,414,022		
Cash and Cash Equivalents (Beg. of Period) Cash and Cash Equivalents (End of Period) 53,074,719 52,414,022 Adjustment to Reconcile Net Income to Net Cash Flow Net (Loss) Income Net (Loss) Income Net (Increase) in Receivables Decrease/(Increase) in Receivables Decrease/(Increase) in Prepaids & Other Current Assets (924,477) (Decrease)/Increase in Payables (Decrease)/Increase in LT Liabilities (678,333) Purchase of fixed Assets (20,731) Changes in Withhold / Risk Incentive Pool Change in MCO Tax Liability 1,851,653 Changes in Claims and Capitation Payable 22,825,861 Changes in IBNR 23,748,422 52,414,022	Net Cash Provided/(Used) by Investing/Financing	(20,731)
Cash and Cash Equivalents (Beg. of Period) Cash and Cash Equivalents (End of Period) 53,074,719 52,414,022 Adjustment to Reconcile Net Income to Net Cash Flow Net (Loss) Income Net (Loss) Income Net (Increase) in Receivables Decrease/(Increase) in Receivables Decrease/(Increase) in Prepaids & Other Current Assets (924,477) (Decrease)/Increase in Payables (Decrease)/Increase in LT Liabilities (678,333) Purchase of fixed Assets (20,731) Changes in Withhold / Risk Incentive Pool Change in MCO Tax Liability 1,851,653 Changes in Claims and Capitation Payable 22,825,861 Changes in IBNR 23,748,422 52,414,022		
Cash and Cash Equivalents (End of Period) 53,074,719 52,414,022 Adjustment to Reconcile Net Income to Net Cash Flow Net (Loss) Income Net (Loss) Income Pereciation & Amortization Decrease/(Increase) in Receivables Decrease/(Increase) in Prepaids & Other Current Assets (924,477) (Decrease)/Increase in Payables (Decrease)/Increase in LT Liabilities (678,333) Purchase of fixed Assets (20,731) Changes in Withhold / Risk Incentive Pool Change in MCO Tax Liability Changes in Claims and Capitation Payable Changes in IBNR 23,748,422 52,414,022	Net Cash Flow	52,414,022
Cash and Cash Equivalents (End of Period) 53,074,719 52,414,022 Adjustment to Reconcile Net Income to Net Cash Flow Net (Loss) Income Net (Loss) Income Pereciation & Amortization Decrease/(Increase) in Receivables Decrease/(Increase) in Prepaids & Other Current Assets (924,477) (Decrease)/Increase in Payables (Decrease)/Increase in LT Liabilities (678,333) Purchase of fixed Assets (20,731) Changes in Withhold / Risk Incentive Pool Change in MCO Tax Liability Changes in Claims and Capitation Payable Changes in IBNR 23,748,422 52,414,022	Cook and Cook Emitted arts (Donald Davied)	660.607
Adjustment to Reconcile Net Income to Net Cash Flow Net (Loss) Income Depreciation & Amortization Decrease/(Increase) in Receivables Decrease/(Increase) in Prepaids & Other Current Assets (Decrease)/Increase in Payables (Decrease)/Increase in LT Liabilities (Decrease)/Increase in LT Liabilities (Decrease) in Withhold / Risk Incentive Pool Changes in Withhold / Risk Incentive Pool Changes in Claims and Capitation Payable Changes in IBNR 52,414,022		
Adjustment to Reconcile Net Income to Net Cash Flow Net (Loss) Income Depreciation & Amortization Decrease/(Increase) in Receivables (2,817,141) Decrease/(Increase) in Prepaids & Other Current Assets (924,477) (Decrease)/Increase in Payables (Decrease)/Increase in LT Liabilities (678,333) Purchase of fixed Assets (20,731) Changes in Withhold / Risk Incentive Pool Change in MCO Tax Liability 1,851,653 Changes in Claims and Capitation Payable 22,825,861 Changes in IBNR 23,748,422 52,414,022	Cash and Cash Equivalents (End of Period)	
Cash Flow Net (Loss) Income Depreciation & Amortization Decrease/(Increase) in Receivables (2,817,141) Decrease/(Increase) in Prepaids & Other Current Assets (924,477) (Decrease)/Increase in Payables (Decrease)/Increase in LT Liabilities (678,333) Purchase of fixed Assets (20,731) Changes in Withhold / Risk Incentive Pool Change in MCO Tax Liability 1,851,653 Changes in Claims and Capitation Payable Changes in IBNR 23,748,422 52,414,022		52,414,022
Cash Flow Net (Loss) Income Depreciation & Amortization Decrease/(Increase) in Receivables (2,817,141) Decrease/(Increase) in Prepaids & Other Current Assets (924,477) (Decrease)/Increase in Payables (Decrease)/Increase in LT Liabilities (678,333) Purchase of fixed Assets (20,731) Changes in Withhold / Risk Incentive Pool Change in MCO Tax Liability 1,851,653 Changes in Claims and Capitation Payable Changes in IBNR 23,748,422 52,414,022	Adjustment to Reconcile Net Income to Net	
Net (Loss) Income Depreciation & Amortization Decrease/(Increase) in Receivables (2,817,141) Decrease/(Increase) in Prepaids & Other Current Assets (924,477) (Decrease)/Increase in Payables (Decrease)/Increase in LT Liabilities (678,333) Purchase of fixed Assets (20,731) Changes in Withhold / Risk Incentive Pool Change in MCO Tax Liability 1,851,653 Changes in Claims and Capitation Payable Changes in IBNR 23,748,422 52,414,022		
Depreciation & Amortization 13,491 Decrease/(Increase) in Receivables (2,817,141) Decrease/(Increase) in Prepaids & Other Current Assets (924,477) (Decrease)/Increase in Payables (721,606) (Decrease)/Increase in LT Liabilities (678,333) Purchase of fixed Assets (20,731) Changes in Withhold / Risk Incentive Pool - Change in MCO Tax Liability 1,851,653 Changes in Claims and Capitation Payable 22,825,861 Changes in IBNR 23,748,422		9.136.884
Decrease/(Increase) in Receivables Decrease/(Increase) in Prepaids & Other Current Assets (924,477) (Decrease)/Increase in Payables (721,606) (Decrease)/Increase in LT Liabilities (678,333) Purchase of fixed Assets (20,731) Changes in Withhold / Risk Incentive Pool Change in MCO Tax Liability 1,851,653 Changes in Claims and Capitation Payable Changes in IBNR 23,748,422 52,414,022		
Decrease/(Increase) in Prepaids & Other Current Assets (Decrease)/Increase in Payables (Decrease)/Increase in LT Liabilities (Decrease)/Increase in LT Liabilities (Era, 333) (·	·
(Decrease)/Increase in Payables(721,606)(Decrease)/Increase in LT Liabilities(678,333)Purchase of fixed Assets(20,731)Changes in Withhold / Risk Incentive Pool-Change in MCO Tax Liability1,851,653Changes in Claims and Capitation Payable22,825,861Changes in IBNR23,748,42252,414,022		
(Decrease)/Increase in LT Liabilities (678,333) Purchase of fixed Assets (20,731) Changes in Withhold / Risk Incentive Pool Change in MCO Tax Liability 1,851,653 Changes in Claims and Capitation Payable 22,825,861 Changes in IBNR 23,748,422 52,414,022		
Purchase of fixed Assets (20,731) Changes in Withhold / Risk Incentive Pool Change in MCO Tax Liability 1,851,653 Changes in Claims and Capitation Payable 22,825,861 Changes in IBNR 23,748,422 52,414,022		
Changes in Withhold / Risk Incentive Pool Change in MCO Tax Liability 1,851,653 Changes in Claims and Capitation Payable 22,825,861 Changes in IBNR 23,748,422 52,414,022		
Change in MCO Tax Liability1,851,653Changes in Claims and Capitation Payable22,825,861Changes in IBNR23,748,42252,414,022	Changes in Withhold / Risk Incentive Pool	-
Changes in Claims and Capitation Payable22,825,861Changes in IBNR23,748,42252,414,022	_	1,851,653
Changes in IBNR 23,748,422 52,414,022	-	
	-	
Net Cash Flow from Operating Activities 52,414,022		52,414,022
	Net Cash Flow from Operating Activities	52,414,022

GOLD COAST HEALTH PLAN – BUSINESS STRATEGY AND OPERATIONS – OPERATIONAL REVIEW AND PRIORITIES

BUILDING BLOCKS FOR SUCCESS

5.	New	New	New	Other
	Products	Services		New
			Markets	Initiatives

Ease of implementation	
Effective arbitrage (ie Fees> Cost), product line/service line profitability	4. CONSIDERATION S FOR NEW
Market receptivity	INITIATIVES
Required capital/financial results (operate with appropriate margin)	

Excellent data collection, management, controls and reporting: Economic data Clinical data Customer service data • Internal operations data **INFRASTRUCTURE** • Financial management, reporting, accountability **BASIC** COLLECTIVELY DECISION SUPPORT DEVELOPMENT AND Excellent systems and access to best practices **PERFORMANCE** • Case Management **CRITERIA** Medical Management • Claims Management Excellent operations management, regulatory compliance Appropriate Pricing, Reserves Returns

	2. CRITICAL SUCCESS	S FACTORS	
Superior Programs	Superior Provider Network Physicians Mid-levels Acute care/facilities Alternate site	Effective Risk Management: Business risk - contracting Case management Medical management	Market Share

1. FOUNDATION

GOAL: MISSION, VISION, VALUES, OBJECTIVES "REASON FOR BEING"

- Improve Health of the Community
 - Patient Safety, Satisfaction
 - Employee Safety, Satisfaction
- Community Wellness Economic and Health

DRAFT April 23, 2012



Gold Coast Health Plan

January 1, 2012 - March 31, 2012 Pharmacy Plan Analysis

October 1, 2011 – December 31, 2011

Prepared by: Scott Holtmyer, R.Ph. sholtmyer@scriptcare.com





Current Plan

	Jan-Mar 2012
Total Cost	\$9,413,179
Member Paid	\$0
Plan Paid	\$9,413,179
Rx	212,328
Generics - Total Cost	\$3,912,496
Member Paid	\$0
Plan Paid	\$3,912,496
Rx	177,737
Months	æ
Average Enrollment	108,756
Member Paid Plan Paid Rx Enrollment	\$3,912,

Total cost to the plan was \$9,413,179 for the first quarter of 2012

	Jan-Mar 2012	
Average Enrollment	108,756	
Total Cost Per Month	\$3,137,726	
Member Paid Per Month	\$0	
Plan Paid Per Month	\$3,137,726	
Total Cost PMPM	\$28.85	
Member Paid PMPM	\$0.00	
Plan Paid PMPM	\$28.85	
Total Cost Per Rx	\$44.33	
Member Paid Per Rx	\$0.00	
Plan Paid Per Rx	\$44.33	
Rx PMPM	0.65	
Member Paid/Total Cost	%00'0	
Generic Utilization - Total Cost	41.56%	
By Plan Paid	41.56%	
By Rx	83.71%	

Generic utilization was 83.71%



ന



Summary

	Oct-Dec 2011	Jan-Mar 2012
Total Cost	\$9,016,315	\$9,413,179
Member Paid	\$0	\$
Plan Paid	\$9,016,315	\$9,413,179
RX	191,632	212,328
Generics - Total Cost	\$3,508,560	\$3,912,496
Member Paid	\$0	\$0
Plan Paid	\$3,508,560	\$3,912,496
RX	157,893	177,737
Months	ന	ĸ
Average Enrollment	109,347	108,756

prescription volume increased 10.8% Plan cost increased 4.4% while

Enrollment decreased 591 members quarter over quarter







Statistics

Average Enrollment 109,347 108,756 Utilizing Members 37,063 40,349 Total Cost Per Month \$0 \$0 Member Paid Per Month \$3,005,438 \$3,137,726 Plan Paid Per Month \$27.49 \$28.85 Total Cost PMPM \$0.00 \$0.00 Plan Paid PMPM \$27.49 \$28.85 Total Cost Per Rx \$47.05 \$44.33 Rx PMPM 0.58 0.65 Member Paid Fer Rx \$47.05 \$44.33 Rx PMPM 0.00% 0.00% Generic Utilization - Total Cost 38.91% 41.56% By Plan Paid 38.91% 41.56%		Oct-Dec 2011	Jan-Mar 2012	
\$3,005,438 \$3,13 \$0.05 \$27.49 \$27.49 \$27.49 \$47.05 \$47.05 \$0.00 \$47.05 0.00% 38.91%	Average Enrollment	109,347	108,756	-0.54%
\$3,005,438 \$3,118 \$005,438 \$3,118 \$27.49 \$0.00 \$27.49 \$47.05 \$0.00 \$47.05 0.58 0.00% 38.91% 438.91%	Utilizing Members	37,063	40,349	8.87%
\$3,005,438 \$3,13 \$27.49 \$0.00 \$27.49 \$47.05 \$0.00 \$47.05 0.00% 38.91%	Total Cost Per Month	\$3,005,438	\$3,137,726	4.40%
\$3,005,438 \$3,13 \$27.49 \$0.00 \$27.49 \$47.05 \$0.00 \$47.05 0.58 0.00% 38.91%	Member Paid Per Month	\$0	\$	
\$27.49 \$0.00 \$27.49 \$47.05 \$0.00 0.58 0.00% 38.91%	Plan Paid Per Month	\$3,005,438	\$3,137,726	4.40%
\$0.00 \$27.49 \$47.05 \$0.00 \$47.05 0.58 0.00% 138.91%	Total Cost PMPM	\$27.49	\$28.85	4.97%
\$27.49 \$ \$47.05 \$ \$0.00 847.05 \$ 0.58 0.00% (38.91% 4:	Member Paid PMPM	\$0.00	\$0.00	
\$47.05 \$0.00 \$47.05 0.58 0.00% (1.38.91% 38.91% 47.3	Plan Paid PMPM	\$27.49	\$28.85	4.97%
\$0.00 \$47.05 0.58 0.00% 38.91% 43.91%	Total Cost Per Rx	\$47.05	\$44.33	-5.77%
0.58 0.00% 38.91% 4	Member Paid Per Rx	\$0.00	\$0.00	
0.58 0.00% 38.91% 38.91%	Plan Paid Per Rx	\$47.05	\$44.33	-5.77%
0.00% 38.91% 38.91% 4	Rx PMPM	0.58	0.65	11.40%
38.91% 38.91%	Member Paid/Total Cost	0.00%	0.00%	
38.91%	Generic Utilization - Total Cost	38.91%	41.56%	2.65%
	By Plan Paid	38.91%	41.56%	2.65%
By Rx 83.71%	By Rx	82.39%	83.71%	1.31%

pharmacy benefit increased Utilizing members of the from 33.9% to 37.1% or 3,286 more utilizing members

decreased \$2.72 to \$44.33 Cost per prescription

Generic utilization increased 1.32 points quarter over quarter








Total Cost Trends

average monthly drug spend for Average total drug spend was \$3,137,726 per month. The the first 9 months was \$2,906,088

Average total drug spend was \$44.33 per prescription Average total cost was \$28.85 PMPM











Generic Utilization

Generic fill rate was 83.71% and cost the plan 41.56% of the total cost The average generic prescription cost \$22.01 Single source brands, including specialty products, accounted for 15.9% of prescriptions and 56.7% of the total cost The average single source brand cost \$158.21 and multi source was \$190.31

All Claims - Total Cost	\$9,413,179	Utilization by Number of Claims	Utilization by Plan Cost
Plan Paid	\$9,413,179	Brand Brand w /o	Brand
××	212,328	W /Jehendro	w /Generic \$166,906
Generics - Total Cost	\$3,912,496		
Plan Paid	\$3,912,496		Generic \$3,912,49
, X	177,737		9
Jtilization - Total Cost	41.56%		Brand w /o
Plan Paid	41.56%		\$5,333,77
æ	83.71%	Generic	
		177,737	





Plan Variance

	Oct-Dec 2011	Jan-Mar 2012	Variance
Total Cost/Rx	\$47.05	\$44.33	(\$520,656)
Percentage Paid By Plan	100.00%	100.00%	\$0
Rx/Member Per Month	0.58	0.65	\$968,673
Enrollment	109,347	108,756	(\$51,153)
# Months	æ	8	
Plan Paid	\$9,016,315	\$9,413,179	\$396,864

Plan cost increased \$396,864 quarter over quarter

The increase in prescriptions PMPM cost the plan \$968,673 and was partially offset by the decrease in cost per prescription and enrollment





Enrollment Statistics

Understanding your membership composition






Utilization By Age

Range	¥.	Member Paid	Plan Paid	% of Total	Per Rx
12 and Under	42,475	0\$	\$1,496,440	15.90%	\$35.23
13-18 Years	12,962	0\$	\$644,716	6.85%	\$49.74
19-30 Years	21,721	\$0	\$873,529	9.28%	\$40.22
31-45 Years	37,717	\$0	\$1,816,685	19.30%	\$48.17
46-49 Years	14,475	0\$	\$731,121	7.77%	\$50.51
50-59 Years	39,091	0\$	\$2,155,582	22.90%	\$55.14
60-64 Years	16,848	\$0	\$953,280	10.13%	\$56.58
65 and Over	27,039	\$	\$741,828	7.88%	\$27.44
Total	212,328	0\$	\$9,413,179	100.00%	\$44.33

The 50-59 age group spent 22.9% of the total drug spend with a census of 6,021





10



Age Variance


	Oct-Dec 201	ec 2011	Jan-M	Jan-Mar 2012	Plan Paid Vari	Plan Paid Variances - Increase/(Decrease)	crease)
	& X	Plan Paid	RX	Plan Paid	Total =	- - +	Avg Paid/Rx
12 and Under	34,661	\$1,330,699	39,969	\$1,496,440	\$165,741	\$203,784	(\$38,043)
13-18 Years	11,516	\$620,554	12,256	\$644,716	\$24,162	\$39,876	(\$15,714)
19-30 Years	18,849	\$834,418	20,060	\$873,529	\$39,111	\$53,609	(\$14,498)
31-45 Years	33,026	\$1,807,507	35,476	\$1,816,685	\$9,177	\$134,088	(\$124,911)
46-49 Years	12,677	\$670,030	13,729	\$731,121	\$61,090	\$55,602	\$5,488
50-59 Years	33,859	\$2,149,115	37,371	\$2,155,582	\$6,467	\$222,915	(\$216,448)
60-64 Years	15,048	\$871,363	16,181	\$953,280	\$81,916	\$65,607	\$16,309
65 and Over	21,877	\$732,629	25,911	\$741,828	\$9,199	\$135,093	(\$125,894)
	181,513	\$9,016,315	200,953	\$9,413,179	\$396,864	\$910,575	(\$513,711)

The 12 and under age group experienced the greatest increase quarter over quarter

Increase in volume is driving the increase in overall cost



Utilization by Highest Users





Top 1% translates to 1,088 members





Providers

Most plans offer a variety of provider types to their membership






Provider Utilization

	죖	%	<u>Plan Paid</u>	%
Retail				
Brand w/o Generic	33,090	15.58%	\$3,745,325	39.79%
Brand w/Generic	862	0.41%	\$158,399	1.68%
Generic	177,286	83.50%	\$3,711,543	39.43%
Total	211,238	99.49%	\$7,615,268	80.90%
Specialty				
Brand w/o Generic	617	0.29%	\$1,582,727	16.81%
Brand w/Generic	15	0.01%	\$8,506	0.09%
Generic	445	0.21%	\$200,418	2.13%
Total	1,077	0.51%	\$1,791,651	19.03%


The 1,077 specialty prescriptions was 0.51% of the prescription volume and 19.03% of total cost








Retail Chain Utilization





providers processed 55.4% of the total prescriptions The top 4 pharmacy





Specialty Statistics

Average Enrollment 109,347 Utilizing Members 329 Total Cost Per Month \$596,453 Member Paid Per Month \$596,453 Total Cost PMPM \$5.45 Member Paid PMPM \$5.45	109,347 329 596,453 \$0 596,453	108,756	-0 54%
oth \$599 sid Per Month \$599 ser Month \$599 sid PMPM WPM	329 596,453 \$0 596,453	353	
S59 Per Month Month \$59 PMPM M	,596,453 \$0 ,596,453		7.29%
Per Month \$594 Month PMPM M	\$0 596,453	\$597,217	0.13%
Month \$59 PMPM M	596,453	\$0	
MPM M		\$597,217	0.13%
PMPM M	\$5.45	\$5.49	0.67%
N.	\$0.00	\$0.00	
	\$5.45	\$5.49	0.67%
	\$1,699.30	\$1,711.22	0.70%
Member Paid Per Net Rx \$0.00	\$0.00	\$0.00	
Plan Paid Per Net Rx \$1,699.30	1,699.30	\$1,711.22	0.70%
Rx PMPM 0.00	0.00	00:00	
Member Paid/Total Cost 0.00%	0.00%	%00.0	

from 329 to 353 quarter over Utilizing members increased quarter

increased \$11.92 quarter over Plan cost per net prescription quarter





Provider Type Variance

	Oct-Dec 2011	c 2011	Jan-Ma	Jan-Mar 2012	Plan Paid Variances - Increase/(Decrease)	ınces - Increas	e/(Decrease)
	& &	Plan Paid	RX.	Plan Paid	Total =	Rx	+ Paid/Rx
Retail							
Brand w/o Generic	32,135	\$3,731,674	33,090	\$3,745,325	\$13,652	\$76,559	(\$62,907)
Brand w/Generic	925	\$171,240	862	\$158,399	(\$12,841)	(\$8,049)	(\$4,792)
Generic	157,446	\$3,318,156	177,286	\$3,711,543	\$393,387	\$418,374	(\$24,987)
Total	190,506	\$7,221,070	211,238	\$7,615,268	\$394,198	\$486,884	(\$92,687)
Specialty							
Brand w/o Generic	639	\$1,570,658	617	\$1,582,727	\$12,070	(\$25,961)	\$38,031
Brand w/Generic	33	\$28,940	15	\$8,506	(\$20,433)	(\$13,971)	(\$6,462)
Generic	439	\$189,762	445	\$200,418	\$10,656	\$8,152	\$2,504
Total	1,111	\$1,789,359	1,077	\$1,791,651	\$2,292	(\$31,780)	\$34,072
Grand Total	191,632	\$9,016,315	212,328	\$9,413,179	\$396,864	\$453,445	(\$56,581)

Plan cost increased \$396,864 quarter over quarter

The volume cost increased while the cost per prescription decreased





Therapeutic Utilization

Usage by Therapeutic Class





Drug Variance - Top 15 Drugs

	Oct-Dec 2011	2011	Jan-Mar 2012	r 2012	Plan Paid Vari	Plan Paid Variances - Increase/(Decrease)	/(Decrease)
	æ	Plan Paid	X.	Plan Paid	Total	= Rx +	Paid/Rx
SINGULAIR - Antiasthmatic	1,667	\$240,407	1,643	\$255,098	\$14,691	(\$3,461)	\$18,152
ADVAIR DISKU - Antiasthmatic	952	\$211,741	938	\$212,369	\$628	(\$3,114)	\$3,742
ACTOS - Antidiabetic	791	\$170,810	779	\$178,694	\$7,885	(\$2,591)	\$10,476
INCIVEK - Antiviral	14	\$231,759	11	\$177,612	(\$54,147)	(\$49,663)	(\$4,484)
LANTUS - Antidiabetic	1,007	\$142,692	1,144	\$176,860	\$34,168	\$19,413	\$14,755
PROAIR HFA - Antiasthmatic	3,305	\$141,236	3,634	\$160,957	\$19,721	\$14,060	\$5,661
DIVALPROEX - Anticonvulsant	1,268	\$143,810	1,299	\$140,475	(\$3,334)	\$3,516	(\$6,850)
LANSOPRAZOLE - Ulcer Drugs	955	\$127,411	626	\$127,752	\$342	\$3,202	(\$2,860)
VENLAFAXINE - Antidepressants	741	\$109,416	844	\$119,266	\$9,850	\$15,209	(\$5,359)
FLUTICASONE - Systemic And Topical Nasal Products	2,187	\$102,659	2,423	\$110,633	\$7,974	\$11,078	(\$3,104)
ENBREL - Analgesics-Anti- Inflammatory	43	\$82,655	52	\$106,729	\$24,074	\$17,300	\$6,774
OMEPRAZOLE - Ulcer Drugs	2,383	\$88,157	2,972	\$106,608	\$18,451	\$21,790	(\$3,339)
HYDROCO/APAP - Analgesics- Narcotic	6,725	\$94,642	7,400	\$105,908	\$11,266	\$9,499	\$1,767
ENOXAPARIN - Anticoagulants	89	\$65,202	81	\$102,237	\$37,035	\$12,465	\$24,570
FOCALIN XR - Stimulants/Anti- Obesity Anorexiants	438	\$80,813	491	\$98,420	\$17,607	\$9,779	\$7,829
	22,544	\$2,033,409	24,690	\$2,179,621	\$146,212	\$78,481	\$67,731



greatest decrease in cost while Enoxaparin had the greatest increase Singulair once again was the greatest expenditure. Incivek had the



Therapeutic Class Variance

	Oct-Dec 2011	c 2011	Jan-M	Jan-Mar 2012	Plan Paid Var	Plan Paid Variances - Increase/(Decrease)	e/(Decrease)
	& &	Plan Paid	- X	Plan Paid	Total	= &	+ Paid/Rx
Antiasthmatic	11,797	\$978,190	12,526	\$1,030,371	\$52,181	\$60,448	(\$8,267)
Antidiabetic	9,048	\$695,169	10,049	\$792,168	\$96,999	\$76,908	\$20,091
Anticonvulsant	11,296	\$612,837	11,727	\$628,992	\$16,155	\$23,383	(\$7,228)
Stimulants/Anti-Obesity Anorexiants	2,834	\$419,529	3,119	\$485,285	\$65,756	\$42,190	\$23,567
Antidepressants	11,441	\$450,129	12,464	\$470,191	\$20,062	\$40,248	(\$20,186)
Analgesics-Narcotic	11,695	\$410,815	12,749	\$407,015	(\$3,799)	\$37,024	(\$40,824)
Antiviral	633	\$436,506	296	\$401,904	(\$34,602)	\$230,321	(\$264,923)
Ulcer Drugs	6,617	\$397,196	7,416	\$402,548	\$5,352	\$47,961	(\$42,609)
Antineoplastics	697	\$378,610	691	\$353,093	(\$25,516)	(\$3,259)	(\$22,257)
Analgesics-Anti- Inflammatory	908'6	\$272,560	10,636	\$342,125	\$69,565	\$38,954	\$30,611
Antihyperlipidemic	6,361	\$231,175	7,230	\$270,587	\$39,412	\$31,582	\$7,830
Assorted Classes	521	\$231,514	527	\$254,018	\$22,504	\$2,666	\$19,838
Misc. Cardiovascular	75	\$232,298	9/	\$248,455	\$16,157	\$3,097	\$13,060
Dermatological	6,366	\$192,994	6,688	\$210,577	\$17,583	\$9,762	\$7,821
Misc. Psychotherapeutic and Neurological Agents	475	\$190,580	616	\$203,546	\$12,965	\$56,572	(\$43,607)
All Others	102,470	\$2,886,215	114,847	\$2,912,304	\$26,090	\$348,616	(\$322,526)
	191,632	\$9,016,315	212,328	\$9,413,179	\$396,864	\$1,046,473	(\$649,609)



Antidiabetic therapeutic class had the greatest increase quarter over quarter





Therapeutic Class Variance

Antiasthmatic Variances	_		
	Oct-Dec 2011	Jan-Mar 2012	Variance
Total Cost/Rx	\$82.92	\$82.26	(\$7,786)
Percentage Paid By Plan	100.00%	100.00%	\$0
Rx/Util. Mmbr Per Month	69'0	0.70	\$4,661
Utilizing Members	2,677	5,999	\$55,306
# Months	က	33	\$0
Plan Paid	\$978,190	\$1,030,371	\$52,181
	_		

riali raiu ireliu							
L	\$1,200,000	000,00	3600,000	00,00	\$400,000	\$200,000	2
	\$1,20	0,10	100	ο · ·	74 74	\$7	

Top 'Antiasthmatic'	Oct-Dec 201	: 2011	Jan-Mar 2012	ır 2012	Plan Paid Variar	Plan Paid Variances - Increase/(🏻	(Decrease)
Medications	Š.	Plan Paid	& &	Plan Paid	Total =	RX +	Avg Paid/Rx
PROAIR HFA AER	3,305	\$141,236	3,634	\$160,957	\$19,721	\$14,060	\$5,661
SINGULAIR TAB 10MG	823	\$116,326	824	\$124,370	\$8,044	\$141	\$7,903
ADVAIR DISKU AER 250/50	532	\$118,851	543	\$122,673	\$3,822	\$2,457	\$1,364
SINGULAIR CHW 5MG	442	\$65,624	419	\$67,213	\$1,589	(\$3,415)	\$5,004
SPIRIVA CAP HANDIHLR	221	\$49,728	269	\$55,867	\$6,139	\$10,801	(\$4,661)
SINGULAIR CHW 4MG	329	\$47,642	349	\$55,352	\$7,710	\$2,896	\$4,813
ADVAIR DISKU AER 100/50	272	\$49,075	256	\$47,983	(\$1,092)	(\$2,887)	\$1,795
ADVAIR DISKU AER 500/50	148	\$43,815	139	\$41,713	(\$2,102)	(\$2,664)	\$563
BUDESONIDE SUS 0.5MG/2	115	\$33,851	150	\$40,478	\$6,628	\$10,302	(\$3,675)
BUDESONIDE SUS 0.25MG/2	155	\$38,169	160	\$38,715	\$545	\$1,231	(\$89\$)
	6,342	\$704,318	6,743	\$755,322	\$51,004	\$32,923	\$18,081



Utilizing members increased 322 quarter over quarter





21



Therapeutic Class Variance II

Antidiabetic Variances	_		
	Oct-Dec 2011	Jan-Mar 2012	Variance
Total Cost/Rx	\$76.83	\$78.83	\$18,090
Percentage Paid By Plan	100.00%	100.00%	\$0
Rx/Util. Mmbr Per Month	1.20	1.22	\$9,360
Utilizing Members	2,504	2,745	\$69,549
# Months	3	3	\$0
Plan Paid	\$695,169	\$792,168	\$96,999
	_		

rend						
Plan Paid Irend						
_	\$1,000,000	\$800,000	\$600,000	\$400,000	\$200,000	\$0

Top 'Antidiabetic'	Oct-Dec 201	2011	Jan-Mar 2012	r 2012	Plan Paid Variar	Plan Paid Variances - Increase/(Decrease	Jecrease)
Medications	~X	Plan Paid	~X	Plan Paid	Total =	RX +	Avg Paid/Rx
LANTUS INJ 100/ML	968	\$121,163	995	\$147,999	\$26,836	\$13,387	\$13,449
HUMALOG INJ 100/ML	458	\$89,621	470	\$89,542	(\$78)	\$2,348	(\$2,426)
ACTOS TAB 30MG	316	\$76,929	346	\$87,257	\$10,328	\$7,303	\$3,025
JANUVIA TAB 100MG	196	\$39,167	318	\$55,749	\$16,582	\$24,379	(\$7,797)
ACTOS TAB 45MG	203	\$49,008	195	\$50,065	\$1,057	(\$1,931)	\$2,989
ACTOS TAB 15MG	272	\$44,873	238	\$41,373	(\$3,500)	(\$2,609)	\$2,109
LANTUS INJ SOLOSTAR	111	\$21,529	149	\$28,861	\$7,332	\$7,370	(\$38)
LEVEMIR INJ	155	\$24,709	157	\$27,707	\$2,999	\$319	\$2,680
NOVOLOG INJ 100/ML	94	\$16,667	122	\$19,390	\$2,723	\$4,965	(\$2,242)
ACTOPLUS MET TAB 15/850MG	125	\$28,480	69	\$16,500	(\$11,980)	(\$12,759)	\$779
	2,826	\$512,144	3,059	\$564,443	\$52,299	\$39,773	\$12,526



Utilizing members increased 241 quarter over quarter





Therapeutic Class Variance III

Anticonvulsant Variances			
	Oct-Dec 2011	Jan-Mar 2012	Variance
Total Cost/Rx	\$54.25	\$53.64	(\$6,962)
Percentage Paid By Plan	100.00%	100.00%	\$0
Rx/Util. Mmbr Per Month	1.04	1.03	(\$10,205)
Utilizing Members	3,611	3,813	\$33,322
# Months	8	m	\$0
Plan Paid	\$612,837	\$628,992	\$16,155

\$800,000		
\$600,000		
\$400,000		
\$200,000		
0\$		

Top 'Anticonvulsant'	Oct-Dec 2011	c 2011	Jan-Mar 2012	ır 2012	Plan Paid Variances - Increase/	=	Decrease)
Medications	X.	Plan Paid	\X	Plan Paid	Total =	RX +	Avg Paid/Rx
DIVALPROEX TAB 500MG ER	663	\$101,032	685	\$98,087	(\$2,945)	\$3,352	(\$6,297)
OXCARBAZEPIN TAB 600MG	95	\$23,066	102	\$26,284	\$3,218	\$1,700	\$1,518
GABAPENTIN TAB 600MG	397	\$24,642	404	\$24,220	(\$422)	\$434	(\$857)
LEVETIRACETA SOL 100MG/ML	500	\$21,674	218	\$24,132	\$2,458	\$933	\$1,525
DIVALPROEX TAB 500MG DR	279	\$21,754	286	\$21,471	(\$283)	\$546	(\$859)
OXCARBAZEPIN TAB 300MG	132	\$20,272	131	\$18,756	(\$1,516)	(\$154)	(\$1,362)
TOPIRAMATE TAB 100MG	447	\$18,014	425	\$17,704	(\$309)	(\$887)	\$577
LEVETIRACETA TAB 500MG	313	\$15,554	325	\$14,965	(\$288)	\$596	(\$1,186)
GABAPENTIN CAP 300MG	920	\$11,714	1,030	\$12,714	\$1,000	\$1,401	(\$400)
LEVETIRACETA TAB 1000MG	117	\$11,300	139	\$12,596	\$1,296	\$2,125	(\$859)
	3,572	\$269,021	3,745	\$270,929	\$1,908	\$10,047	(\$8,140)



Utilizing members increased 202 members quarter over quarter





Therapeutic Class Variance IV

Stimulants/Anti-Obesity Anorexiants Variances	Oct-Dec 2011	Jan-Mar 2012	Variance
Total Cost/Rx	\$148.03	\$155.59	\$21,413
Percentage Paid By Plan	100.00%	100.00%	\$0
Rx/Util. Mmbr Per Month	0.81	0.85	\$17,514
Utilizing Members	1,162	1,230	\$26,829
# Months	3	က	\$0
Plan Paid	\$419,529	\$485,285	\$65,756

|--|

Top 'Stimulants/Anti-Obesity	Oct-Dec 2011	: 2011	Jan-Mar 2012	r 2012	Plan Paid Variar	Plan Paid Variances - Increase/(Decrease)	Jecrease)
Anorexiants' Medications	\X	Plan Paid	ž	Plan Paid	Total =	RX +	Avg Paid/Rx
METHYLPHENID TAB 36MG ER	132	\$28,910	167	\$35,865	\$6,955	\$7,666	(\$711)
FOCALIN XR CAP 10MG	134	\$23,982	152	\$30,653	\$6,671	\$3,222	\$3,449
AMPHETAMINE CAP 20MG ER	123	\$25,224	132	\$28,185	\$2,961	\$1,846	\$1,116
METHYLPHENID TAB 54MG ER	105	\$17,101	141	\$23,781	\$6,681	\$5,863	\$817
PROVIGIL TAB 200MG	18	\$23,333	24	\$23,733	\$400	\$7,778	(\$7,377)
FOCALIN XR CAP 15MG	97	\$16,760	120	\$23,034	\$6,274	\$3,974	\$2,300
FOCALIN XR CAP 20MG	117	\$22,778	111	\$22,790	\$12	(\$1,168)	\$1,180
FOCALIN XR CAP 5MG	87	\$16,926	96	\$19,954	\$3,028	\$1,751	\$1,277
VYVANSE CAP 30MG	96	\$15,131	102	\$17,372	\$2,241	\$946	\$1,295
VYVANSE CAP 40MG	6	\$14,533	102	\$16,379	\$1,846	\$749	\$1,097
	1,006	\$204,677	1,147	\$241,745	\$37,068	\$32,625	\$4,443



Provigil has recently gone generic



Therapeutic Class Variance V

Variances Oct-Dec 2011 Jan-Mi t/Rx \$39.34 100.00% 1 ge Paid By Plan 100.00% 1 1 4 mbr Per Month 0.90 0.90 0 Members 3 3	Antidepressants	-		
;/Rx \$39.34 \$100.00% 1	Variances	Oct-Dec 2011	Jan-Mar 2012	Variance
je Paid By Plan 100.00% 100.00	Total Cost/Rx	\$39.34	\$37.72	(\$18,529)
Imbr Per Month 0.90 Aembers 4,238	Percentage Paid By Plan	100.00%	100.00%	\$0
Aembers 4,238 3	Rx/Util. Mmbr Per Month	06'0	06'0	(\$2,330)
3	Utilizing Members	4,238	4,642	\$40,921
	# Months	3	3	\$0
\$450,129	Plan Paid	\$450,129	\$470,191	\$20,062

	Plan Paid Trend	
\$500,000		
\$400,000		
\$300.000		
\$200,000		
\$200,000		
0000016		
000		

Top 'Antidepressants'	Oct-Dec 201	2011	Jan-Mar 2012	r 2012	Plan Paid Varia	Plan Paid Variances - Increase/(Decrease	Jecrease)
Medications	X.	Plan Paid	X.	Plan Paid	Total =	- - - -	Avg Paid/Rx
VENLAFAXINE CAP 75MG ER	297	\$50,277	331	\$55,521	\$5,244	\$5,756	(\$511)
CYMBALTA CAP 60MG	258	\$50,539	266	\$55,322	\$4,782	\$1,567	\$3,215
VENLAFAXINE CAP 150MG ER	288	\$42,186	329	\$44,891	\$2,705	\$6,006	(\$3,301)
BUPROPN HCL TAB 150MG XL	282	\$41,531	324	\$44,037	\$2,506	\$6,186	(\$3,680)
BUPROPN HCL TAB 300MG XL	288	\$30,473	307	\$30,895	\$422	\$2,010	(\$1,588)
LEXAPRO TAB 20MG	318	\$42,568	200	\$29,264	(\$13,304)	(\$15,796)	\$2,492
BUPROPION TAB 150MG SR	325	\$20,877	421	\$26,013	\$5,136	\$6,167	(\$1,030)
CYMBALTA CAP 30MG	95	\$19,636	102	\$23,554	\$3,918	\$1,447	\$2,471
LEXAPRO TAB 10MG	185	\$23,434	101	\$14,352	(\$9,082)	(\$10,640)	\$1,559
VENLAFAXINE CAP 37.5MG	74	\$10,076	91	\$10,934	\$858	\$2,315	(\$1,457)
	2,410	\$331,599	2,472	\$334,784	\$3,186	\$5,016	(\$1,831)





Gold Coast Health Plan Diabetic Overview

Usage from 7/1/11-3/31/12

3,465 Members on medication for Diabetes

5,580 Members on medication acquired testing supplies

47,976 Prescriptions processed

26,547 processed for medications

21,429 processed for supplies

\$2,883,258 plan cost (11.0% of total drug spend)





Gold Coast Health Plan

Non-Diabetic

Total Drug Spend \$18,318,275

Total Members 33,318

\$61.09 Per Member Per Month

Diabetic

Total Drug Spend \$7,836,522

Total Members 7,031

\$123.84 Per Member Per Month

Diabetes are three times more than a person without Diabetes Annually, health care costs for a person with





Diabetic Overview, Cont.

Plan members who have co-morbidities. This is the number of The following table identifies the number of Gold Coast Health concurrent disease states.

5 co-morbidities	388
4 co-morbidities	726
3 co-morbidities	1,295
2 co-morbidities	2,688
Diabetes Only	1,934

The following table identifies the co-morbidities of Gold Coast Health Plan members with diabetes.

Asthma	2,433
Ulcers	1,181
Depression	1,030
Hyperlipidemia	1,890
Hypertension	2,538





AGENDA ITEM 7b

To: Ventura County Medi-Cal Managed Care Commission

From: Cassie Undlin, CEO

Date: April 23, 2012

Re: HEDIS Vendor

Recommendation: That the Commission authorize GCHP Management to proceed in contracting with Verisk Health as the Plan HEDIS Vendor.

Background: GCHP is contractually obligated to collect HEDIS measures selected by the DHCS and DMHC. In order to comply with this contract requirement, GCHP must contract with an NCQA certified HEDIS vendor to produce the statistically appropriate sample for each of the required measures. Programming is extremely complex and samples and programming structure will be further audited by the State EQRO, HSAG. In addition to administrative data pulls, GCHP will be required to assist the State of CA in meeting its obligation to CMS by collecting a second set of measures for the SPD only population. This doubles the work to the vendor in separating out these members and pulling a statistically valid SPD only sample. Since nine of the thirteen required DHCS selected measures require manual medical record review, GCHP can expect to collect data from in excess 3500 medical records. The record collection timeline is short and without contracting for outside nurse review, data collection could not be completed. Verisk has the ability to provide trained nurses to abstract data on behalf of GCHP. In addition, GCHP is required to submit data to the State for the NCQA CAHPS survey which requires additional programming. The cost for this service is included in the Verisk contract pricing. HEDIS data collection is an annual State requirement thus it is important that the vendor is familiar with GCHP processes and claims data. Verisk has worked with IKA data in the past is very familiar with the IKA data layout.

Attached for your information is a list of the required measure for 2012.

Discussion: Management has reviewed several HEDIS vendors. Several other COHS and LI plans were survey to determine which vendors are being used. The preferred vendor for GCHP is Verisk. The cost for the service and the extra benefits provided (CAHPS data pull and nurse abstractor availability) make Verisk the best choice for GCHP. Result of the HEDIS measures will be used to determine the quality of the medical care delivered to Ventura County members. A reliable, experienced and certified HEDIS vendor such as Verisk is essential to our success



	Milliman	Verisk	VIPS
Pricing	MILLIMAN IS NOT ABLE TO PROVIDE HEDIS DATA PROGRAMMING SERVICES.	Implementation: \$5,000 (ONE TIME) Annual Fees: \$100,000.00 Medical record abstraction - \$25/chart	Implementation: \$65,000.00(ONE TIME) Annual Fees: \$83,000.00 No medical record capabilities
Project Timeline	N/A	60 ~ 90 days	90 days
Functionality	N/A	Web based reporting portal for HEDIS reporting.	Web based HEDIS reporting software.
Current Installation and Utilization sites	N/A	LA Care - Los Angeles Health Net - Woodland Hills Molina Healthcare - Long Beach Sharp Health - San Diego Central California Alliance for Health - Santa Cruz Santa Clara Family Health - Santa Clara Contra Costa Health Plan Health Plan of San Joaquin Kern Health Systems - Bakersfield San Francisco Health Plan - SF Western Health Advantage - Sacramento	CenCal Health - Santa Barbara
System profile	NA/	Using Oracle database and JAVA development	SQL Server based supporting database
		programming language.	witi application using 3AVA programmig language.



Pros and Cons

PROPOSED 2013 HEDIS MEASURES FOR FULL-SCOPE PLANS: November 18, 2011

	HEDIS Reporting year 2011 ¹	HEDIS Reporting Year 2012 ²	Proposed: HEDIS Reporting Year 2013 ³	Notes
1.	Well-Child Visits in the 3 rd , 4 th , 5 th , & 6 th Years of Life	Well-Child Visits in the 3 rd , 4 th , 5 th , & 6 th Years of Life	Well-Child Visits in the 3 rd , 4 th , 5 th , & 6 th Years of Life	Hybrid measure; Used for Auto Assignment
2.	Adolescent Well-Care Visits	Adolescent Well-Care Visits	Deleted	Hybrid measure; Used for Auto Assignment
3.	Childhood Immunization Status – Combo 3	Childhood Immunization Status – Combo 3	Childhood Immunization Status – Combo 3	Hybrid measure; Used for Auto Assignment
4.	Appropriate Treatment for Children with Upper Respiratory Infection	Deleted		Admin measure
5.	Prenatal & Postpartum Care (2 indicators): Timeliness of Prenatal Care Postpartum Care	Prenatal & Postpartum Care (2 indicators): Timeliness of Prenatal Care Postpartum Care	Prenatal & Postpartum Care (2 indicators): • Timeliness of Prenatal Care • Postpartum Care	Hybrid measure; Prenatal indicator used for Auto Assignment
6.	Use of Imaging Studies for Low Back Pain - 1 st year	Use of Imaging Studies for Low Back Pain – 2 nd year	Use of Imaging Studies for Low Back Pain	Admin measure
7.	Breast Cancer Screening	Deleted		Admin measure
8.	Cervical Cancer Screening	Cervical Cancer Screening	Cervical Cancer Screening	Hybrid measure; Used for Auto Assignment
9.	Weight Assessment & Counseling for Nutrition & Physical Activity for Children & Adolescents - 1st year	Weight Assessment & Counseling for Nutrition & Physical Activity for Children & Adolescents – 2 nd year	Weight Assessment & Counseling for Nutrition & Physical Activity for Children & Adolescents	Hybrid measure
10.	Comprehensive Diabetes Care (8 indicators): • Eye Exam (Retinal) Performed • LDL-C Screening Performed • LDL-C Control (<100 mg/Dl) • HbA1c Testing • HbA1c Poor Control (>9.0%) • HbA1c Control (<8.0%) • Medical Attn. for Nephropathy • Blood pressure control (<140/90 mm Hg	Comprehensive Diabetes Care (8 indicators): Eye Exam (Retinal) Performed LDL-C Screening Performed LDL-C Control (<100 mg/Dl) HbA1c Testing HbA1c Poor Control (>9.0%) HbA1c Control (<8.0%) Medical Attn. for Nephropathy Blood pressure control (<140/90 mm Hg)	Comprehensive Diabetes Care (8 indicators): • Eye Exam (Retinal) Performed • LDL-C Screening Performed • LDL-C Control (<100 mg/Dl) • HbA1c Testing • HbA1c Poor Control (>9.0%) • HbA1c Control (<8.0%) • Medical Attn. for Nephropathy • Blood pressure control (<140/90 mm Hg)	Hybrid measure; HbA1c Testing indicator used for Auto Assignment

Uses data from January 1, 2010, through December 31, 2010, measurement year.

Uses data from January 1, 2011, through December 31, 2011, measurement year.

Uses data from January 1, 2012, through December 31, 2012, measurement year.

	HEDIS Reporting year 2011 ¹	HEDIS Reporting Year 2012 ²	Proposed: HEDIS Reporting Year 2013 ³	Notes
11.	Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis	Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis	Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis	Admin measure
12.		Children & Adolescents' Access to Primary Care Practitioners - 1st year	Children & Adolescents' Access to Primary Care Practitioners - 2 nd year	Admin measure
13.		Immunizations for Adolescents - 1 st year	Immunizations for Adolescents	Hybrid measure
14.		Annual Monitoring for Patients on Persistent Medications (w/out anticonvulsant indicator) 1st year	Annual Monitoring for Patients on Persistent Medications (w/out anticonvulsant indicator) 2 nd year	Admin measure; Addresses members 18 yrs & older
15.		Ambulatory care: Outpatient visits Emergency Department visits 1st year	Ambulatory care: Outpatient visits Emergency Department visits 2 nd year	Admin measure; Addresses members <1 yr through 85+ yrs
16.			NEW FOR 2013 Controlling High Blood Pressure (CBP)	Hybrid measure
17.			NEW FOR 2013 Medication Management for People with Asthma (MMA)	Admin measure
	7 Hybrid & 4 Admin measures	8 Hybrid & 5 Admin measures	8 Hybrid & 6 Admin measures	

¹ Uses data from January 1, 2010, through December 31, 2010, measurement year. ² Uses data from January 1, 2011, through December 31, 2011, measurement year. ³ Uses data from January 1, 2012, through December 31, 2012, measurement year.

Verisk Health, Inc. 201 Jones Road, 4th Floor West Waltham, MA 02451

GENERAL VERISK MASTER SERVICES AGREEMENT COVER PAGE

Client:	Gold Coast Health Plan
Type of entity (e.g., corporation, partnership):	Medi-Cal Managed Care Health Plan (Public Entity)
State (if applicable) and Country of Organization:	California
Address:	2220 E. Gonzales Road, Suite 200, Oxnard, CA 93036
Administrative Contacts:	
Client:	
Verisk:	

Verisk Health, Inc. on behalf of itself and its subsidiaries ("Verisk"), a Massachusetts corporation having offices at 201 Jones Road, 4th Floor West, Waltham, Massachusetts 02451, has developed certain software, services and other data network/Internet-available applications and decision analytics designed to assist service providers, employers, insurance carriers and other health care industry participants, in processing and analyzing data and claims to identify, manage and minimize clinical and financial risk. This Verisk Master Services Agreement ("Agreement") and its Appendices and any Schedules set forth the terms and conditions on which Verisk and the above-referenced entity ("Client") have agreed that Client will have access to such services and applications.

In consideration of the mutual covenants set forth herein, Verisk and Client agree to all of the provisions of this Agreement, including the provisions of this Cover Page, Terms and Conditions, Appendices, and any schedules attached hereto and documents expressly referenced above or described herein, all of which are incorporated by reference herein and, together, constitute the Agreement. Accordingly, intending to be legally bound, Verisk and Client have executed this Agreement as of the last date set forth below.

Verisk Health, Inc.	Client	
Signature	Signature	_
Ву:	By:	_
Title:	Title:	_
Date:	Date:	

TERMS AND CONDITIONS

- **1. DEFINITIONS.** Whenever the following terms or phrases are used in this Agreement, they will have the following meaning unless the context clearly requires otherwise:
- 1.1 "Deliverable" means the provision of an Internet- or other data network-available application or consulting, programming, professional or other service by Verisk to Client, per Client's requirements as defined and agreed to per a Statement of Work coincident with this Agreement as of the Effective Date or subsequently appended to this Agreement.
- **1.2** "Effective Date" means the last date on the Cover Page on which this Agreement is signed by the Parties required to execute it.
- 1.3 "Intellectual Property" means the sum of any patentable or unpatentable discoveries, ideas, concepts, or products, or any works fixed in any medium of expression, including copyright and mask work rights, which are brought to bear to generate a Deliverable or are inherent in the Deliverable itself.
- **1.4** "Party" or "Parties" means, as applicable, Client and/or Verisk.
- **1.5** "Master Agreement" means the terms and conditions of this Agreement exclusive of any Appendices and Statements of Work.
- **1.6** "**Person**" includes, without limitation, any corporation, company, partnership, entity or individual.
- 1.7 "Statement of Work" means any additional terms and conditions agreed to by the Parties and addended to this Agreement containing instructions for Verisk to provide one or more specific Deliverables for specific fees.
- **1.8** "**Term**" has the meaning ascribed to it in Section 8.1 of this Agreement.
- **1.9** "**Third Party**" means a Person other than Client or Verisk.
- 1.10 "Application Data" Includes but is not limited to individuals' personal, medical, pharmacy, disability, provider or insurance claim information provided by Client or Client's business partners, including without limitation, third party administrators, pharmacy benefit companies and utilization management companies, to Verisk to create an Application Service, pursuant to the Applications Agreement. Application Data includes, but is not necessarily limited to, claims and membership information for Client insurance plan members.

- **1.11** "Application Service" means any Deliverable whereby users gain access, via an interface provided by Verisk, to information compiled by Verisk, in any Internetavailable or private data network.
- 1.12 "Verisk Applications" means any and all Application Services, the software source, object and executable code used to implement such Application Services, any reports generated from data available through such Application Services, and any modifications or enhancements thereto, but not including any stored Application Data provided by Client to Verisk hereunder.
- 1.13 "Comparative Data" will mean aggregated data, including De-identified Data and that provided by other Verisk clients, compiled by Verisk, which allows Client to compare its calculated values against the calculated values of a broader base of similar clients. For purposes of explanation and not exclusion, Protected Health Information (as defined in Appendix B) will be excluded from Comparative Data.
- **1.14** "**De-identified Data**" means Application Data that has undergone de-identification of protected health information as specified by HIPAA privacy rule 45 C.F.R. Part 164.514(a)-(c).
- 1.15 "Ancillary Verisk Services" will include but are not limited to Comparative Data and other benchmarking, comparative reporting and analysis services used by Verisk as part of or ancillary to an Application Service or consulting service.

2. STRUCTURE OF THE AGREEMENT

- **2.1 Scope**. This Agreement between the Parties will contain the sole and exclusive terms and conditions that will govern the rights, responsibilities, and obligations of the Parties with respect to the Deliverables.
- **2.2 Appendices.** The terms of a General Appendix will govern all Deliverables described in any Statement of Work. The terms of a Specific Appendix governs all Deliverables in any Statement of Work specifically referencing that appendix. As of the Effective Date of this Agreement, the Parties agree that the Appendices listed below are addended to this Agreement upon the Effective Date:
- (a) Appendix A—Verisk Application Services is a Specific Appendix for Statements of Work requesting Internet- or other data network-available application Deliverables.
- **(b) Appendix B—Business Associate Agreement** is a general appendix.

- (c) Appendix C—Service Change Request is a general appendix.
- (d) Appendix D—License for Permitted Contractors sets forth the terms and conditions of Application Service Use by Permitted Contractors.
- 2.3 Order of Precedence. In the event of contrary, additional or inconsistent terms and conditions within Appendices or Statements of Work incorporated into this Agreement, the following order of precedence will apply: (i) the Statement of Work; (ii) the Specific Appendix(es), if any, to which the Statement of Work relates, (iii) any General Appendices, and (iii) the Master Agreement, each for their limited purposes. For clarity, the terms of the applicable Statement of Work will apply to the subject matter of such Statement of Work, and will control in the event that there are any conflicts between the terms of the Statement of Work, its related Specific Appendix(es), any General Appendix or the Master Agreement. Specific Appendix will apply for the limited purposes of the applicable Statement(s) of Work, and will control in the event of any conflicts with a General Appendix or the Master Agreement, Each General Appendix will apply for its limited purposes and will control in the event of any conflicts with the Master Agreement. To the extent there are no conflicts applied in accordance with the foregoing, the Master Agreement will apply broadly across all Appendices and Statements of Work.
- **2.4 Deliverables** Coincident with the Effective **Date**. Subject to the terms and conditions of this Agreement, Client hereby orders and Verisk agrees to provide Deliverables defined in Statements of Work coincident with this Agreement.
- **2.5 Deliverables Subsequent to the Effective Date.** Subject to the terms and conditions of this Agreement, as modified by or appended to by any subsequent Statement of Work, Verisk agrees to provide Deliverables defined in such Statement of Work.

3. CONFIDENTIAL INFORMATION.

- **3.1 Definition**. "Confidential Information" means the terms and conditions of this Agreement (including, but not limited to, the financial terms herein), the Deliverables, Statements of Work, and any information disclosed by a Party (the "Disclosing Party") to the other Party (the "Receiving Party") and marked as confidential or proprietary. No information of the Disclosing Party will be considered Confidential Information to the extent that an exception is provided for it in Section 3.3 herein.
- **3.2** Use and Disclosure of Confidential Information. The Receiving Party acknowledges that it will have access to the Disclosing Party's Confidential Information. The Receiving Party agrees that it will not (i) use any such Confidential Information in any way, for its

own account or the account of any Third Party, except for the exercise of its rights and performance of its obligations under this Agreement, or (ii) disclose any such Confidential Information to any Third Party, other than furnishing such Confidential Information to its employees who are required to have access to the Confidential Information in connection with the exercise of its rights and performance of its obligations under this Agreement. The Receiving Party agrees that it will not allow any unauthorized Person access to the Disclosing Party's Confidential Information, and that the Receiving Party will take all action reasonably necessary to protect the confidentiality of such Confidential Information, including implementing and enforcing procedures to minimize the possibility of unauthorized use or copying of such Confidential Information. In the event that the Receiving Party is required by applicable law to make any disclosure of any of the Disclosing Party's Confidential Information, by subpoena, judicial or administrative order or otherwise, the Receiving Party will first give written notice of such requirement to the Disclosing Party, and will permit the Disclosing Party to intervene in any relevant proceedings to protect its interests in the Confidential Information, and provide full cooperation and assistance to the Disclosing Party in seeking to obtain such protection. In addition, neither Party will disclose the terms of this Agreement to any Third Party without the prior written consent of the other Party, except that either Party may disclose the terms of this Agreement to its (a) attorneys for all purposes and (b) accountants, advisors, investors, acquirers and/or potential investors or acquirers and their advisors (collectively, "Investment Representatives") of such Party, which Investment Representatives have a "need-to-know" solely for the purpose of evaluating, negotiating or documenting a contemplated investment or acquisition; that each such Investment provided. however. Representative is bound by a written agreement (or in the case of attorneys or other professional advisors, formal ethical duties) requiring such Investment Representative to treat, hold and maintain the terms of this Agreement as Confidential Information in accordance with the terms and conditions of this Section 3.

3.3 **Exceptions.** Information will not be deemed Confidential Information hereunder if such information: (a) is known to the Receiving Party prior to receipt from the Disclosing Party directly or indirectly from a source other than one having an obligation of confidentiality to the Disclosing Party; (b) becomes known (independently of disclosure by the Disclosing Party) to the Receiving Party directly or indirectly from a source other than one having an obligation of confidentiality to the Disclosing Party; (c) becomes publicly known or otherwise ceases to be secret or confidential, except through a breach of this Agreement by the Receiving Party; or (d) is independently developed by the Receiving Party. Each Party has the right to refuse to accept any trade secret, Confidential Information or similar proprietary information prior to full disclosure.

3.4 Verisk's Rights in Application Data. Notwithstanding anything to the contrary, Verisk Health is expressly permitted to aggregate and de-identify PHI obtained from Client ("De-Identified Information") for use in an aggregate database, and to use and disclose De-Identified Information without any further written consent of Client. Verisk Health may use, reproduce, transfer, retain and combine De-Identified Information for preparing commercially available normative and benchmarking data, and for internal and external research, analysis and product development purposes.

3.5 <u>Intellectual Property Ownership</u>

Verisk owns and retains all right, title, and interest in and to, including without limitation all Intellectual Property rights, in all software programs (whether or not installed on a Client-owned system), methodology, techniques, the identity of edits and materials, enhancements, derivatives, and modifications to all Verisk owned intellectual property, including without limitation all source code, object code, and documentation associated therewith, and all documentation, report formats, methodologies, algorithms, templates, logic flow, formulae, inventions, methods, systems, processes, works of authorship, and materials which have been or are in the future created, conceived, developed or acquired by Verisk and which are included in or used in providing the Services, including without limitation the Licensed Products and Services and all modifications, improvements, derivative works and compilations thereof and thereto (all the foregoing, collectively, Verisk IP or Verisk Intellectual Property). Client agrees that all Verisk IP constitutes the Confidential Information of Verisk, and Client shall not use or disclose such Confidential Information except as permitted herein.

Client agrees that it will not use or disclose such Verisk IP except solely as necessary to receive the Services described in this Agreement. Without limiting the foregoing, Client shall not, and shall cause its employees or authorized users to: 1) reverse engineer, decompile, reverse compile, or disassemble the Verisk IP; 2) create a derivative work or compilation of the Verisk IP, including without limitation any product or service derived or compiled from or based on, in whole or in part, any Verisk services or products. Client may not copy, distribute, market, sell, lease, sublicense or otherwise transfer the Licensed Programs or Services to third parties.

Notwithstanding the above, in no way shall Client be prevented from implementing changes to its systems, processes, or contracts that are done in the ordinary course of business or were otherwise arrived at independent of and without reliance on or benefit of the results of the Licensed Programs or Services provided herein.

4. BILLING AND PAYMENT.

- **4.1 Billing.** Client agrees to pay Verisk within thirty (30) days from the date an invoice is received by Client. Verisk will render invoices to Client at the address on the Cover Page or such other address that Client provides in writing to Verisk. Payments to Verisk must be in United States dollars and mailed to Verisk at the address listed on the Cover Page, Attn. Accounting.
- **4.2 Overdue Payments.** Overdue payments are subject to a late payment charge, calculated and compounded monthly at a monthly rate of two percent (2%). If the late payment rate exceeds the maximum permitted by law, the charge will be reduced to that maximum allowable rate.
- 4.3 Taxes. Client will be responsible for, either through direct payment or the reimbursement of any amounts incurred by Verisk, all sales or use taxes, duties, or levies imposed by any authority, government or government agency (other than those levied on Verisk's net income or property) in connection with this Agreement with respect to which Client is not exempt from taxation. If Verisk is required to collect a tax to be paid by Client, Client will pay this tax or provide evidence of exemption on demand. If Client fails to pay these taxes, duties or levies, Client will pay all reasonable expenses incurred by Verisk, including reasonable attorney's fees, to collect such taxes, duties or levies.
- **4.4** Collection for Non-Payment. If Client fails to pay any undisputed fee, expense, tax or any other sum due under this Agreement, Client will pay all reasonable expenses incurred by Verisk in collecting those sums, including reasonable attorneys' fees.

5. REPRESENTATIONS AND WARRANTIES.

- Verisk Warranty. 5.1 Verisk warrants that Deliverables will be performed using sound, professional practices and in a competent and professional manner by knowledgeable, trained and qualified personnel. Verisk does not warrant or guaranty that Deliverables will be error free, or that any access to such Deliverables will always be uninterrupted. Client's sole and exclusive remedy for breach by Verisk of the foregoing warranty will be for: (i) Verisk to re-perform the nonconforming whole or part of the Deliverable; and (ii) if within thirty (30) business days of receiving notice from Client Verisk fails to provide a specific conforming Deliverable, Verisk will provide to Client a proportional refund of the fees (as set forth in Statements of Work) paid by Client for the nonconforming portion of the Deliverable.
- **5.2 Disclaimer of Verisk Warranty.** EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN SECTION 5.1 OR THE APPLICABLE APPENDIX, ("VERISK WARRANTY"), VERISK: (A) MAKES NO EXPRESS

OR IMPLIED WARRANTIES OF ANY KIND, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, NON-INFRINGEMENT OR WARRANTIES ALLEGED TO ARISE AS A RESULT OF CUSTOM AND USAGE; ALL SERVICES AND PRODUCTS ARE ADVISORY AND PROVIDED ON AN "AS IS" BASIS.

5.3 Client's Right to Provide Information. Client represents and warrants to Verisk that it has the right to provide Application Data, information, specifications, and/or other data that it has provided or will provide to Verisk in order for Verisk to provide Deliverables Client further represents and warrants to hereunder. Verisk that possession and/or use of that Application Data. information, specifications, and other data by Verisk under the terms and conditions of this Agreement will not constitute a violation or an infringement upon any patent, copyright, trade secret, other Intellectual Property right or privacy right of any Third Party. Client represents and warrants that it shall only provide de-identified or group level Confidential Information to each of its employer groups unless and until such employer group certifies that it has complied with the requirements of 45 CFR164.504(f)(2) of the Privacy Rule.

6. LIMITATION OF LIABILITY.

- **6.1 Limited Liability.** Even if advised of the possibility of loss, liability, damage or expense, Verisk is not liable for any indirect damages, including any lost profits, data, business, goodwill, anticipated savings, opportunity or use or other incidental or consequential damages, which Client or any Third Party may suffer as a result of or in connection with the furnishing of a Deliverable.
- **6.2** Exclusion from Liability. Verisk will not be liable for any damages, expenses or loss due to impairments to a Deliverable caused by acts of Client's Representatives, subcontractors, or suppliers.
- **6.3** Exclusion from Liability Transaction Loss. Even if VERISK is advised of the possibility of loss, liability, damage or expense, VERISK will not be liable for any damages, expenses or loss due to: (a) misuse of any data or Deliverable by Client; (b) any error or omission in data results or information provided by the Deliverable and not caused by VERISK; (c) any inability to use the Deliverable; (d) any error or omission in data provided to VERISK; and/or (e) any failure, delay, corruption, error, inaccuracy, discrepancy, incompletion or omission in or made through the Deliverable and not caused by VERISK.
- **6.4 Liability Not to Exceed Amounts Paid.** Notwithstanding anything to the contrary, or any failure of essential purpose of any limited remedy or invalidity of

this Section 6, VERISK's aggregate liability, if any, to Client or to any Third Party for claimed loss or damage arising under this Agreement during any specific period will not exceed the lesser of (i) twice the amount actually paid by Client to VERISK during the corresponding period or (ii) the total amount actually paid by Client to VERISK since the Effective Date pursuant to this Agreement only.

6.5 Reasonableness. Client hereby expressly acknowledges and agrees that in view of the amount of the fees paid or to be paid hereunder, the limitations of liability in this Section 6 and the indemnities given in Section 7 ("Indemnification") below are in all respects fair and reasonable and reflect a duly considered allocation of risk between the Parties.

7. INDEMNIFICATION.

- 7.1 Mutual Indemnity. Each Party will protect, indemnify, hold harmless and defend the other Party and its affiliates, with counsel reasonably acceptable to each Party, at the indemnifying Party's expense, from and against any and all damages, whether direct, indirect, consequential or special, to the extent arising from (a) breach by the indemnifying Party of any duty owed to any Third Party, or (b) any act or omission of the other Party based upon, made or omitted in reliance or consequence of any instruction, message or information made or provided to the other Party by or on behalf of the indemnifying Party.
- 7.2 Additional Client Indemnity. Client will protect, indemnify, hold harmless and defend VERISK and its affiliates, with counsel reasonably acceptable to each Party, at Client's expense, from and against any and all damages, whether direct, indirect, consequential or special, to the extent arising from (a) Client's right to provide information as described in Section 5.3 herein: (b) Client's or a Third Party's misuse of a Deliverable; (c) the content of any information, specifications, or data that Client has or will provide or arrange to be provided to Verisk; or (d) the termination of, disciplinary action against, or other employment, ERISA, employee benefits, human resources, legal, administrative, or regulatory event to or by any physician, health care provider, or other health care or insurance services professional or entity pertaining to or resulting directly or indirectly from Client's use of a Deliverable.

8. TERM AND TERMINATION.

8.1 Term. The Term of this Agreement will commence on the Effective Date and remain in effect, subject to prior termination in accordance with this Section 8, for a short implementation period, to be followed by a production period of thirty-six (36) months. Thereafter, the Term of this Agreement will be automatically extended for successive renewal periods of one (1) year at a time, provided that either Party may terminate this Agreement as

of the end of the initial or any renewal period by written notice to the other Party given not later than sixty (60) days prior to the end of the initial or relevant renewal period. Verisk reserves the right, not later than ninety (90) days prior to the end of the initial or relevant renewal period, to make revisions to pricing, as described in Statements of Work, without revision to any other section or appendix of this Agreement.

8.2 Termination for Cause.

- (a) Termination for Breach. Either Party may terminate this Agreement for cause, if the other Party has breached a material term of the Agreement, and has not cured such breach within sixty (60) days after receipt of written notice thereof from the other Party specifying the breach in reasonable detail, unless such breach is nonpayment of invoices in which case the period to cure such breach will be thirty (30) days. Notwithstanding the foregoing to the contrary, (i) if the applicable breach (other than for nonpayment of invoices) cannot reasonably be cured within thirty (30) days, then there will be no termination so long as the breaching Party has begun the cure within the thirty (30) day period and, thereafter, proceeds diligently to cure such breach and (ii) a cure period will not be longer than one hundred eighty (180) days from receipt of written notice of the alleged breach. without the written consent of the non-breaching Party.
- **(b) Rights and Obligations Upon Termination.**Upon any termination of this Agreement, and except as expressly provided in section 3.4 of this Agreement, each Party will return to the other Party any Confidential Information of such other Party which is in its possession. Upon such termination, all rights and obligations of the Parties under this Agreement will cease except for: (i) Client's obligation to make any payment of any fees accrued hereunder on or prior to the date of termination, and (ii) the provisions of Sections 1 (Definitions), 2 (Structure of the Agreement), 3 (Confidential Information), 5 (Representations and Warranties), 6 (Limitation of Liability), 7 (Indemnification), this Section 8.2, 8.3 (Non-Exclusive Rights) and 9 (General).
- **8.3 Non-Exclusive Rights.** These termination rights are in addition to all other rights and remedies available to the either Party.

9. GENERAL.

9.1 Use of Other Party's Name. Notwithstanding anything to the contrary in this Agreement, each Party, with the documented consent of the other, is allowed to use in advertising, publicity, promotion, marketing, or other similar activity, any name, trade name, trademark, or other designation including any abbreviation, contraction or simulation of the other Party. Parties agree, upon mutual agreement of content, to a timely released media announcement regarding the Agreement. Notwithstanding

the foregoing, either Party may use the name of the other Party, with reference to the existence of this Agreement, without consent, in all of its materials provided to Investment Representatives.

- 9.2 Assignment. Except as otherwise permitted herein, neither Party will assign, in whole or in part, this Agreement or any license, rights or obligations granted hereunder, to any other Person or entity, without the prior written consent of the other Party, which consent may not be unreasonably withheld. Any attempted assignment. delegation or transfer by a Party in violation hereof will be null and void. However, either Party may assign this Agreement without the written consent of the other Party to a corporation or other business entity succeeding to all or substantially all the assets and business of the assigning Party by merger or purchase, provided that such corporation or other business entity is not a direct competitor of Verisk's, and will expressly assume all of the assigning Party's obligations under this Agreement by a writing delivered to the other Party. Subject to the foregoing, this Agreement will be binding on the Parties and their successors and assigns.
- **9.3 Waiver.** The failure of either Party at any time to enforce any of the provisions of this Agreement or any right under this Agreement, or to exercise any option provided, will in no way be construed to be a waiver of the provisions, rights, or options, or in any way to affect the validity of this Agreement. The failure of either Party to exercise any rights or options under the terms or conditions of this Agreement will not preclude or prejudice the exercising of the same or any other right under this Agreement.
- 9.4 Force Majeure. Neither Party will be liable for delay or damages if prevented from fulfilling its obligations by reason of Force Majeure causes, including but not limited to acts of God, acts of war (whether declared or undeclared), insurrection, terrorism, or acts of hostilities (such as invasion or bombing), lockouts, strikes, riots, floods, fires, governmental restrictions covering the use of Internet-based application and support services, priority given to U.S. Government work, export restrictions imposed by any Government, mobilization of technical personnel in general, or any other cause beyond the control of such Party. In case of Force Majeure, the Party's performance obligations will be extended by a reasonable period of time corresponding to the delay caused by the Force Majeure. The Party experiencing the Force Majeure will inform the other Party in writing within fifteen (15) days after a fact or event of Force Majeure has been recognized to have occurred.
- **9.5 Schedule Delay.** In those instances where a responsibility or performance obligation of Verisk or Client is dependent on a precedent performance activity or responsibility of the other Party, and the other Party does not perform its precedent performance activity or

responsibility as of the scheduled date or in accordance with the specifications for such precedent performance activity or responsibility, then the performance activity or responsibility of the other Party may be allowed to delay its performance by a reasonable amount of time; an allowance at least equal to the length of the delay engendered by the other party. The Parties understand that there may be instances where such a corresponding delay may reduce the amount of time for the non-delaying Party to perform its performance activity or its responsibility such that the non-delaying Party does not have adequate or sufficient time to fulfill its obligations in a commercially reasonable manner and stay within the agreed upon schedule as set forth herein, in which case the nondelaying Party will be entitled to take a reasonably necessary amount of time to complete its performance activity or obligation. The Parties agree that a delay, other than a minimal delay, may require a negotiation between the Parties to address the effect of such delay upon performance, schedule and/or price or costs.

- 9.6 Governing Law; Consent to Jurisdiction. This Agreement, including all matters of construction, validity, and performance, will be governed, construed and enforced in accordance with the laws of New York, if suit is brought by Client, or in accordance with the laws of the Client's state, as listed on the Cover Page of this Agreement, if suit is brought by Verisk. The Parties hereto agree that the exclusive jurisdiction and venue for any action under this Agreement, if brought by Client, will be the state and federal courts in New York, NY, and if brought by Verisk, will be the state and federal courts in Client's state, as listed on the Cover Page of this Agreement, and each of the Parties hereby agrees and submits itself to the exclusive jurisdiction and venue of such courts for such purposes.
- 9.7 Interpretation. Each Party hereby acknowledges that it has been represented by legal counsel in connection with this Agreement and the matters contemplated hereby. Accordingly, any rule of law or any legal decision that would require interpretation of any claimed ambiguities in this Agreement against the Party that drafted it has no application and is expressly waived. No course of dealing, course of performance, or usage of trade may be considered in the interpretation or enforcement of this Agreement. Both parties waive any right they may have to introduce any such evidence.
- **9.8** Severability. If any provision or portion of a provision of this Agreement is held invalid or unenforceable, the remainder of the Agreement will not be affected, and the remaining terms will continue in effect and be binding on the Parties, provided that such holding of invalidity or unenforceability does not materially affect the essence of the Agreement.
- **9.9 Notice.** Any notice or other written communication required or permitted to be given by a

Party under this Agreement must be addressed to the attention of the administrative contact of the other Party at the address set forth on the Cover Page. The administrative contacts of Verisk and Client are set forth on the Cover Page. Any such notice or other written communication_will be deemed delivered either: (1) five (5) business days after the notice has been mailed by certified mail or (2) the next business day after receipted delivery to a recognized overnight courier.

- **9.10 Compliance with Laws**. The Parties agree to comply with all applicable laws. If Verisk requires any government licenses or approvals to proceed with the provision of any Deliverable, Verisk will provide Client with prior notice of the requirement and an estimate of any resulting increase in the price of the Deliverable and Client will have the right to terminate this Agreement without further obligation, excepting obligations as defined in Section 8.2(b) ("Rights and Obligations upon Termination") herein, if Client determines in its reasonable discretion that such price increase is materially large.
- **9.11 Headings Not Controlling.** The headings and numbering of the sections and attachments of this Agreement are inserted for convenience of reference only and will not be construed to define or limit any of the terms herein or to affect the meaning of this Agreement.
- **9.12** Relationship of the Parties. The Parties to this Agreement are independent contractors. Nothing herein will be deemed to create a separate corporation, a merger or partnership of the Parties, a joint venture, a master-servant relationship, an employer-employee relationship, a contractor-subcontractor relationship, a principal-agent relationship, or any other relationship whatsoever besides that of independent contractors. Further, neither of the Parties to this Agreement, nor their respective officers, directors or employees will be construed to be the agent, employee or representative of the other except, and unless, specifically provided in this Agreement.
- 9.13 Entire Agreement. This is the entire Agreement between the Parties about its subject. It consists of the Cover Page, Sections 1 through 9, inclusive, any of Appendices A through I, if attached, any attached Statements of Work, and documents expressly referenced or described herein. It incorporates and supersedes all written and oral communications about its subject. This Agreement may not be amended, supplemented or changed in any manner except by a written instrument executed by an authorized representative of both Parties.
- **9.14** If any applicable federal or state laws either now or hereafter in effect may render any of the material terms of this Agreement unlawful or unenforceable, then the Parties will work together in good faith to restructure the arrangement and amend this Agreement to conform to the then-existing law.

9.15 Dispute Resolution.

- (a) Any dispute arising out of, or relating to this Agreement, not resolved between the parties within fifteen (15) days shall be resolved in accordance with the following procedures. The parties shall refer the dispute to the Chief Executive Officer of each party, who shall have authority to resolve the dispute between the parties. Such executives shall use all reasonable efforts to confer in person or by telephone within forty-eight (48) hours after referral of a dispute, and thereafter as they reasonably deem necessary, to exchange relevant information and to attempt to resolve the dispute.
- (b) Subject to the provisions of this paragraph 9.15, in the event of any dispute under this Agreement, or if it becomes necessary for a party to bring legal action to enforce its rights under this Agreement, the prevailing party in any such dispute or legal action or other proceeding shall be entitled to recover its reasonable legal fees, costs, and expenses from the other party.

[END OF TEXT]

APPENDIX A – VERISK APPLICATION SERVICES

All Deliverables rendered under this Appendix A will be set forth in a related Statement of Work. All Statements of Work will be governed in accordance with the Master Agreement, with the terms and conditions of this Appendix A and in the use and Confidentiality of Protected Health Information by Appendix B (collectively, the "Applications Agreement").

APPENDIX A.1 TERMS AND CONDITIONS FOR VERISK APPLICATION SERVICES

A.1.1 Definitions

- (a) "Application Service" means any Deliverable whereby users gain access, via an interface provided by Verisk, to information compiled by Verisk, in any Internet-available or private data network.
- **(b)** "Application Data" Includes but is not limited to individuals' personal, medical, pharmacy, disability, provider or insurance claim information provided by Client or Client's business partners, including without limitation, third party administrators, pharmacy benefit companies and utilization management companies, to Verisk to create an Application Service, pursuant to the Applications Agreement. Application Data includes, but is not necessarily limited to, claims and membership information for Client insurance plan members.
- (c) "Client Customer" means a Third Party making payments to Client for Client's services and for whom the Application Data used by Verisk to provide an Application Service is uniquely specific.
- (d) "Authorized User" means (a) any employee of a Client, or (b) any employee of a Permitted Contractor, or a Client Customer ("Approved Authorized User").
- (e) "Permitted Contractor" means each person or entity who contracts with Client to provide consulting, programming, analytical, or processing services, by installing or accessing the Application Service on computers operated by such person or entity and accessing or executing the Application Service or manipulating related input or output in support of the purposes authorized hereunder for Client's use of the Application Service, provided that, in the absence of further authorization from Verisk, to qualify as an Approved Authorized User, such person or entity must provide such services insofar as they pertain to the Application Service solely to Client for its sole account, and Client must cause each such entity to enter into, be bound by, and comply with the restrictions and obligations applicable to Client as detailed below.
- (f) "Ancillary Verisk Services" will include but are not limited to Comparative Data and other benchmarking, comparative reporting and analysis services used by Verisk as part of or ancillary to an Application Service or consulting service.
- **(g)** "Documentation" will mean the printed user manuals provided by Verisk to Client for use with an Application Service.
- (h) "Verisk Applications" means any and all Application Services, the software source, object and executable code used to implement such Application Services, any reports generated from data available through such Application Services, and any modifications or enhancements thereto, but not including any stored Application Data provided by Client to Verisk hereunder.
- (i) "Application Service Use" means any access to, visualization of any screen or print display of, or any written or oral description of any such visualization of any component of Verisk Applications.

A.1.2 Use of an Application Service

- (a) Client may permit its Authorized Users to access and use an Application Service only for Client's own internal use and for Client's use in providing services to Client Customers, and not for the use or benefit of any other Third Party.
- **(b)** Client will limit access to an Application Service to those of its Authorized Users that have a reasonable need for such access and will inform the Authorized Users who are allowed such access of the restrictions contained in the Applications Agreement on the use of the Application Service.

- (c) Client will not grant access to Approved Authorized Users without first identifying the prospective user to Verisk and receiving approval from Verisk to grant such access, such approval not to be unreasonably withheld.
 - (d) Each Authorized User account will be used by one and only one individual.
- **(e)** Client will be responsible for the acts and omissions of its Authorized Users with respect to the provisions of the Applications Agreement and use of an Application Service.
- **(f)** The Parties agree to abide by restrictions, as described in Appendix B of this Agreement, on the use of protected health information.

A.1.3 Rights in Application Service Use.

- (a) Subject to the terms and conditions of this Agreement, Verisk grants to Client a personal, nontransferable and nonexclusive right to Application Service Use solely within and for the benefit of Client's own internal business operations and for Client's use in providing services to Client Customers, and for no other purpose.
 - **(b)** Additional limitations on Client's rights are as follows:
- (i) The right to Application Service Use will not extend to any Third Party other than an Authorized User, or any business or operation of a Third Party, unless and until (i) Verisk is notified in writing of the desire for such extension, and (ii) Verisk and Client agree in writing as to appropriate increases, if any, in the payments required under this Agreement.
- (ii) Client will not modify, add to, transfer, copy, adapt, translate, create derivative works of, reverse engineer, de-compile or disassemble the Verisk Applications ("Adaptations"). Client will not contract with any Third Party to create Adaptations, nor use Adaptations created by any Third Party independently.
- (iii) No right is granted to Client to (i) make Verisk Applications available in any public electronic bulletin board, public computer based information system, or the equivalent; (ii) publish, translate or transfer possession of Verisk Applications or copy any portion thereof; or (iii) without prior written permission from Verisk, frame or deep-link into any page of any Verisk Application, or otherwise mask the appearance of Verisk -identifying information on such page.
- (iv) No right is granted to Client (i) for the use of the Documentation or Comparative Data except as part of the corresponding Application Service; (ii) for Application Service Use for or by any Third Party; (iii) to sell, transfer, export, license, sublicense or provide any Verisk Applications to Third Parties other than Application Services made available to Client Customers as Approved Authorized Users, (iv) to transmit Verisk Applications to any Third Party other than an Authorized User in accordance with the terms hereof, (v) for Application Service use for any purpose other than as expressly permitted under this Agreement.
- (c) Except as specifically provided in this Agreement, Verisk assumes no responsibility for (i) providing any improvements to Verisk Applications, (ii) maintaining the Verisk Applications, or (iii) providing other services with respect to the Verisk Applications.

A.1.4 Ownership of Intellectual Property.

(a) Verisk owns and retains all right, title, and interest in and to, including without limitation all Intellectual Property rights, in all software programs (whether or not installed on a Client-owned system), methodology, techniques, the identity of edits and materials, enhancements, derivatives, and modifications to all Verisk owned intellectual property, including without limitation all source code, object code, and documentation associated therewith, and all documentation, report formats, methodologies, algorithms, templates, logic flow, formulae, inventions, methods, systems, processes, works of authorship, and materials which have been or are in the future created, conceived, developed or acquired by Verisk and which are included in or used in providing the Services, including without limitation the Licensed Products and Services and all modifications, improvements, derivative works and compilations thereof and thereto (all the foregoing, collectively, Verisk IP or Verisk Intellectual Property). Client agrees that all Verisk IP constitutes the Confidential Information of Verisk, and Client shall not use or disclose such Confidential Information except as permitted under Paragraph 3 of the Master Agreement.

- (b) Client agrees that it will not use or disclose such Verisk IP except solely as necessary to receive the Services described in this Agreement. Without limiting the foregoing, Client shall not, and shall cause its employees or authorized users to not: 1) reverse engineer, decompile, reverse compile, or disassemble the Verisk IP; 2) create a derivative work or compilation of the Verisk IP, including without limitation any product or service derived or compiled from or based on, in whole or in part, any Verisk services or products. Client may not copy, distribute, market, sell, lease, sublicense or otherwise transfer the Licensed Programs or Services to third parties.
- (c) Notwithstanding the above, in no way shall Client be prevented from implementing changes to its systems, processes, or contracts that are done in the ordinary course of business or were otherwise arrived at independent of and without reliance on or benefit of the results of the Licensed Programs or Services provided herein.
- (d) As between the Parties, Verisk and its licensors are the owners of all right, title and interest, including all intellectual property rights, in and to Verisk Applications, Comparative Data and Ancillary Verisk Services. Except as expressly provided herein, Verisk and its licensors reserve all rights with respect to Verisk Applications and Client will not have or exercise any such rights not expressly granted.
- (e) As between the Parties, unless otherwise specified in a Statement of Work, Verisk will be the owner of all right, title and interest, including all intellectual property rights, in and to any code required to provide Deliverables, and Client will be the owner of all right, title and interest, including all intellectual property rights, in and to Application Data and printed or displayed output from Deliverables that includes Application Data.
- **(f)** Third Party Intellectual Property in the Application Services. To provide the Application Services, Verisk is required to acknowledge the following licenses of third-party data.
- (i) AMA Sublicense. CPT (current procedural terminology) Codes, CPT descriptions, and CPT material only are copyright American Medical Association ("AMA"). All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in CPT. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for data contained or not contained in the Application Services provided. CPT is a trademark of the American Medical Association. Future updates to CPT are contingent upon Verisk continuing its contractual relationship with the AMA.
- (ii) U.S. Government Rights. The Application Services include CPT which is commercial technical data and/or computer data bases and/or commercial computer software and/or commercial computer software documentation, as applicable, which were developed exclusively at private expense by the American Medical Association, 515 North State Street, Chicago, Illinois, 60610. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose their technical data or and/or computer data bases and/or computer software and/or computer software documentation are subject to the limited rights restrictions of DFARS 252.227-7015(b)(2) (June 1995) and/or subject to the restriction of DFARS 227.7202-1(a) (June 1995) and DFARS 227.7202-3(a) (June 1995), as applicable for the U.S. Department of Defense procurements and the limited rights provisions of FAR 52.227-14 (June 1987) and FAR 52.227-19 (June 1987), as applicable, and any applicable agency FAR Supplements, for non Department of Defense Federal procurements.

A.1.6 Additional Verisk Indemnity. In addition to the provisions of Section 7 ("Indemnity") of the Master Agreement:

- (a) Verisk will protect, indemnify, hold harmless and defend Client with counsel reasonably acceptable to each Party, at Verisk's expense, against so much of any claim, action or suit brought against Client by a Third Party as may allege or claim that an Application Service or any portion thereof (other than those portions which are Third Party software), or the use or possession thereof infringes or violates any existing United States patent (except for claims under patents of which Verisk is unaware as of the Effective Date), United States copyright or trade secret of a Third Party. Verisk will pay, indemnify and hold harmless Client from and against any and all final judgments or settlements agreed to by Verisk which are attributable to such claims, including costs and reasonable attorneys' fees as finally awarded or agreed to in such settlements; provided, however, Client notifies Verisk promptly in writing of such claim and grants Verisk sole control of the defense and of all negotiations for settlement or compromise thereof.
- (b) In the event an injunction is obtained against Client's use of an Application Service or any portion thereof, or in the opinion of Verisk it appears likely that such an injunction will be obtained, Verisk will at its option, (i) secure Client's right to continue using such Application Service or portion thereof, (ii) replace or modify such Application Service or portion thereof to make it non-infringing, or if (i) and (ii) are unreasonable in Verisk's opinion, then (iii) terminate or cancel Client's licenses and rights with respect thereto, and refund Client an amount representing the value of the unused portion of any prepaid Application Service fees.

General VH Master Services Agreement 2011

- (c) The foregoing defense, indemnification and other obligations of Verisk, pursuant to this Section will not apply to the extent that (i) without the written consent of Verisk, Client modifies an Application Service or any portion thereof, (ii) Client or any of its subsidiaries uses an Application Service or any portion thereof, in a manner not permitted or contemplated hereunder or in violation of this Agreement, including without limitation any method of framing any Application Service screen or subset of a screen, (iii) the infringement claim is based on a patent or copyright owned or controlled by Client or that could reasonably have been licensed by Client, or (iv) infringement results from the combination of an Application Service or any portion thereof with any hardware, data or other applications or services not provided or specified by Verisk.
- (d) The foregoing will be Client's sole and exclusive remedy with respect to Intellectual Property infringement as it relates to Application Services.
- A.1.7 Client's Authorized User Warranty. Client represents and warrants to Verisk that it will have obtained, prior to the commencement of the use of an Application Service, appropriate agreements with its Authorized Users who may access and use the Application Service sufficient to enable Client and its Authorized Users to comply with the terms of the Applications Agreement. The requirements of the previous sentence will be considered fulfilled if an Authorized User acknowledges acceptance of the terms of an End User License Agreement (EULA) describing such compliance, which such EULA has been made available for Authorized User viewing and acceptance upon the Authorized User's first attempt to gain access to the Application Service. In the event Client learns or has determined that an Authorized User is in breach of such EULA, Client will notify Verisk within five (5) days of such breach. In that event, or if Verisk otherwise learns or has determined that an Authorized User is in breach of such EULA, Verisk will have the right to terminate such Authorized User's access to any Application Service forthwith. Furthermore, Client hereby expressly guarantees the performance of Authorized User obligations under any EULA.
- **A.1.8** Additional Exclusion from Liability. Verisk will not be liable for any damages, expenses or loss due to impairments to a Deliverable caused by acts of Client or its Authorized Users.
- **A.1.9** Additional Rights and Obligations upon Termination. Upon any termination of this Applications Agreement, Client will cease all use of any Application Services. Verisk will not be obligated to return to Client or Client Customers any De-identified Data.
- **A.1.10** Additional Confidentiality. The identities of and other information about Client Customers is included as Confidential Information protected under the terms of the section on Confidential Information in the Master Agreement.
- **A.1.11** No Rights by Implication. Except as expressly set forth in this Applications Agreement, no direct or indirect ownership interest or license rights are granted or created by implication in this Applications Agreement. Any other grant of an ownership interest or license rights must be negotiated in a Statement of Work or separate agreement.
- **A.1.12** Trademarks. Neither Party has a right to and hereby agrees not to use in any manner the name, trade name or any trademark of the other Party except as allowed in Section 9.1 of the Master Agreement.
- **A.1.13** Similar Work for Other Customers. Verisk may perform the same or similar services for others.

APPENDIX A-2D—STATEMENT OF WORK FOR PERFORMANCE MEASUREMENT (APPLICATION SERVICE PROVIDER)

A2D.1. General

- (a) Reference to Applications Agreement. The Parties agree that this Appendix A.2D is a Statement of Work subject to Appendix A Verisk Application Services, and as such is governed by the Applications Agreement terms defined therein. Unless explicitly amended by a term in this Appendix, the terms and conditions of the Applications Agreement remain in force. If there is any discrepancy or ambiguity in interpretation such that a term of this Appendix potentially conflicts with a term of the Applications Agreement, the Parties agree that the term of this Appendix takes precedence.
- **(b)** Effect of Termination of the Terms of this Appendix. If this Appendix A.2D represents the only Statement of Work in effect between Verisk and Client, termination under the terms of this Appendix A.2D will be treated as a termination of the Master Agreement as described in the Term and Termination Section. In all other cases, termination under the terms of this Appendix will be a termination of the obligations of the Parties as described in this Statement of Work only.

(c) Additional Definitions

- (i) "Upgrade" "means an updated version or new instance of a module, report or form added to the base Application Service described herein and offered by Verisk to its clients at no additional charge beyond the applicable base Application Service fees.
- (ii) "Payor" is strictly limited to the following types of organizations: Health Plan, Pharmacy Benefits Manager (PBM), and Third Party Administrator (TPA) unless otherwise agreed to in writing by the Parties.
- (iii) "Clean and Complete" means data from a Client Payor which includes required data elements and control totals delivered to Verisk in a consistent format. More specifically, "complete" refers to receiving files required for processing and "clean" refers to the data elements being correctly populated in those files.
- (iv) "Data," unless otherwise explicitly indicated, is strictly limited to medical claims data, or pharmacy claims data, or eligibility data. Eligibility data is sourced from the Payor data files. For clarification, this definition is not meant to exclude supporting data such as data dictionaries, crosswalk tables or data maps.

A2D.2. Application Service Description

(a) Base Application Service Description

Performance Measurement is a suite of software modules, which provide for the calculation and analysis of Healthcare Effectiveness Data and Information Set (HEDIS®) measures. HEDIS is developed and maintained by the National Committee for Quality Assurance (NCQA), a not-for-profit organization committed to assessing, reporting on and improving the quality of care provided by organized delivery systems.

Performance Measurement consists of: (i) Quality Engine ("Quality Engine"), which calculates HEDIS administrative rates and is 100% certified by the NCQA HEDIS Software Certification program, a systematic sampling module that is also 100% certified under the NCQA Software Certification program, a medical record chase module, which identifies health care providers which are likely to possess the medical records needed for the HEDIS hybrid methodology chart review process, a patient level detail (PLD) file generator used for submission of Medicare data to NCQA, and other utilities for extraction of demonstration data, NCQA IDSS submission file creation, and administrative updates to sample data; (ii) Quality Reporter Viewer ("Quality Reporter Viewer"), which provides HEDIS reports, detailed data drills for analysis, audit, comparative studies, intervention support, and other data analysis features.

HEDIS[®] is a registered trademark and HEDIS Software CertificationSM is a service mark of the National Committee for Quality Assurance (NCQA).

All Performance Measurement Application Services including HEDIS databases, will be installed and hosted on Verisk servers. The Quality Engine component of the Licensed Program is not available for access by Client. Client will have access to Quality Reporter via a secure remote desktop connection.

A2D.3. Deliverables

The following Deliverables Schedule details the support included in the statement of work. The deliverable schedule assumes the enrolled members are less than 150,000. The number of enrolled members is defined by the number of members loaded into the software.

Item	Deliverable description	Assigned to	Completion Date
1	Kickoff meeting, Web Portal Set up, Software access	Vendor	SOW execution plus 14 days
2	Client Questionnaire completed	Client	SOW execution plus 7 days
3	Input File Walkthrough	Vendor	SOW execution plus 14 days
4	Define Custom Input (if applicable)	NA	NA – if client will use standard format
5	Test Admin Data prepared	Client	SOW execution plus 21 days
6	Translate Custom Input (if applicable)	NA	NA – if client will use standard format
7	Install and Train Quality Engine in Person	NA	NA for ASP model
8	Install and Train Measures Developer in Person (if applicable)	NA	NA
9	Train Quality Reporter via webinar - Viewing	Vendor	SOW execution plus 14 days
10			The later of 21 days from the receipt of usable input files or 42 days after SOW
	Test Run completed	Vendor	execution
11	Data Analysis - Test	Client	Test Run plus 14 days
12	Retest (if necessary)	Client	tbd
13	Location/Provider cleanup performed	Client	Test Run plus 14 days
14	Sample Configuration Completed	Client	
15	Chase Configuration Completed	Client	
16	CAHPS - Files made available	Client	
17	CAHPS Extract Completed	Vendor	7 days from the receipt of usable input files. Input files should be standard or in the same format as test input
18	Production Software Validation	Client	
19	Production Input Files Prepared	Client	
20	Production Datamart with Sample Pull Available	Vendor	7 days from the receipt of usable input files. Input files should be standard or in the

Item	Deliverable description	Assigned to	Completion Date
			same format as test input
21	Data Analysis - Production	Client	Delivery of Production Data plus 14 days
22	Train Quality Reporter	Vendor	Viewing features and managing chart review – In Person (July-Nov) Performing Chart Review – In Person (Dec-March)
23	Administrative Refresh Input Prepared	Client	
24	Final Datamart Created	Vendor	7 days from the receipt of usable input files. Input files should be standard or in the same format as test input
25	Chart Review	Client	,
26	IDSS Plan Lock	Client	
27	IDSS Mark Final	Client	
28	PLD Submission	Client	
29	Feedback Meeting	Client and Vendor	
30	Proactive Run	Vendor	

- (a) Initial Implementation. Implementation is considered completed ("Initial Implementation") upon the successful provision of the scheduled Deliverables one (1) through ten (10) described in Section A2D.3 above. Such success is to be reasonably determined by Verisk and Client jointly as reflecting the accurate representation of Client's data in the Application Services provided. By means of explanation and not exclusion, success will be considered realized if Verisk has provided the appropriate Application Services, even if such Application Services include flawed data that has been provided by Client or Third Parties acting on behalf of Client. Although Verisk will use its best effort to cleanse and quality control all data submissions, there can be no assurance that the Application Services will not include flawed data from parties other than Verisk.
- **(b)** *Remote Access.* Verisk will provide remote access to the Application Services to five (5) named users. User connections allocated to Permitted Contractors will be deducted from the total number of connections allotted to Client.
- (c) Measurement Production Services. Verisk will: audit and load Client data; execute measure logic; perform sampling extractions and chase logic; execute two (2) production HEDIS runs, one test run, CAHPs extracts, and one proactive (Summer) run. Additional HEDIS runs are available at the rate specified in A2D.5(a).
- (d) Verisk represents and warrants that it has and will maintain NCQA certification.

A2D.4. Client Responsibilities

- (a) Client will provide computers and operating systems (Microsoft Windows) for remote access to Verisk servers.
- (b) Client will provide input data formatted according to the Verisk data input specifications
- (c) Input Data

- (i) Input Data Format. The Verisk data input specifications ("Input Specifications") are published on Verisk's Web Portal.
- (ii) Correction of Client Input Data. In the event that Client is unable or unwilling to create input data to utilize Quality Engine to process data and produce correct results, Client will send its then-current input data ("Client-Formatted Input Data") to Verisk for analysis and processing. Once analyzed, Verisk will do one of the following:
 - (1) If the Client-Formatted Input Data is determined to be incorrectly formatted for input to the Quality Engine, Verisk will create a client translation process ("Client Data Translation") and translate Client-Formatted Input Data in order for Client-Formatted Input Data to correctly be presented as input to the Quality Engine at Verisk's standard hourly support rate noted in A2D.5(a) (\$200 an hour). If data that is required for Quality Engine was omitted from Client-Formatted Input Data, Client agrees to modify Client-Formatted Input Data as requested by Verisk, and send such data to Verisk as needed. Once the Client Data Translation is developed, Verisk will provide a "plug-in" to its Quality Engine, which will incorporate the Client Data Translation into the Quality Engine for Client to use for future HEDIS runs. Client agrees to utilize the Client-Formatted Input Data format for future runs of the Quality Engine.
 - (2) If the Client-Formatted Input Data is determined to be correctly formatted, Vendor will correct the problem at no charge.
- (d) Failure to Provide Data. In no event, excepting cases of true impossibility, shall Client's failure to provide data to Verisk constitute a "frustration of the venture" or otherwise discharge Client's obligation to pay the annual fee.

(e) Project Management

Each party shall designate in writing one person ("Project Manager") who will be the contact person for all implementation issues associated with the performance of this Statement of Work. Each party may substitute or replace its Project Manager at any time upon providing written notice to the other party. Each party shall make its Project Manager available for planning sessions, status meetings, telephone consultation, and otherwise as reasonably required to facilitate the implementation of this Statement of Work.

A status meeting will be conducted regularly. Normally every 2 weeks to track deliverables, answer questions, and discuss any open items.

Verisk's Web Portal will be used for meeting minutes, open issue tracking, communication, software downloads and training materials.

(f) Change Management. Deliverable completion dates cannot be changed except via this change control process. If a deliverable date is to change, a change control request (Appendix C) shall be submitted to Client's Project Manager for review and consideration. The request should indicate why the change is necessary and what it will cost, as well as the impact on the planned activity dates. Should the Client Project Manager believe the change should be approved, it must be reviewed and approved by an officer authorized to bind the Client. Once approved, the Project Manager must submit the change via appropriate standard Client request documentation to the Client approval process for additional funding; if additional funding is approved, the project plan will be changed and the purchase order altered to reflect the increased cost.

A2D.5. Application Service Pricing

(a) Application pricing for Performance Measurement Application Services is calculated as follows:

Annual Fees:		Price and Description
Annual Service License Fee	\$100,000	Includes five (5) named user licenses ; pricing valid for up to 150,000 members loaded into software.
One-Time Fees		
Implementation Fee	\$5,000	Implementation

Data Translation	\$200/hour	For data translation from IKA Systems claims file. Estimate of thirty eight (38) hours of translation work to be validated upon receipt of IKA data layouts.
Claims data file delivery	Included	Accept IKA Systems data file – IKA will post data file to Verisk secure FTP site.
On-Site Training	Included	Two days on-site training included. All reasonable travel costs and expenses are the responsibility of the client.
Rates for As-Requested Services		
Additional On-Site Training	\$3000 per day	Plus reasonable travel and expenses
Additional User Licenses	\$1,000	Per Year Per Named User
Additional Support	\$200/hour	Rate for Additional Support and Client Data Translation after the first 40 hours of Data Translation.
Additional HEDIS Process Runs	\$5,000	Per run as requested by Client.
Additional DataMarts	\$15,000 annually per Datamart	Additional datamarts (e.g. quarterly, 2 years prior, etc.) are available upon request. 15 business days notice is required for request fulfillment.

- (i) Annual Service License Fees.
 - (1) The Annual Service License Fee for year one shall be invoiced on the Agreement Effective Date. The Annual Service License Fee in each subsequent year shall be invoiced on the anniversary date of the contract.
- (ii) Implementation Fee. \$5,000
- (iii) *Discount:* A \$10,000 per year discount (\$30,000 total over three years), will be applied only if a fully executed agreement is received by Verisk on or before June 29, 2012.
- (iv) Additional Support. \$200 per hour.
- (v) Five (5) users will be licensed to access the Performance Measurement Application Services. Additional users may be added at the rate of \$1,000 per user per year.
- (vi) Annual Application Service Price Escalation. The annual license fee will increase by 5% for each year following year one of the contract.
- (vii) Providing access to the current year DataMart and a single DataMart from the prior year is included in license fee. This will be provided up to June 30. Dedicating one or more of the user connections towards these DataMarts is free

A2D.6. Support & Training

(a) Support. Provide Standard Support - Provide support for work specified in the statement of work up to 15 hours per month. Support in excess of 15 hours per month or for items not specified in the statement of work will be charged at the rate of \$200 hour.

Vendor's Standard support hours are 8:00am – 5:00pm Central Time, Monday through Friday, except for holidays. For support outside the standard support hours, specific arrangements for after-hours support must be made by Client with Vendor a minimum of forty-eight (48) hours in advance of the support being conducted.

Services are accessible via: Email: hedis-support@veriskhealth.com; Phone: 952.368.9970 during standard support hours

(b) Training. Two days on-site training included. All reasonable travel costs and expenses are the responsibility of the Client. Verisk offers scheduled webinars free of charge – normally scheduled each month from December – May. Additional onsite training will be billed to the client at a cost of \$3000 per day plus travel and expenses.

(c) Application Consulting Services. Verisk may, upon written and properly authorized request, provide consultative assistance in the use and value extraction from an Application Service described herein. For the sole purpose of such assistance, the following rates apply:

Role title	Expertise/Role	Hourly rate
Sr. Scientist/Principle	Physician or principle officer of	\$350
_	Verisk Health with substantial	
	healthcare experience	
Clinical Consulting	RN or Engineer with specific	\$200
	healthcare and clinical skills	
Bioinformatics Analyst	Bioinformatics Analyst with 5+	\$200
	years experience in computer	
	science and healthcare analytics	
	experience	
Programmer/Processor	Verisk Health data processor or	\$200
	programmer	

Both parties agree to the above Statement of Work by their respective signatures below.

Client	Verisk Health	Verisk Health, Inc.	
Signature:	Signature:		
Print Name:	Print Name:		
Title:	Title:		
Date:	Date:		

APPENDIX A-2E—STATEMENT OF WORK FOR PERFORMANCE MEASUREMENT MEDICAL RECORD RETRIEVAL

A2E.1 General

- (a) Reference to Applications Agreement. The Parties agree that this Appendix A.2E is a Statement of Work subject to Appendix A Verisk Application Services, and as such is governed by the Applications Agreement terms defined therein. Unless explicitly amended by a term in this Appendix, the terms and conditions of the Applications Agreement remain in force. If there is any discrepancy or ambiguity in interpretation such that a term of this Appendix potentially conflicts with a term of the Applications Agreement, the Parties agree that the term of this Appendix takes precedence.
- (b) Reference to Appendix A-2D—Statement of Work for Performance Measurement Application Services. This Statement of Work is entered into in conjunction with Appendix A-2D. Because Performance Measure Application Service is necessary to utilization of the Medical Record Retrieval functionality within that Application Service this Statement of Work is governed by Appendix A-2D as well, and shall remain in effect only for so long as that Appendix is in effect.
- **(c)** *Term of This Statement of Work.* This Statement of Work shall commence as of the last dated signature below, and shall remain in effect, unless terminated in accordance with Master Agreement, for a period of three years.

A2E.2 Project Background

- (a) The purpose of this Statement of Work is to define the medical record review capabilities Verisk will be providing to Client to support HEDIS reporting and management using the Verisk Performance Measurement Application Service.
- **(b)** This Statement of Work outlines the functions and deliverables Verisk will provide to Client to support the medical record review process used to potentially improve HEDIS scores.

A2E.3 Project Objectives

(a) Verisk will put in place to complete medical record review and then provide the results of that review within the Performance Measurement Application Service.

A2E.4 Approach and Deliverables

(a) Verisk will put in place a robust end to end solution to complete medical record review. This includes the creation of a chase report list, contacting the providers to obtain the medical records, completion of the medical record review, and provision of the results of the review within the Performance Measurement Application Service.

(b) Specifics of the project

- (i) Verisk will create an extract from Sightlines Performance Measurement that reflects the list of Providers and Member medical records that require medical review.
- (ii) Representatives will then contact the offices and obtain the medical records from the physician offices for the members identified for medical record review.
- (iii) The review of the medical record will be completed by a certified clinical coder. Each clinical coder is certified by either AAPC or AHIMA (the two national certifying agencies in the US). In addition to Verisk's extensive training programs, each coder also attends annual trainings and examinations to keep their certifications current.

- (iv) Verisk has eight (8) HEDIS experienced professional coders who also are clinicians that provide medical record review. They will be assigned to this Project.
- (v) The results of the completed medical record review will be available to Client staff within the Performance Measurement Application Service. Client will be able to view reporting in the application.
- (vi) Medical Record Review data entry will be performed on the ASP instance of Client's Performance Measurement Application Service. Data updates will be visible immediately within the Client's Application Service and available for review by Client staff at any time.
- (vii) Verisk will provide reporting on the chart extraction/chase process.
- (viii) A copy of the medical record will also be available within the Performance Measurement Application Service for audit validation.

A2E.5 The Key Deliverable is:

(a) Publish the results of the medical record review within Performance Measurement Application Service for Client staff to access.

A2E.6 Project Timeframe

(a) Verisk will perform medical record review for Client in the 2013, 2014, and 2015 HEDIS seasons.

A2E.7 Professional Fees

- (a) Each medical record review will be at a cost of \$25.00 (Twenty five dollars) per review. There is a minimum commitment of 3,500 charts with an expected volume of between 4,000 to 5,000 charts reviewed per HEDIS season. Client will be billed monthly.
- **(b)** Client will be invoiced and responsible for all provider chart retrieval fees charged to Verisk.

APPENDIX A.3—SERVICE LEVEL SUPPORT FOR VERISK APPLICATION SERVICES

The following schedule and technical support will be available to Client throughout the term of this Agreement.

A.3.1 Application Service Performance Levels.

(a) Definitions.

- (i) "Host Server" means the server(s) on which Verisk has installed an Application Service for Client's Application Service Use.
- (ii) "Downtime" means time when an Application Service is not accessible or does not correctly respond to user input because of Application Service failure or error, failure of hardware within the control of Verisk or its hosting subcontractor, electrical failure at the hosting facility, or a failure of the local area network to which the Host Server is connected.
- (iii) "Availability" means the percentage of time, between the hours of 8:00 am and 5:00 pm, Eastern time, from Monday through Friday excepting holidays, during which an Application Service is not experiencing Downtime. Availability will exceed ninety-seven percent (97%) per month ("Availability Target").
- **(b) Response times.** During any period for which Client has paid the applicable monthly Application Service fees, Verisk agrees that it will use its best efforts to respond to Client's requests for services and resolve the problems indicated within the time frames set forth in this Section.
 - (i) <u>Severity Level 1 problems</u> render an Application Service totally inoperable. No workaround exists. Response time: 1 business day. Verisk action: Immediately and continuously work toward resolution or acceptable workaround. Escalate if not resolved within 2 business days.
 - (ii) <u>Severity Level 2 problems</u> severely restrict operation or result in lack of key Application Service functionality. Response time: 2 business days. Verisk action: Immediately and continuously work toward resolution or acceptable workaround. Escalate if not resolved within 3 business days.
 - (iii) <u>Severity Level 3 problems</u> have a minor impact on operation, but some functionality is not available. Response time: 5 business days. Verisk action: Workaround provided within 2 weeks, with fix provided in the next release of the Application Service.
 - **(iv)** <u>Severity Level 4 problems</u> are usage questions. Response time: These are normally quick answers that can be provided within 2 business days. We can commit to addressing all within 5 business days. Verisk action: Question answered.
- (c) Escalation Procedure. If a Severity Level 1 or Severity Level 2 problem, as described above, is not resolved in the response time indicated in section A.3.1.b, the problem will be escalated to a senior Verisk support manager who will update Client's senior IS personnel twice a day until the problem is resolved.

APPENDIX B—BUSINESS ASSOCIATE AGREEMENT

This Agreement is entered into on this	day of	20, b	y and between th	ie
Verisk Health, Inc., on behalf of itself and its subs	sidiaries (each a '	"Business Associate"), and «Covered_	Entity
name», a «Type_and_Jurisdiction» ("Covered	d Entity").			

WHEREAS, Covered Entity will make available and/or transfer to Business Associate certain information, in conjunction with services that are being provided by Business Associate to Covered Entity, that is confidential and must be afforded special treatment and protection; and

WHEREAS, Business Associate will have access to and/or receive from Covered Entity certain information that can be used or disclosed only in accordance with this Agreement; and

WHEREAS, Business Associate and Covered Entity desire to comply with the applicable business associate provisions of the privacy regulations (45 C.F.R. Parts 160-164), the provisions of the security regulations (45 C.F.R Part 164), the provisions of the standards for electronic transactions regulations (45 C.F.R. Parts 160 and 162), and the securities regulations (45 C.F.R. Part 142) of the Health Insurance Portability and Accountability Act of 1996 ("HIPAA").

NOW, THEREFORE, Covered Entity and Business Associate agree as follows:

- 1. **Definitions.** Capitalized Terms used but not otherwise defined in this Agreement shall have the same meaning as those terms in the Privacy Rule and the Security Rule.
- 1.1 "Individual" shall have the same meaning as the term "individual" in 45 CFR §164.501 and shall include a person who qualifies as a personal representative in accordance with 45 CFR §164.502(g).
- 1.2 "Privacy Rule" shall mean the Standards for Privacy of Individually Identifiable Health Information at 45 CFR Part 160 and Part 164, Subparts A and E.
- 1.3 "Protected Health Information" shall have the same meaning as the term "protected health information" in 45 CFR §164.501, limited to the information created or received by Business Associate from or on behalf of Covered Entity.
 - 1.4 "Related Agreement" shall mean that certain «Related Agreement Name, and effective date».
- 1.5 "Required By Law" shall have the same meaning as the term "required by law" in 45 CFR §164.501.
- 1.6 "Secretary" shall mean the Secretary of the Department of Health and Human Services or his designee.
- 1.7 "Security Rule" shall mean the Standards for the Security of Electronic Protected Health Information at 45 CFR Part 164, Subpart C.

General VH Master Services Agreement 2011	Page 12
General vii Master Services Agreement 2011	Page 12

2. Obligations and Activities of Business Associate

- 2.1 Business Associate agrees to not use or disclose Protected Health Information other than as permitted or required by this Agreement or the Related Agreement or as Required by Law.
- 2.2 Business Associate agrees to use appropriate safeguards to prevent use or disclosure of the Protected Health Information other than in accordance with the terms of this Agreement.
- 2.3 Business Associate agrees to report to Covered Entity any use or disclosure of the Protected Health Information not provided for by this Agreement of which it becomes aware.
- 2.4 Business Associate agrees to require that any agent, including a subcontractor, to whom it provides Protected Health Information received from, or created or received by Business Associate on behalf of, Covered Entity agrees to the same restrictions and conditions that apply through this Agreement to Business Associate with respect to such information.
- 2.5 Business Associate agrees to provide access, at the request of Covered Entity, and in such time and manner as the parties may mutually agree, to Protected Health Information in a Designated Record Set, to Covered Entity or, as directed by Covered Entity, to an Individual in order to meet the requirements under 45 CFR §164.524.
- 2.6 Business Associate agrees to make any amendment(s) to Protected Health Information in a Designated Record Set that the Covered Entity directs or agrees to pursuant to 45 CFR §164.526 at the request of Covered Entity or an Individual, in such time and manner as the parties may mutually agree.
- 2.7 Business Associate agrees to make its internal practices, books, and records, including policies and procedures, relating to the use and disclosure of Protected Health Information received from, or created or received by Business Associate on behalf of, Covered Entity available to Covered Entity or the Secretary, in such time and manner as the parties may mutually agree or as may be designated by the Secretary, for purposes of the Secretary determining Covered Entity's compliance with the Privacy Rule and Security Rule.
- 2.8 Business Associate agrees to use commercially reasonable efforts to document such disclosures of Protected Health Information and information related to such disclosures as would be required for Covered Entity to respond to a request by an Individual for an accounting of disclosures of Protected Health Information in accordance with 45 CFR §164.528.
- 2.9 Business Associate agrees to provide to Covered Entity or an Individual, in such time and manner as the parties may mutually agree, information collected in accordance with Section 2.8 of this Agreement, to permit Covered Entity to respond to a request by an Individual for an accounting of disclosures of Protected Health Information in accordance with 45 CFR §164.528.
- 2.10 Business Associate agrees to (i) implement administrative, physical, and technical safeguards that reasonably and appropriately protect the confidentiality, integrity, and availability of the electronic protected health information that it creates, receives, maintains, or transmits on behalf of the covered entity as required by the Security Rule §164.314; (ii) ensure that any agent, including a subcontractor, to whom it provides such information agrees to implement reasonable and appropriate safeguards to protect it: and
- (iii) report to the covered entity any security incident of which it becomes aware;

3. Permitted Uses and Disclosures by Business Associate

- 3.1 Except as otherwise limited in this Agreement, Business Associate may use or disclose Protected Health Information to perform functions, activities, or services for, or on behalf of, Covered Entity as specified in the Related Agreement, provided that such use or disclosure would not violate the Privacy Rule or Security Rule if done by Covered Entity.
- 3.2 Except as otherwise limited in this Agreement, Business Associate may use Protected Health Information for the proper management and administration of the Business Associate or to carry out the legal responsibilities of the Business Associate.
- 3.3 Except as otherwise limited in this Agreement, Business Associate may disclose Protected Health Information for the proper management and administration of the Business Associate, provided that disclosures are Required By Law, or Business Associate obtains reasonable assurances from the person to whom the information is disclosed that it will remain confidential and used or further disclosed only as Required By Law or for the purpose for which it was disclosed to the person, and the person notifies the Business Associate of any instances of which it is aware in which the confidentiality of the information has been breached.
- 3.4 Except as otherwise limited in this Agreement, Business Associate may use Protected Health Information to provide data aggregation services to Covered Entity as permitted by 42 CFR §164.504(e)(2)(i)(B).
- 3.5 Business Associate may use Protected Health Information to report violations of law to appropriate Federal and State authorities, consistent with §164.502(j)(1).

4. Obligations of Covered Entity

- 4.1 Covered Entity shall promptly notify Business Associate of any limitation(s) in the notice of privacy practices of Covered Entity in accordance with 45 CFR §164.520, to the extent that such limitation may affect Business Associate's use or disclosure of Protected Health Information.
- 4.2 Covered Entity shall promptly notify Business Associate of any changes in, or revocation of, permission by any Individual to use or disclose Protected Health Information, to the extent that such changes may affect Business Associate's use or disclosure of Protected Health Information.
- 4.3 Covered Entity shall promptly notify Business Associate of any restriction in the use or disclosure of Protected Health Information that Covered Entity has agreed to in accordance with 45 CFR §164.522, to the extent that such restriction may affect Business Associate's use or disclosure of Protected Health Information
- **5. Permissible Requests by Covered Entity.** Covered Entity shall not request Business Associate to use or disclose Protected Health Information in any manner that would not be permissible under the Privacy Rule or Security Rule if done by Covered Entity.

6. Term and Termination

6.1 <u>Term.</u> The Term of this Agreement shall be effective as of the date first written above, and shall terminate when all of the Protected Health Information provided by Covered Entity to Business Associate, or created or received by Business Associate on behalf of Covered Entity, is destroyed or returned to Covered Entity, or, if it is infeasible to return or destroy Protected Health Information,

Page | 23

protections are extended to such information, in accordance with the termination provisions in this Section

- 6.2 <u>Termination for Cause.</u> Upon Covered Entity's knowledge of a material breach by Business Associate, Covered Entity shall either:
 - (a) Provide an opportunity for Business Associate to cure the breach or end the violation and terminate this Agreement if Business Associate does not cure the breach or end the violation within thirty (30) days after the date on which Covered Entity first notifies Business Associate in writing of such breach or violation;
 - (b) Immediately terminate this Agreement if Business Associate has breached a material term of this Agreement and cure is not possible; or
 - (c) To the extent required by law, Covered Entity may report the violation to the Secretary.

6.3 Effect of Termination.

- (a) Except as provided in paragraph (b) of this section, upon termination of this Agreement, for any reason, Business Associate shall return or destroy all Protected Health Information received from Covered Entity, or created or received by Business Associate on behalf of Covered Entity. This provision shall also apply to Protected Health Information that is in the possession of subcontractors or agents of Business Associate. Business Associate shall retain no copies of the Protected Health Information.
- (b) In the event that Business Associate determines that returning or destroying the Protected Health Information is infeasible, Business Associate shall provide to Covered Entity notification of the conditions that make return or destruction infeasible. Upon the parties' mutual agreement that return or destruction of Protected Health Information is infeasible, Business Associate shall extend the protections of this Agreement to such Protected Health Information and limit further uses and disclosures of such Protected Health Information to those purposes that make the return or destruction infeasible, for so long as Business Associate maintains such Protected Health Information.
- 7. Limitation on Liability. To the maximum extent permitted by law, the parties agree that any claims for liability that Covered Entity may have against Business Associate relating to this Agreement, including any cause of action arising in contract, tort, or strict liability, shall be subject to the limitations on liability described in the Related Agreement, it being the parties' express intention that in no event shall Business Associate's liabilities arising under this Agreement and the Related Agreement collectively exceed such limitation. Should the Related Agreement not provided for a limitation on Business Associate's liability, then, to the maximum extent permitted by law, the cumulative liability of Business Associate to Covered Entity for all claims relating to this Agreement, including any cause of action arising in contract, tort, or strict liability, shall not exceed the total amount of all fees paid to Business Associate under the Related Agreement. In no event shall Business Associate be liable for any loss of profits; any incidental, special, exemplary, or consequential damages; or any claims or demands brought against a party, even if the other party has been advised of the possibility of such claims or demands.
- **8. Insurance**. Contractor shall maintain insurance coverage sufficient to cover liability incurred for noncompliance with this agreement or HIPAA.

9. Miscellaneous

- 9.1 Effect. The terms and provisions of this Agreement shall supercede any other conflicting or inconsistent terms and provisions in any other agreement between the parties. This Agreement shall be binding upon, and shall inure to the benefit of the parties hereto, and their respective permitted successors and assigns, but neither party may assign this Agreement without the prior written consent of the other, which consent shall not be unreasonably withheld or delayed; provided, however, that Business Associate may assign its rights hereunder without such consent to any parent, subsidiary or affiliate or to any successor to all or substantially all of its business.
- 9.2 Regulatory References. A reference in this Agreement to a section in the Privacy Rule or Security Rule means the section as in effect or as amended.
- 9.3 Amendment. Business Associate and the Covered Entity agree to amend this Agreement to the extent necessary to allow either party to comply with the requirements of the Privacy Rule, the Security Rule, the Standards for Electronic Transactions (45 C.F.R. Parts 160 and 162) and the Security Standards (45 C.F.R. Part 142) promulgated or to be promulgated by the Secretary or other regulations or statutes, and the Health Insurance Portability and Accountability Act of 1996, Pub. L. No. 104-191. This Agreement may be amended only by a written agreement executed by both parties
- <u>9.4 Survival</u>. The respective rights and obligations of Business Associate under Section 6.3 of this Agreement shall survive the termination of this Agreement.
- 9.5 Interpretation. Any ambiguity in this Agreement shall be resolved to permit Covered Entity to comply with the Privacy Rule and the Security Rule. The article headings used are for reference and convenience only, and shall not enter into the interpretation of this Agreement.
- <u>9.6 Counterparts.</u> This Agreement may be executed in separate counterparts, each such counterpart being deemed to be an original instrument, and all such counterparts shall together constitute the same agreement.
- <u>9.7 Choice of Law</u>. This Agreement is entered into and shall be construed under the laws of the New York.
- <u>9.8 Notices</u>. Except as otherwise set forth herein, all notices shall be in writing and deemed given (a) upon delivery, if delivered in person or by prepaid telegraph, (b) five (5) business days after mailing if sent registered mail, return receipt requested, or (c) the next business day after sending, if sent by commercial overnight courier (unless returned undelivered or the courier reports a later delivery). Notices shall be addressed to each party at the address listed beneath such party's signature below, or such other address as the recipient may have specified by earlier notice to the sender.
- <u>10.9 Force Majeure</u>. Business Associate shall be excused from performance under this Agreement for any period Business Associate is prevented from performing any services pursuant hereto, in whole or in part, as a result of an act of god, war, civil disturbance, court order, labor dispute or other cause beyond its reasonable control, and such nonperformance shall not be grounds for termination.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be signed and delivered as in instrument under seal by their duly authorized representatives, as of the date set forth above.

Verisk Health, Inc.	«Covered_Entity»
By:	<i>By</i> :
Print Name:	Print Name:
Title:	Title:
Address:	Address: Street
	«City», «State» «Zip»
	Attn: «Attn To»

APPENDIX C. SERVICE CHANGE REQUEST

Client has submitted the attached change request to Verisk dated to modify the scope of services defined in the Agreement. In response to such request, Verisk submitted the attached proposal to Customer dated outlining the costs for implementing the change.		
Both parties shall indicate their agreem which shall become a part of this Attac	ent to the terms and conditions of Verisk's proposal, hment, by executing below.	
CLIENT	VERISK	
Corporate Officer's Signature	Corporate Officer's Signature	
Name (type or print)	Name (type or print)	
Title	Title	
Date	Date	